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In the recent era, no congenital heart defect has undergone a more dramatic change in
diagnostic approach, management, and outcomes than hypoplastic left heart syndrome (HLHS).
During this time, survival to the age of 5 years (including Fontan) has ranged from 50% to 69%,
but current expectations are that 70% of newborns born today with HLHS may reach adulthood.
Although the 3-stage treatment approach to HLHS is now well founded, there is significant
variation among centers. In this white paper, we present the current state of the art in our
understanding and treatment of HLHS during the stages of care: 1) pre-Stage I: fetal and
neonatal assessment and management; 2) Stage I: perioperative care, interstage monitoring, and
management strategies; 3) Stage II: surgeries; 4) Stage III: Fontan surgery; and 5) long-term
follow-up. Issues surrounding the genetics of HLHS, developmental outcomes, and quality of life
are addressed in addition to the many other considerations for caring for this group of complex
patients.
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now a number of therapeutic options available for families,
though there continues to be a debate as to the optimal
treatment approach. Although the 3-stage treatment ap-
proach to HLHS is now well founded, there is significant
variation among centers (1). The goals of Stage I palliation
are to relieve systemic outflow tract obstruction, provide
nonrestrictive coronary blood flow and adequate pulmonary
blood flow, and create a nonrestrictive atrial septal defect.
The second stage eliminates the existing, high-pressure,
arterial or ventricular source of pulmonary blood flow and
connects the superior vena cava (SVC) with the pulmonary
artery. Conversion to a bidirectional superior cavopulmo-
nary shunt results in reduced pressure and volume work for
the single ventricle, improved circulatory efficiency because
the source of pulmonary blood flow is now more desaturated
venous blood rather than an arteriovenous admixture, gen-
erally higher arterial saturation, and growth potential. The
third stage directs the remaining desaturated blood return-
ing from the lower body to the pulmonary arteries.
Despite the effort devoted to this condition, there re-
mains a lack of definitive evidence of cause and agreement
on many management issues. In this white paper, we
present the current state of the art in our understanding and
treatment of HLHS during the stages of care: 1) pre-Stage I:
fetal and neonatal assessment and management; 2) Stage I:
perioperative care, interstage monitoring, and management
strategies; 3) Stage II: surgeries; 4) Stage III: Fontan surgery;
and 5) long-term follow-up. Issues surrounding the genetics of
HLHS, developmental outcomes and quality of life will be
addressed.
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Prenatal Diagnosis and Outcome
Possible mechanisms of development of HLHS. The ability to
identify and follow the fetus with HLHS with fetal echo-
cardiography has shown the progressive nature of HLHS
and highlighted the importance of abnormal flow patterns
in the mechanisms of development of HLHS. The struc-
tures are all generally present albeit severely hypoplastic, or
may be atretic, and at least some forms of HLHS occur
relatively late in development after embryogenesis. Al-
though fetal demise has been reported, most pregnancies
reach term gestation with relatively normal growth and
development of other organ systems although with an
increased prevalence of central nervous system abnormalities
(2,3).
There are likely several inciting mechanisms resulting in
the underdevelopment of the left ventricle (LV). In fetal life,
the LV is predominantly filled by flow through the foramen
ovale and any perturbation of flow into or out of the LV may
result in growth impairment. It has been observed that the
fetus with HLHS has a smaller foramen ovale than the fetus
with a normal heart (4). In addition, there is a known
association between HLHS and an anatomic abnormality of
the atrial septum, namely posterior deviation of the septum
primum (5). In this anomaly, the superior edge of the
septum primum is deviated posterior and leftward, attaching
anomalously to the left atrial wall, restricting atrial level
shunting. An intact atrial septum in association with HLHS
has also been observed in utero (6); often, there is a small
communication early in gestation that closes over time. This
diagnosis carries a very poor prognosis.
In addition to atrial septal anomalies, HLHS may result
primarily from abnormal development of the cardiac valves
or the left ventricle itself, caused by an intrinsic genetic
abnormality or cause. The ventricle often appears dilated
and echo bright with poor systolic function. Endocardial
fibroelastosis, a poorly understood phenomenon whereby
the endocardium of the LV becomes fibrotic, is often
observed (7). Fetal restrictive cardiomyopathy is present
with endocardial fibroelastosis, resulting in elevation of LV
end-diastolic and left atrial pressures, and subsequent dim-
inution of flow through the foramen ovale into the left
heart. Typically, the LV initially appears dilated, poorly
contractile, and larger than the right ventricle (RV), and
later in gestation, hypoplastic in comparison to the normally
growing RV (Fig. 1) (8,9). In some forms of the disease,
there is an inherent abnormality of the mitral (parachute,
arcade) and/or the aortic valve (bicuspid or unicuspid), and
multiple animal models have produced left ventricular
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obstruction (inflow or outflow) (10,11).
Fetal Flow Patterns in HLHS
The normal fetal circulation allows both ventricles to
contribute to the work of supplying blood for the developing
fetus and permits immediate postnatal adaptation to terres-
trial existence. As a consequence, there are important
communications between the pulmonary and systemic cir-
culations, including the foramen ovale and the ductus
arteriosus. As a consequence of these communications, if
one ventricle should be hypoplastic, the contralateral ven-
tricle can compensate, permitting essential normal growth
and development of the remaining organ systems.
In HLHS, in utero shunting across the atrial septum is
reversed from the normal pattern. The minimal blood flow
that enters the left atrium from the pulmonary veins must
predominantly cross the atrial septum into the right atrium.
The mixture of pulmonary and systemic venous blood then
passes from the RV into the pulmonary artery. A small
amount of blood enters the branch pulmonary arteries,
whereas the majority goes through the ductus arteriosus. In
the most extreme form of HLHS with aortic atresia, the
myocardial and cerebral circulations are supplied solely by
the ductus in a retrograde fashion. The lower body blood
flow is also provided by the ductus arteriosus. This “adap-
tation” allows for hemodynamic stability during fetal life.
However, flow inefficiencies are poorly tolerated in the fetus
Figure 1
Fetal Echocardiograms
(A) Four-chamber view of a fetal echocardiogram at 20 weeks’ gestation demonstra
elastosis. The position of the atrial septum suggests abnormal left atrial to right atr
imaged at 33 weeks’ gestation demonstrates that the left ventricle has become hyp
ventricle; RA  right atrium; RV  right ventricle; Sp  spine.with HLHS. For example, severe tricuspid regurgitationresults in volume overload and systemic venous hyperten-
sion, and may eventually cause hydrops fetalis (12). In rare
forms of HLHS, there is severe mitral regurgitation with a
markedly dilated left atrium. In these cases, the LV may
actually be enlarged, though noncontractile, and may impact
RV performance in utero. Finally, ductal constriction may
occur in cases of maternal exposure to arachadonic acid
inhibitors such as indomethacin or aspirin; this negatively
affects right ventricular performance and systemic perfusion
in these patients.
Impact of Fetal Diagnosis on Outcome
Infants with HLHS present in different ways. Many infants
are now diagnosed prenatally and are physiologically stable
at presentation; some infants are diagnosed due to a murmur
or cyanosis that is discovered in the newborn nursery prior
to discharge; and still other infants are diagnosed only after
becoming acutely and critically ill following ductal closure.
There is conflicting data regarding the impact of fetal
diagnosis on surgical outcome in neonates with HLHS. The
majority of reports have concluded that mortality is not
reduced if a prenatal diagnosis is made (13–15), though
some have reported improved survival (16). In most cases,
the inherent risks associated with the Norwood procedure
likely outweigh the benefit of prenatal recognition of the
disease. Though mortality may not be significantly altered,
there is an improvement in morbidity when HLHS is
diagnosed before birth. Infants with a prenatal diagnosis of
ilated left ventricle with echo bright endocardium suggestive of endocardial fibro-
nting in utero. (B) Four-chamber view of a fetal echocardiogram in the same fetus
ic. The echo bright endocardium is even more evident. LA  left atrium; LV  lefttes a d
ial shu
oplastHLHS have overall better pre-operative condition, includ-
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Neurological events that carry a poor prognosis, such as
post-operative seizures, occur in fewer patients with a
prenatal diagnosis of HLHS (13), and this is likely due to
the rapid initiation of prostaglandin therapy and the pre-
vention of cardiovascular collapse that occurs with ductal
constriction or closure. As expected, a prenatal diagnosis of
HLHS does not protect against neurodevelopmental abnor-
malities. Microcephaly and impaired somatic growth may
be more prevalent in this population, though conflicting
studies exist (18,19).
Prenatal recognition of disease allows families to prepare
for a child with a life-threatening defect by meeting with the
multidisciplinary team that will care for their newborn and
learning about the short- and long-term prognosis of the
disease. Counseling also provides an opportunity to discuss
the option of pregnancy termination or comfort care after
birth. Genetic testing and evaluation for extracardiac anom-
alies has become imperative for prognosis. Genetic syn-
dromes in which HLHS has been seen include Turner
syndrome, trisomy 13, trisomy 18, Holt-Oram, Smith-
Lemli-Opitz, partial trisomy 9, Jacobsen syndrome, and
others (20). Extracardiac anomalies associated with HLHS
include agenesis of the corpus callosum, diaphragmatic
hernia, and omphalocele, among others (21). It is well
recognized that genetic disorders and extracardiac anomalies
in association with a diagnosis of HLHS carry a worse
prognosis (22). Finally, prenatal diagnosis allows for poten-
tial fetal intervention. In select cases, prenatal balloon
dilation of the aortic valve has been associated with de-
creased progression of left ventricular hypoplasia (23). Fetal
atrial septostomy to provide an adequate atrial communica-
tion in fetuses with HLHS and intact atrial septum may also
improve prognosis for this particularly high-risk subset of
patients (23).
In the high-risk fetus with unfavorable anatomy, consid-
eration for fetal listing for heart transplantation may be
offered, and increases the potential window of opportunity
for a donor organ to become available (24). In the current
era of improved Stage I palliation, this option is rarely
pursued.
Pre-Operative Assessment and Management
HLHS and related functional single RV conditions remain
the highest risk and costliest group of lesions among the
commonly occurring congenital heart defects (25). Regard-
less of presentation, infants with HLHS require careful
management during the interim period between diagnosis
and surgery. The goals of pre-operative management in-
clude clinical stabilization, complete definition of cardiacanatomy, recognition of noncardiac diagnoses, and family
education.
Pre-operative medical management varies tremendously
between institutions and providers (1,26–29). Neonates
with HLHS require continuous intravenous infusion of
prostaglandin E1 (PGE) to maintain ductal patency for
adequate systemic blood flow. Infants who present in
cardiac shock need immediate, effective resuscitation and
often require intubation, volume expansion, and inotropic
support. For all neonates, pulmonary vascular resistance
(PVR) falls following birth, and for neonates with HLHS,
ensuring adequate systemic perfusion (i.e., balancing the
systemic and pulmonary circulations) becomes crucial. Some
institutions use medical management including intubation
and hypoventilation or inhaled nitrogen or carbon dioxide
to increase PVR and redirect cardiac output to the body
(30). Other management strategies seek to increase overall
cardiac output via inotropic support, whereas some institu-
tions pursue early surgical intervention prior to significant
decrease in PVR.
Transthoracic echocardiography is used to determine
patency of the ductus arteriosus, presence of an adequate
atrial level communication, myocardial function, and degree
of tricuspid regurgitation. Treatment and stabilization of
secondary organ system involvement and impairment re-
quires prompt diagnosis and treatment to optimize the
pre-operative status.
The patient with HLHS and an intact or nearly intact
atrial septum presents a particularly challenging clinical
scenario. The decision to intervene using transcatheter
versus surgical techniques varies by institution. In either
procedure, the primary goal is to reduce the obstruction at
the atrial level and then allow for recovery before performing
the complete first-stage palliation, as banding is usually not
well tolerated in the critical newborn.
These important pre-operative days allow for family
education, which is particularly important if the cardiac
lesion was not diagnosed prenatally. Although most centers
counsel and encourage a staged palliation approach (31),
some centers focus on primary transplantation (32). In
recent years, and with significant improvements in out-
comes, controversy has developed as to whether comfort
care should still be offered as a treatment option (33,34).
In centers located at altitude, pre-operative issues (e.g.,
pulmonary overcirculation) and management are similar. In
the long term, unpublished and anecdotal evidence suggests
similar outcomes and no significant correlation between
altitude and PVR, pulmonary artery pressure, or trans-
pulmonary gradient at pre-bidirectional cavopulmonary
anastomosis and pre-Fontan.
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Three basic strategies for the neonatal management of HLHS
have evolved over the last 4 decades: surgical palliation with a
Norwood procedure, hybrid palliation with surgical bilateral
pulmonary artery banding and transcatheter ductal stenting,
and orthotopic transplantation. Each strategy has a common
set of objectives: provide unobstructed systemic cardiac output,
a controlled source of pulmonary blood flow, a reliable source
of coronary blood flow, and unobstructed egress of pulmonary
venous drainage.
In the average-risk newborn, the optimal timing for
surgical or hybrid palliation is not known and may be center
specific. Although after 30 days, risks increase, the physio-
logical parameters of pulmonary vascular resistance, ventric-
ular performance, and atrioventricular valve competency are
the determinants of palliative feasibility and success.
Norwood Procedure
Theoretical surgical strategies have long been put forth for
palliation of HLHS, and several unsuccessful attempts
occurred during the 1970s, but it was Norwood and col-
leagues who achieved the first real success in the 1980s
(35–46). In addition to the formidable surgical obstacles to
be overcome, this early success was codependent on the
simultaneous developments in neonatal management.
Among these developments was the use of PGE for
maintenance of ductal patency that permitted resuscitation
of profoundly ill neonates prior to complex surgery (47–57).
The Norwood procedure with modified Blalock-Taussig shunt. In
the classic Norwood procedure, pulmonary blood flow is
provided by a Blalock-Taussig (BT) shunt, which directs
blood from the innominate or subclavian artery to the
pulmonary arteries via a polytetrafluoroethylene tube. Due
to the lower PVR relative to systemic vascular resistance,
there is continuous forward flow into the BT shunt, not only
throughout systole, but also during diastole. This results in
lower systemic diastolic blood pressure and “coronary steal”
that may result in decreased myocardial perfusion (58–60).
Utilizing nuclear imaging at rest and after administration of
adenosine, coronary arterial flow and oxygen delivery have
been shown to be significantly decreased in patients after the
Norwood procedure compared with patients after anatomic
repair of a congenital heart defect. It has been suggested that
this relative coronary arterial insufficiency secondary to the
coronary steal that occurs with a BT shunt may play an
important role in the significant mortality of the palliated
patient (61–63).
The Norwood procedure with RV-to-pulmonary artery conduit.
Early in the development of the operation that bears his
name, Dr. William Norwood attempted to use an RV-to-pulmonary-artery conduit/shunt (RV-PA) to supply pulmo-
nary artery blood flow (44). Although this source of pulmo-
nary blood flow was abandoned in favor of the BT shunt,
decades later, several authors have resurrected this technique
in an attempt to address the issue of coronary artery steal.
The RV-PA has the advantage of eliminating the diastolic
runoff and coronary artery steal (46,59,64,65), but the
ventriculotomy adds the risks of direct myocardial injury
and arrhythmias (66).
A number of historically controlled case series have
reported a decrease in hospital mortality with the RV-PA
compared with the BT shunt (46,67–69). Sano et al. (46)
reported an 89% hospital survival with the RV-PA com-
pared with 53% with the BT shunt, and similar results were
reported by Pizarro et al. (69) (BT shunt 70%, RV-PA 92%)
and Mair et al. (68) (BT shunt 72%, PV-PA conduit 93%).
Other recent, nonrandomized studies have shown no im-
provement in hospital survival comparing the 2 shunts
(63,67,70,71).
SVR (Single Ventricle Reconstruction) Trial. In an attempt
to resolve the question of which Norwood modification is
superior, the SVR trial was undertaken (19). The trial, a
Pediatric Heart Network, 15-center, National Institutes of
Health–sponsored, randomized trial compared the BT
shunt and RV-PA. Patients with single RV malformations
undergoing a Norwood procedure were randomized to
receive either a BT shunt or RV-PA. The primary endpoint
was death or transplantation at 1 year. Secondary endpoints
included hospital course, RV function by echo, pulmonary
artery size by angiography, unintended cardiovascular inter-
ventions, and serious adverse events and complications
between shunts. Between May 2005 and July 2008, 555
newborns were enrolled.
The RV-PA was found to be superior to the BT shunt
(26% vs. 36%, p  0.01) for the primary endpoint of death
or transplant at 12 months. All patients enrolled were
followed annually until study close out, with a final mean
follow-up of 32  11 months. Although there was a
significantly higher risk of mortality in the BT shunt at
12-month endpoint, this was no longer significant with the
longer follow-up.
The need for cardiopulmonary resuscitation during the
Norwood hospitalization was greater in the BT shunt group
(20% vs. 13%, p 0.04), whereas unintended cardiovascular
interventions on the shunt or neoaorta were more common
in the RV-PA group (92 vs. 70 per 100 infants, p  0.003).
Echo measures of RV end-diastolic volume and ejection
fraction were both superior for the RV-PA group up to
Stage II, but had equalized by 14 months. Pulmonary artery
size was larger in the BT shunt group (169 vs. 145, p 
0.009). The complication rate was higher in the RV-PA
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although the percentage of infants with at least 1 compli-
cation was the same in both groups at 91%.
Post-Operative Management Strategies
The newborn with univentricular anatomy has a high risk of
shock before and after an initial palliative surgical proce-
dure. The syndrome of inadequate cardiac output, charac-
terized by reduced systemic oxygen delivery, high systemic
oxygen extraction, and anaerobic end-organ dysfunction, is
a stereotypical finding following neonatal cardiac surgery.
Myocardial edema and post-ischemic systolic and diastolic
dysfunction result in reduced stroke volume, and the met-
abolic response to trauma and inflammatory stimulus from
cardiopulmonary bypass result in increased oxygen demand.
The superimposition of these processes results in a high risk
of shock (inadequate oxygen supply/demand economy) in
the first 6 to 12 h after surgery following both complete
repair of 2 ventricle defects and palliation of single-ventricle
lesions (72–75). The newborn with HLHS has additional
vulnerabilities: total ventricular mass—the source for me-
chanical circulatory energy—is reduced; the parallel anat-
omy of pulmonary and systemic circulations results in
obligate desaturation of arterial blood, and the need exists
for double the normal total cardiac output from a single
ventricle. These superimposed vulnerabilities are implicated
in the high mortality risk and are the focus of the strategies
to mitigate that risk.
Optimizing oxygen delivery. Achieving normal systemic
xygen delivery at the lowest total cardiac output requires an
rteriovenous oxygen saturation difference of 20% to 25%
nd a pulmonary to systemic blood flow ratio (Qp/Qs) close
o 1.0 (76–80). These conditions are not reliably met using
tandard monitoring; because univentricular output is ap-
ortioned by the balance of system and pulmonary resis-
ances, arterial blood pressure and saturation will be rela-
ively unchanged as systemic vascular resistance rises or falls
78,81). Standard perioperative hemodynamic monitoring
rovides inadequate warning of circulatory failure, resulting
n a high rate of cardiac arrest, cardiopulmonary resuscita-
ion, extracorporeal circulatory support, and organ dysfunc-
ion in this population. In addition to improved operative
echniques and perfusion strategies, application of venous
xygen (SvO2) monitoring with invasive devices or near-
infrared spectroscopy, and pharmacological control of vas-
cular resistance in the postoperative period have been
associated with reduced operative mortality to 10%
(79,80,82,83).
Balancing the circulation: managing pulmonary vascular resistance.
Early efforts to address circulatory failure recognized that
pulmonary overcirculation would result in an increase in farterial oxygen saturation (SaO2) if systemic blood flow
ere maintained. Because venous oxygen measures were
ifficult to obtain, the variability in systemic blood flow was
theoretic concept (84) not visible at the bedside, and
linical management focused on preventing a rise in SaO2.
anipulation of inspired gas mixtures to control PVR,
articularly inspired carbon dioxide (CO2), was reported to
increase stability after Norwood palliation for HLHS
(85– 87). Both reduced fraction of inspired O2 and
inspired CO2 will acutely lower SaO2, but only hyper-
carbia will improve systemic oxygen delivery and cerebral
oxygenation (30,88,89).
Balancing the circulation: targeting systemic venous oxygenation.
After reports of the usefulness of intermittent measures of
SvO2 (76), the use of continuous venous oximetry via an
oximetric catheter placed in the SVC at the time of surgery
has become more common. Routine use of venous oximetry
during the first 48 h after surgery (Fig. 2) has been
associated with improved early and intermediate survival,
fewer complications, and improved neurodevelopment at 4
to 6 years of age, particularly when SvO2 is 50%
78,80,90). More recently, application of near-infrared
pectroscopy as a measure of regional venous-weighted
xygen saturation can provide a continuous and non-
nvasive estimate of SvO2 (91–93). Strategies measuring
egional venous-weighted oxygen saturation in both cerebral
nd noncerebral regions provide better estimates of SvO2
and stronger relationship to outcome (93–95).
Early experience with venous oximetry demonstrated the
occurrence of life-threatening falls in SvO2 without signif-
cant perturbations in SaO2, blood pressure, or heart rate
Fig. 3). Episodes of falling SvO2, and thus reduced
ystemic oxygen delivery, were ineffectively managed by
entilator and medical gas manipulation, but rather reversed
ith additional anesthetic and inotropic support. These
bservations led to strategies that targeted measures of
xygen delivery and control of systemic vascular resistance
o avoid circulatory collapse.
alancing the circulation: managing systemic vascular
esistance. Alpha-adrenergic blockade has been the
fterload-reducing agent most extensively studied in this
opulation. Unlike nitrovasodilators, phenoxybenzamine
nd phentolamine directly block the systemic vasoconstric-
ion that results from increased endogenous or exogenous
atecholamines. Phenoxybenzamine has been shown to be
uccessful in attenuating the expected low cardiac output
yndrome (Fig. 4) (73–74,96) and to increase SvO2 and
reduce Qp/Qs over a wide range of SaO2 and blood
ressure, reducing the vulnerability to runaway vasocon-
triction that precedes cardiovascular collapse (81). Ef-
ective control of systemic vascular resistance has been
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collapse (73,97,98).
Adjunctive therapies. Maintenance of systemic oxygen de-
ivery is dependent on optimizing cardiac output and arterial
xygen content. Optimal cardiac output requires attention
o volume status (preload), vascular resistance (afterload),
eart rate, rhythm, and myocardial contractility, whereas
rterial oxygen content is predominately dependent on
emoglobin and arterial saturation. In addition to venous
ximetry or near-infrared spectroscopy and pulse oximetry,
entral venous pressure (CVP) and invasive arterial blood
ressure monitoring, electrocardiography, capnography,
rine output, and biochemical assessment of perfusion
hould be part of the routine perioperative monitoring.
djunctive medical therapy may include inotropic agents
nd/or vasoactive medications. Sedative-analgesic medica-
ions can be used for reduction in systemic vascular resis-
ance, but also have the advantage of reducing metabolic
emands, allowing for better matching of oxygen consump-
ion to oxygen delivery. In the presence of strategies that
rioritize afterload reduction to balance the circulation,
entilator management can be targeted at preventing atel-
ctasis while avoiding hypocarbia, inspired oxygen rather
han promoting disproportionate hypoxia, and avoiding
xcessive work of breathing. Delayed sternal closure is
ommonly employed to reduce the risk of tamponade
hysiology, and has been associated with less circulatory
Figure 2
Complication Risk Associated With Superior Ven
Risk of complication according to post-operative superior venous oximetry saturation
in time-series regression. CPR  cardiopulmonary resuscitation; ECMO  extracorpoollapse and a reduced need for mechanical circulatorysupport (99). Finally, extracorporeal membrane oxygenator
(ECMO) support may be needed for infants with inade-
quate systemic oxygen delivery or to rescue infants with
acute cardiovascular collapse that most commonly occurs
from cardiogenic shock or acute shunt obstruction. In a
multicenter randomized control trial of infants who had
Stage I palliation, approximately 75% had delayed sternal
closure, 10% were placed on ECMO during the postoper-
ative period, and 15% required cardiopulmonary resuscita-
tion (19).
Outcomes and Complications
Outcomes have improved over the last 3 decades, likely due
to broad improvements in perioperative care (79). Single-
center retrospective analyses have identified factors in peri-
operative care and technical modifications associated with
improved outcomes, and several recent large series report
survival rates between 74% and 93% (13,22,79,100). The
Society of Thoracic Surgeons Congenital Heart Surgery
Database has shown an improvement in hospital survival
from 68.6% of 303 reported cases in 2002 to 81.4% of 2,320
cases in 2009 (Table 1). The post-operative period is
significant for morbidity from both cardiac and noncardiac
etiologies, often related to decreased cardiac output. Mul-
tiple studies report the need for chest compressions in 10%
to 17% of patients and the emergent use of ECMO support
in 7% to 10% (19,22,80,101). Arrhythmias, most commonly
Oximetry
) assessed hourly during first 48 h. *Significant difference from risk at lower SvO2
embrane oxygenator. Reprinted with permission from Tweddell et al. (80).ous
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cardia, and complete heart block have been reported
(80,101).
Bleeding with coagulopathy and product replacement are
essentially universal problems following the Norwood pro-
cedure, yet little data exist to characterize the bleeding,
transfusion use or specific coagulation abnormalities in these
patients. A recent study of patients following the Norwood
procedure found chest tube output for the first 24 h was
20.9  21.9 ml/kg, and the patients received 14.5  20.2
l/kg of red cell transfusions (102). Data for the use of
omponent therapy, recombinant factor VIIa, or topical
emostatic agents for correction of coagulopathy and con-
rol of bleeding in this group of patients is lacking.
The use of mechanical ventilation is required, on average,
or 3 to 7 days (80,101). Prolonged chylothorax and the use
f supplemental oxygen for treatment of excessive cyanosis
ot due to inadequate pulmonary blood flow are also not
ncommon post-operative issues and affect mechanical ven-
ilation duration.
Infection due to impaired cardiac output, cyanosis, pro-
onged intensive care unit stay, central venous access, and
nvasive monitoring complicates approximately 10% of pa-
ients and was the sixth leading cause of death following
tage I palliation (76,101,103).
Figure 3
Hemodynamic Monitoring in
the Immediate Post-Operative Period
Multichannel recording of the arterial saturation (SaO2), mean arterial blood pres-
ure (MAP) and superior vena cava saturation (SvO2) during the first 4 h after the
Norwood procedure. Two episodes of decreased SvO2 were identified. Fall in SvO2
was mirrored by changes in MAP. Fall in SvO2 was initially mirrored by changes in
aO2, but with a marked decline in SvO2, the SaO2 decreased as well. These
changes indicate that acute changes in SvO2 can occur and are not reliably identi-
ed by changes in SaO2 or MAP. Reprinted with permission from Tweddell
t al. (73).The most common neurological abnormality identified
n the post-operative period is seizures and is associated
ith neurodevelopmental delay (101,104). The incidence
f seizures varies depending on whether clinical or
lectroencephalogram-identified seizures are reported.
linical seizures occur in up to 4% to 17%, and electro-
Figure 4
Superior Venous Saturation During
the First 48 h After Norwood Procedure
The SvO2 was significantly higher during hours 1 to 10 in infants treated with phe-
oxybenzamine (0.25 mg · kg at commencement of cardiopulmonary bypass 
elective use of continuous infusion 0.25 · mg · kg · day) than in those treated with
ilrinone (load 50 g · kg · min prior to separation from bypass  continuous infusion
.5 g · kg · min after surgery). Reprinted with permission from Tweddell et al. (73).
Table 1
Hospital Discharge Mortality for Patients
Undergoing Stage I Palliation, 2002–2009
Year
Patients Undergoing
Stage 1 Palliation, n
Deaths Prior to
Discharge, n
Discharge
Survival, %
2002 303 95 68.60
2003 391 119 69.60
2004 297 75 74.70
2005 658 140 78.70
2006 1,155 234 79.70
2007 1,535 276 82.00
2008 1,879 334 82.20
2009 2,320 432 81.40From the Society of Thoracic Surgeons, Congenital Heart Database, courtesy of Dr. Jeff Jacobs.
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operative Norwood patients (80,105–107). Similarly, iden-
tification of other central nervous system injury depends on
the method of detection. Stroke and intracranial hemor-
rhage occur at a rate of approximately 5%, and the risk
extends outside the perioperative period due to the ongoing,
obligatory intracardiac shunt (80,101). With more sophis-
ticated imaging techniques, the identification of ischemic
lesions increases. Pre- and post-operative magnetic reso-
nance imaging (MRI) scanning has detected ischemic
events in 20% of patients with HLHS undergoing the
Norwood procedure (108,109). Phrenic nerve injury has an
incidence of 5% (101), whereas recurrent laryngeal nerve
injury as documented by vocal cord paralysis on laryngos-
copy has been reported in 8% to 9% of patients
(101,110,111).
Renal dysfunction (defined as an elevation of creatinine)
has been reported in up to 13% of patients during the
post-operative period, and oliguria with hyperkalemia in
2.5% (80,101). Although peritoneal dialysis is used by some
groups in as many as one-quarter of their patients to remove
excess water in the absence of the usual indications for
dialysis, one large reported experience used dialysis in 2%
of patients (80,101,112).
Biochemical evidence of hepatic dysfunction, such as
elevation of transaminases and even hepatic cellular necro-
sis, has been reported in patients with HLHS, but these
appear to be rare and resolve with improvement in cardiac
output (101,113). The incidence of necrotizing enterocolitis
varies from 1% to 18% (101,103), and the spectrum is broad.
Feeding difficulties are common (gastroesophageal reflux
has been reported in up to 9% of patients) and add to the
length of stay (103). The use of nasogastric and gastrostomy
tubes for feeding is used in up to one-quarter of patients in
some series (103,114).
Late complications can be defined as those that occur
after hospital discharge and prior to Stage II palliation and
are commonly anatomic lesions initially addressed at the
time of Stage I palliation. In a series of 122 postmortem
evaluations, the mechanism of death was associated with
residual lesions in approximately three-quarters of the pa-
tients. Most commonly, impairment of coronary artery
perfusion, excessive pulmonary blood flow, obstruction of
pulmonary arterial blood flow, and neoaortic arch obstruc-
tion were found (76). Aortic arch obstruction is not well
tolerated following the Norwood procedure, and most
centers have a low threshold for transcatheter interventions
to relieve residual obstruction.
Progressive decline in function with or without the
development of tricuspid valve insufficiency occurs in a
subset of patients. It is conceivable that this is due in somecases to coronary insufficiency, whether due to congenital
coronary anomalies or as a consequence of an obstructive
connection to the native ascending aorta. Recurrent or
residual arch obstruction has been reported in up to 33% of
Fontan survivors in some series and may be technique and
materials dependent (115–117). As a cause of interstage
death, arch obstruction is associated with poor weight gain
and decreased ventricular function (76,114,118). Success-
ful interventional catheterization may ameliorate the
impact of recurrent arch obstruction (119,120). Excessive
cyanosis is also common and may be due to shunt
obstruction, branch pulmonary artery stenosis, or rarely, a
restrictive atrial communication (114,121). If these late
complications are detected in a timely manner during the
interstage period, morbidity and mortality can be reduced
significantly (114).
Hybrid (Combination Surgery/
Interventional Catheterization)
In 1992, Gibbs and colleagues proposed palliating a new-
born with HLHS using percutaneous patent ductus arteri-
osus (PDA) stent implantation and surgical bilateral pul-
monary artery banding without cardiopulmonary bypass
(122). These and subsequent efforts by Ruiz and others
(123,124) had poor outcomes. Over the last decade, the
approach has seen renewed interest, improved results, and as
a result, greater though nonuniform adoption. In those who
have not adopted the concept as standard, some still employ
the technique as a “rescue” procedure for high-risk HLHS
and single-ventricle patients or as a bridge to heart trans-
plant in infants with HLHS (125,126).
Galantowicz and Cheatham with one of the largest U.S.
experiences to date have settled on the following approach:
1) placement of surgical bilateral pulmonary artery bands via
a small median sternotomy off cardiopulmonary bypass, and
PDA stent delivery through a surgically placed sheath in the
main pulmonary artery above the pulmonary valve; and
2) subsequent balloon atrial septostomy in a separate pro-
cedure 1 to 2 weeks later. The delay allows the left atrium to
enlarge and permits the use of a larger balloon, which has
decreased the need for repeat septostomy. Only retrograde
aortic arch obstruction with the PDA fully open is consid-
ered a contraindication to the hybrid Stage I palliation. In
attempting to predict which patients are at risk for retro-
grade aortic arch obstruction, one echo study using showed
a tendency for the aortic root to be smaller, the angle
between the aortic isthmus and PDA to be larger, and
retrograde aortic arch Doppler velocities to be higher (127).
In this scenario, obstruction of the retrograde orifice by
stent struts can lead to coronary insufficiency. To avoid
hemodynamic issues related to retrograde obstruction, one
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time of hybrid palliation to protect coronary blood flow, but
this is not universally applied in hybrid palliation (128,129).
A completely percutaneous Stage I procedure remains
elusive as the technology for safe and effective internal
pulmonary artery bands is not yet available.
In Europe, Akintuerk et al. reported an overall actuarial
survival after hybrid palliation of 83% with a 21% combined
mortality for patients through Stage II repair (130–133). In
the current era, Galantowicz et al. have results similar to
those reported by Akintuerk et al. (134–139). A recent
multicenter study of 7 institutions examined all forms of
hybrid procedures performed. Of the 128 procedures,
single-ventricle circulation was present in 60% of the
procedures. The most common hybrid intervention was
PDA stent placement, accounting for 55 of 128 (43%)
procedures, the majority of which (87%) were performed at
the same time as surgical banding of the branch pulmonary
arteries. Sixteen adverse events occurred in 15 of 128 (12%)
procedures. The only major or catastrophic adverse event in
a patient with HLHS was in a 7-day-old infant who
required multiple cardioversions for atrial flutter and su-
praventricular tachycardia during the procedure. Although
the study size was relatively small, the study suggests HLHS
patients may have a lower incidence of adverse events if the
procedure is performed using a direct approach with surgical
exposure rather than a percutaneous approach. The impact
that the hybrid approach will have on neurodevelopmental
outcomes remains unanswered.
Transplantation
The use of orthotopic transplantation for initial palliation in
neonates with HLHS was introduced by Leonard Bailey in
the mid 1980s after development of the model in laboratory
animals (140). Infants and children waiting for hearts in the
United States have the highest waitlist mortality of all solid
organ recipients (17%) and has increased progressively over
the past 2 decades (141). Though a preferred therapeutic
modality in a few centers (32,142), given that waiting times
for neonates in most regions approach several months and
Stage 1 reconstructive palliation at most centers carry
acceptable results, primary heart transplant for HLHS is
rarely offered in this era, and is, in general, limited to
neonates with severe RV dysfunction and/or moderate-to-
severe tricuspid regurgitation. Because the limited supply of
donor organs contributes to significant mortality while
patients are waiting for a suitable donor, attempts have been
made to increase the donor pool through the use of
ABO-incompatible donors (143). In those who received
transplants, perioperative mortality is higher than for older
children, but longer-term outcomes are overall better, withcurrent 30-day, 1-, 5-, and 10-year survival rates of 80% to
85%, 75%, 65%, and 60%, respectively (144).
Interstage Morbidity and Mortality
Following successful Stage I palliation, even the most stable
of survivors remain at risk for acute hemodynamic decom-
pensation during the interstage period (the time from
hospital discharge following Stage I palliation until Stage II
palliation). Interstage death remains an unfortunate, but not
uncommon, occurrence, with published rates of 2% to 16%
(61,82,145–147). The presence of residual, recurrent, or
progressive anatomic lesions such as a restrictive atrial
septum, stenosis/obstruction of the shunt or conduit, aortic
arch, and/or pulmonary arteries, or tricuspid valve insuffi-
ciency has been associated with interstage death (76,148). In
addition, the occurrence of a simple childhood illness such
as a respiratory tract infection or gastroenteritis as well as
fever, may cause hypovolemia, hypoxemia, and/or increased
systemic vascular resistance and may place an interstage
infant with minimal cardiovascular reserve at great risk for
interstage morbidity and mortality (149). Infants discharged
home following Stage I palliation, warrant heightened
surveillance during the interstage period.
Home Monitoring and Other Outcomes Programs
Conventional management of interstage infants consists of
routine outpatient evaluation by a pediatric cardiologist and
primary care provider along with parents observing their
infant at home for signs of respiratory distress or poor
perfusion and alerting the medical team as warranted. This
level of monitoring has proven inadequate in limiting
interstage death. In fact, infants who die during the inter-
stage period had been evaluated by a physician within days
of death and not uncommonly, interstage death occurred
with 24 h of the first symptom (150).
The current best practice for interstage care is heightened
surveillance of this at-risk population through participation
in a home monitoring program (114,151). The goal of
home monitoring is to provide a simple, reliable, in-home
method of detecting worsening systemic oxygenation, acute
dehydration, or growth failure based on the hypothesis that
early, at-home, detection of these parameters may indicate
the development of serious anatomic lesions or an intercur-
rent illness and allow for life-saving intervention.
Home monitoring usually consists of supplying the family
with an infant scale and pulse oximeter at home. Parents are
asked to obtain and record a daily weight and oxygen
saturation, as well as track enteral intake volumes in a log
book. The parents are counseled to notify the cardiology
team if a breach of pre-determined criteria occurs. The goal
of the program is to provide a simple, reliable, in-home
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dehydration, or growth failure based on the hypothesis that
early, at-home, detection of these parameters may indicate
the development of serious anatomic lesions or an intercur-
rent illness and allow for life-saving intervention. The home
monitoring program established in 2000 (114) enrolls all
patients after Norwood palliation. When these infants are
discharged from the hospital, they are sent home with a
digital infant scale and pulse oximeter for daily assessments
of weight and oxygen saturation, and a standardized form
for recording these parameters as well as daily enteral intake
volumes. The parents are counseled to notify the cardiac
care team if a breach of pre-determined criteria occurs.
Concerning physiological criteria include arterial satura-
tion 75% or 90%, acute weight loss of 30 g or more,
inability to gain 20 g over 2 to 3 days, or enteral intake
100 ml/kg/day (149). If a breach of criteria has occurred,
infants need evaluation by a healthcare provider within 24 h
or less based on the severity of the breach and the presence
of compounding factors. An additional strategy utilized to
expand the surveillance that home monitoring provides is
the implementation of a weekly follow-up phone call to
parents by a member of the cardiac team to assess nutri-
tional parameters and other trends in an effort to prevent
call criteria breaches.
Over the past decade, implementation of a home moni-
toring program has been associated with improved inter-
stage survival at several centers (82,114,146). In one series,
128 infants were home monitored over a period of 8 years.
Ninety-eight percent (125 of 128) of the infants survived to
Stage II palliation. A breach of home monitoring criteria
occurred in 62% of home-monitored infants and resulted in
106 hospital admissions, 88% of which required additional
medical or surgical intervention (152).
Another interstage strategy targeted at improving out-
comes for infants discharged home following Stage I palli-
ation is the implementation of a specialized cardiology clinic
dedicated to outpatient care of interstage infants. The
availability of a high-risk or interstage specialty clinic
provides an opportunity for frequent in-depth evaluation of
these fragile infants as frequently as every 1 to 2 weeks
without overburdening a general cardiology clinic setting
(153). Clinic evaluation is provided by a dedicated cardiac
team consisting of pediatric cardiologists, nurse practitio-
ners, and clinic nurses familiar with the multifaceted needs
of interstage infants and their families. In order to provide
the greatest benefit, the clinic should be multidisciplinary,
with routine patient evaluation by a dietician, speech and
feeding specialist, social worker, and case manager. Advan-
tages of a high-risk or interstage clinic include a venue for
constant reassessment of the infant’s cardiorespiratory statusand review of home monitoring data as well as the oppor-
tunity for frequent, thorough evaluation of nutritional status
including oral–motor feeding skills. Growth failure is a
well-described finding in this population, and inadequate
nutrition contributes significantly to interstage morbidity
and mortality (154).
Interventional Procedures
There are numerous studies demonstrating the usefulness of
interventional catheterization after the Norwood procedure.
Although some procedures occur in the acute post-operative
setting, most often due to unexplained cyanosis, the major-
ity are performed during the interstage period either as a
result of detected or suspected anatomic abnormalities, or as
planned pre-Stage II catheterizations. Interventions address
obstructions/stenoses in the BT shunt or RV-PA conduit,
pulmonary arteries, aortic arch, and/or the acquisition/
persistence of aortopulmonary (APCs) and venovenous
collaterals (VVCs).
Stenotic BT shunt and RV-PA conduits with resulting
increased cyanosis often lead to immediate evaluation and
intervention. Although surgery may be used to alleviate
shunt or conduit obstruction, many centers rely on the
effectiveness of catheter intervention (155–166).
In the immediate post-operative time period, various
transcatheter methods have been used to treat thrombosed
BT shunts. Mechanical disruption using catheter manipu-
lation and/or balloon angioplasty, pharmacological dissolu-
tion with urokinase or recombinant tissue plasminogen
activator, and rheolytic catheter thrombectomy have been
used individually or in combination (158–160,165). In cases
of extreme cyanosis, the use of ECMO prior to catheter
intervention has been described (164).
Shunt stenosis is more common than occlusion and is
often due to a physical narrowing of the BT shunt or
RV-PA conduit. Multiple studies have shown the success of
balloon angioplasty for shunt stenosis, with recalcitrant
lesions responding to stent placement (155–157,161–
163,165,166). More recently, the institution of the Sano
modification resulted in documented cases of RV-PA con-
duit stenoses. Several published reports demonstrated en-
dovascular stent placement in obstructed RV-PA conduits
to be effective and safe (163,167–170). Complications in-
clude hypotension and blood loss, less commonly complete
heart block and bradycardia, and rarely, cardiac arrest and
death.
In addition to pulmonary blood source obstruction, pulmo-
nary artery obstruction has also been diagnosed and intervened
upon in the catheterization laboratory. Outside of deferring
until the time of Stage II surgery to plasty pulmonary arteries,
several studies reported successful balloon dilatation of pulmo-
S12 Feinstein et al. JACC Vol. 59, No. 1, Suppl S, 2012
HLHS: Current Considerations and Expectations December 27, 2011/January 3, 2012:S1–S42nary arteries at the pre-operative catheterization for pulmonary
artery stenosis (171–173). For lesions resistant to balloon
dilation, stent placement has been utilized between stages,
although many institutions would favor surgical repair to stent
placement in patients of this size.
Obstruction to systemic blood flow is also a serious and
well-documented finding in HLHS patients, with studies
finding as many as one-third of patients developing arch
obstruction (118,120,174–176). Although studies have dem-
onstrated technical success in treating the arch obstruction
(118,120,172–177), high morbidity and mortality was noted in
this group of patients (118,176,177). Recent studies have
reported similar survival rates between this group and control
groups without recoarctation (120). Blood loss requiring trans-
fusion, decreased lower extremity perfusion, and transient
arrhythmia ranked among the most common complications.
Rarely, obstructive intimal flap development or aortic damage
requiring surgical repair occurred.
The final 2 interventions that occur between Stage I and
II involve vessel embolization. Venovenous collaterals and
left SCV to coronary sinus, or pulmonary venous connec-
tions can cause cyanosis in patients after Stage II. One study
found almost one-third of their patients developed venous
collaterals after superior cavopulmonary anastomosis (178).
Other studies reported successful coil closure of these
venous collaterals with resulting increased saturation
(166,179). The effect of venous collateral embolization on
long-term morbidity remains unknown.
Finally, embolization of APCs can occur during inter-
stage catheterization. Some centers do occlude large APCs
to avoid volume loading the single ventricle. However, the
clinical significance and actual indications for closure are not
currently known or documented. Although one study
showed prolonged post-operative pleural effusions in Fon-
tan patients with significant APCs (180), 2 studies demon-
strated the lack of impact of APC flow on post-operative
hemodynamics, pleural effusions, or outcome (181,182).
The most common risk associated with vessel occlusion
would be coil dislodgment.
Stage II (Glenn; Hemi-Fontan)
Stage II palliation is the conversion from a high pressure
(RV or aorta) “arterial” source of pulmonary blood flow to a
venous source through anastomosis of the SVC to the
pulmonary arteries (183–187). In the case of bilateral
superior caval veins both SVCs are connected to the
pulmonary arteries. The shunt or RV-PA conduit is gener-
ally ligated and/or divided at the same time. Stage II is most
commonly performed at 4 to 6 months of age, but may be
safely performed at 3 months of age (188).After a bidirectional Glenn shunt, an extracardiac conduit
is most commonly used to complete the Fontan procedure.
However, it is possible to allow the SVC to remain
connected to the heart with patch closure of the superior
vena caval/right atrial junction. This patch is removed at the
time of Fontan completion allowing creation of an intra-
atrial lateral tunnel. This hemi-Fontan procedure was de-
scribed by Norwood and Jacobs and involves a side-to-side
anastomosis of the SVC to the right pulmonary artery with
homograft patch augmentation of central pulmonary arter-
ies, creating a baffle between the pulmonary artery and the
right atrium (185,189). Following a hemi-Fontan proce-
dure, the Fontan completion is usually performed by cre-
ation of an intra-atrial lateral tunnel. There is no conclusive
evidence that the type of superior cavopulmonary connec-
tion (i.e., Glenn vs. hemi-Fontan) has a significant impact
on late outcomes for patients with HLHS (185,190,191).
The Glenn is most commonly performed using cardio-
pulmonary bypass with widely varying strategies ranging
from normothermia without cross-clamping to deep hypo-
thermic circulatory arrest (192–194). Techniques have been
described that allow creation of a bidirectional Glenn shunt
without the use of cardiopulmonary bypass; however, these
are not widely utilized (195–197).
The bidirectional Glenn shunt and hemi-Fontan are
physiologically identical and achieve a number of goals:
reduced work of providing pulmonary blood flow and
volume loading of the heart, and improved circulatory
system efficiency, given the source of pulmonary blood flow
is more desaturated venous blood rather than an arterio-
venous admixture (185,198–200). The arterial saturations
are generally improved (though still cyanotic) and the
completion of the Glenn heralds in a period of decreased
risk compared with the preceding interstage period. Inter-
mediate staging with a Glenn/hemi-Fontan reduces the risk
of mortality and morbidity at the subsequent Fontan pro-
cedure (183,185,189).
Management of additional sources of pulmonary blood
flow at the time of superior cavopulmonary anastomosis
remains controversial. Leaving an additional source of
pulmonary blood flow (BT shunt or RV-PA conduit) has
the potential advantage that the increased flow may enhance
pulmonary artery growth; however, the increased flow is not
tolerated in all patients and occasionally leads to unaccept-
able elevation of SVC pressure. There is no definite evi-
dence that leaving additional sources of pulmonary blood
flow improves outcomes (201–202).
Stage II requires a low PVR. A PVR of 2 Wood units
has been associated with improved survival (199). This
maturation includes growth of the pulmonary vascular bed
such that the ratio of arterioles to alveoli increases, com-
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smooth muscle (203). The age at which pulmonary matu-
ration is sufficient to permit conversion from an arterial
source of pulmonary blood flow to a SVC–pulmonary artery
connection is not precisely established and may be depen-
dent on a number of factors such as age at presentation, the
size of the arterial source of pulmonary blood flow, presence
of a restrictive atrial septal defect and presence or absence of
parenchymal lung disease. Whereas in the past, Stage II was
arbitrarily performed at 6 months of age, it is now routinely
performed at 3 to 4 months of age and has been performed
in patients as young as 1 month of age (193) to limit the
duration of the vulnerable interstage period.
Diagnostic studies prior to Stage II. Prior to the use of
cardiac MRI, the debate existed about whether patients
required catheterization prior to Stage II. However, due to
limitations of echocardiography to reliably define pulmo-
nary artery and arch anatomy, studies reported only a subset
of low-risk patients with adequate echo evaluation who
qualified for noninvasive testing only (171,204,205). With
the increased use and improvement of cardiac MRI, the
question surrounding the need for pre-Stage II catheteriza-
tion resurfaced.
Two studies showed the ability of MRI to define aortic and
pulmonary artery anatomy in infants (206,207). One retrospec-
tive study of HLHS patients reported MR sensitivity of 86%
and specificity 97% for neoaortic obstruction (1 false-negative
result that detected a lesser degree of aortic narrowing and 1
false positive that did not require repair upon surgical inspec-
tion), and sensitivity of 100% and specificity 94% for LPA
stenosis (2 false-positive results) with routine right pulmonary
artery reconstruction for all patients at this institution (208).
hey concluded that MR could replace catheterization given
heir institution’s preference for surgical repair of pulmonary
rtery stenosis and coarctation.
The only prospective study randomized patients without
ulmonary vein stenosis, pulmonary hypertension, severe
entricular dysfunction, severe atrioventricular valvar regur-
itation, known large APCs or VVCs, or coarctation of the
orta into MRI versus catheterization. This study showed
hat the patients undergoing catheterization had higher
ates of minor adverse events and longer post-study hospital
tays, and found no detectable differences in immediate or
hort-term post-operative outcomes (209). However, they
pecifically did not randomize patients with suspected vas-
ular lesions or hemodynamic compromise as these patients
ll had catheterizations.
The need for pre-Stage II catheterization remains a
ontroversy in the literature. For those with clearly no
emodynamic or anatomic vulnerabilities, the studies sup-
ort the ability of good-quality echocardiograms and MRIs
o supply pre-operative data (171,204,205,208–210). In thesetting of coarctation, pulmonary artery or vein stenosis,
APCs, VVCs, or elevated PVR, the data remain mixed
(190,209,211). Center preference for angioplasty versus
surgical repair for pulmonary artery stenosis and coarctation
clearly affects the decision for noninvasive imaging versus
catheterization. Finally, the inability to coil collateral vessels
with MRI remains a reason for some institutions to support
catheterization prior to Stage II (211), despite the lack of
data with regard to its impact on long-term morbidity or
outcomes (180–182,212).
Outcomes. The mortality for Stage II remains low.
Among several large recent series, hospital mortality was
virtually zero with a 1-year survival of 95% (193,213).
Patients undergoing Stage II at an earlier age do have
increased utilization of hospital resources and are initially
more cyanotic (Fig. 5) (193). Patients undergoing earlier
Stage II appear to progress to Fontan completion in the
usual fashion (214). As a consequence, indications for Stage
II have changed from an arbitrary age criteria to patient-
specific factors such as worsening cyanosis, congestive heart
failure, decreased function, and/or poor weight gain (215).
Stage II is frequently combined with additional procedures
to address arch obstruction, a restrictive atrial septal defect,
or tricuspid valve insufficiency.
General complications. Complications following Stage II
are substantially less than following Stage I. The complica-
tions center on the procedure itself and the unique physi-
ology of the cavopulmonary connection. Venous return
from the superior circulation, head, and arms, including the
Figure 5
Oxygen Saturation by Age at Surgery for
Stage II Palliation
Patients undergoing early (4 months) Stage II palliation initially had lower arterial
saturation although they were not different than older patients at the time of hospi-
tal discharge. Reprinted with permission from Jaquiss et al. (193).substantial cerebral blood flow, is directed across the pul-
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sine qua non of this procedure. The elevation of CVP is due
to the in-series addition of the pulmonary vascular bed to
the SVC drainage. SVC pressure early after Stage II is
commonly in the high teens, but more significant elevation
will result in impaired cerebral blood flow and a decrease in
pulmonary blood flow resulting in cyanosis (213). This
constellation is recognizable as SVC syndrome and requires
prompt investigation into identification of reversible causes,
including SVC anastomotic narrowing, pulmonary artery
hypoplasia., or a restrictive atrial septal defect (216–218).
Through the same mechanism of backward transmission of
elevated pressure to the pulmonary veins and pulmonary
artery, severe tricuspid valve insufficiency or an elevated RV
end-diastolic pressure can also result in elevation of CVP.
Mechanical ventilation will raise intrathoracic pressure,
adding to the pressure needed to drive blood across the
pulmonary vascular bed. Early extubation will result in a
decrease in CVP and should be part of the post-operative
management strategy of patients following Stage II surgery
(217). The use of pulmonary vasodilators such as inhaled
nitric oxide or sildenafil may be effective in the patient with
a borderline or reactive pulmonary vascular bed (219,220). If
no anatomic issue is identified, and elevation of the CVP
and cyanosis persist despite pulmonary vasodilator therapy,
takedown to an arterial source of pulmonary blood flow
should be considered. Additional causes of cyanosis (SaO2
70%) early after Stage II include pulmonary parenchymal
disease resulting in pulmonary venous desaturation. Venous
collaterals that diverting flow from the SVC can also result
in excessive cyanosis by decreasing pulmonary blood flow
(221). The CVP helps to differentiate the causes of cyanosis
following Stage II. If the CVP is elevated, then anatomic
obstruction, tricuspid valve insufficiency, elevated RV end-
diastolic pressure, and pulmonary parenchymal disease
should be considered. If the CVP is low, venovenous
collaterals are more likely.
Additional complications include arrhythmias, phrenic
nerve injury, and embolic complications. The most common
arrhythmia following Stage II is sinus node dysfunction.
This is more common following the hemi-Fontan than the
bidirectional Glenn shunt, presumably, but is an early
phenomenon, and by hospital discharge, the incidence is
equal (6% to 8%) between the 2 (191). Phrenic nerve injury
can occur during Stage II because the nerve comes into
jeopardy during dissection of the SVC (222). Inability to
wean from positive-pressure ventilation may be an indica-
tion for diaphragm plication. With the obligatory right-to-
left shunt, patients following Stage II are at risk of embolic
complications, especially from femoral or lower extremity
intravenous access (223). Anticoagulation is commonly used
to prevent thrombotic complications in small infants with
central venous lines in place, and care should be taken to
prevent air bubbles from entering intravenous lines.Pleural effusions. All patients with single-ventricle physi-
ology, particularly those with HLHS, are at increased risk
for developing effusions in the pleural, pericardial, and
peritoneal spaces (224–227). The rate of pleural effusions in
patients with functional single ventricles ranges from 12% to
45% (228–231). Persistent pleural effusions may require
long-term chest tube drainage, dietary modifications, reple-
tion of serum proteins (clotting factors, immunoglobulin,
and albumin), fluid restriction, introduction of medications,
and further procedures (228,230,232). Effusions are the
principal cause of prolonged hospital stays following single-
ventricle palliative surgeries (230). Therefore, care of the
child with HLHS necessitates careful attention to factors
that contribute to effusions and vigilance to prevent effusive
complications.
On the most fundamental level, effusions result from
either physical disruption of capillaries and lymphatic ves-
sels, or physiological disruption of their function. Condi-
tions that support the development of effusions when the
vessels are intact include high hydrostatic pressure and/or
low oncotic pressure in the vascular space, and low hydro-
static pressure and/or high oncotic pressure in the tissue
compartment or potential spaces. Among patients with
HLHS, the specific hemodynamic characteristics that favor
these conditions include elevated RV end-diastolic pressure
(231) (such as from poor ventricular compliance or signifi-
cant neoaortic valve regurgitation), tricuspid valve stenosis
or regurgitation, obstruction at the atrial septal level or
pulmonary veins, elevated PVR (233), obstruction at any
level between the systemic and pulmonary microvasculature,
and significant aortopulmonary collaterals (230). The inad-
vertent surgical disruption of lymphatic channels during
repair may increase oncotic pressure in tissue spaces and
potential spaces due to extravasation of chylous fluid and
compromise of local lymphatic function.
Factors that enhance the degree to which vascular and
lymphatic structures behave as porous membranes also
promote the development of effusions. In patients with
HLHS, activation of the inflammatory and complement
cascades during the course of surgical interventions may
induce capillary leakage (234). Hormonal influences that
contribute to fluid retention and elevated systemic venous
pressures, such as elevated aldosterone (235) and atrial
natriuretic hormone (236) may also promote effusions.
Strategies aimed to prevent or reduce effusive complica-
tions address these hydrostatic, oncotic, inflammatory. and
hormonal factors. Most data about such interventions
around Stage II come from retrospective reviews. In 42
patients with HLHS undergoing bidirectional Glenn oper-
ations, a reduced incidence of persistent pleural effusions
was associated with use of the Sano modification versus use
of the BT shunt in the Stage I palliation. Hypothetically,
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pulmonary artery diameter and less discrepant branch pul-
monary artery sizes), also associated with use of the Sano
approach, may have led to improved pulmonary artery
hemodynamics (237). In a series of patients with functional
single ventricles, the presence of accessory pulmonary blood
flow was associated with a 8-fold increase in risk of
prolonged pleural effusions following bidirectional Glenn
(238). These authors postulated that accessory pulmonary
blood flow may increase pressures in systemic venous
pathways, “steal” from systemic circulation, contribute to
low systemic cardiac output, and promote activation of the
renin-angiotensin system. Further review of 142 such cases
suggested that elimination of accessory pulmonary blood
flow was associated with significantly improved survival and
reduced incidence of persistent effusions (233).
Several perioperative strategies are generally considered to
improve hemodynamics and reduce the likelihood of effu-
sions after Stage II palliation (Table 2). Despite judicious
care to prevent or minimize pleural effusions following Stage
II palliation for HLHS, some patients suffer with prolonged
pleural effusions. If the effusions persist, a stepwise increase
in therapy is commonly employed: low-fat diet, medical
therapy with an angiotensin-converting enzyme (ACE)
inhibitor or octreotide, total parenteral nutrition, explora-
tion for identification of a lymphatic leak, thoracic duct
ligation, and pleurodesis (227,239,240).
Stage III (Fontan Operation;
Total Cavopulmonary Connection)
In 1971, Dr. Francois Fontan became the first to place the
pulmonary and systemic circulations in series with one
Table 2
Strategies for Reducing the Likelihood of
Effusion Development Following Stage II Palliation
● Minimize anatomical obstructions in cavopulmonary circuit
● Optimize atrioventricular and semilunar valve function
● Maintain lowest central venous pressure possible (using ultrafiltration and
diuretics)
● Minimize pulmonary vascular resistance (using selective and nonselective
pulmonary vasodilators)
● Enhance systemic output (using inotropes and systemic afterload reduction)
● Enhance diastolic function (using lusitropic agents)
● Minimize systemic inflammatory response (using ultrafiltration and anti-
inflammatory therapies)
● Reduce lymphatic flow (avoiding enteral exposure to long-chain fatty acids,
considering the use of the somatostatin analog, octreotide)ventricle, creating the named procedure (241). This originaloperation, as well as several modifications, was soon realized
to be of benefit, not only to patients with tricuspid atresia,
but to many patients with single-ventricle physiology. In
1988, de Leval et al. introduced the concept of the total
cavopulmonary connection (TCPC) as an alternative to the
atriopulmonary Fontan (Fig. 6), and by the early 1990s,
staging towards the TCPC (i.e., the 3-stage approach) was
being advocated (109,242).
Although the Fontan circulation has become the accepted
final arrangement for the single-ventricle pathway, contro-
versy in timing of the TCPC still remains. Many complete
the Fontan circulation when children are 2 to 3 years of age
to minimize the end-organ exposure to cyanosis (243,244).
However, other programs delay Fontan until it is physio-
logically indicated (i.e., decreasing saturations or symptoms
of cyanosis with activity) and therefore complete the Fontan
in the 3- to 5-year-old timeframe (245). This strategy may
be supported by the literature demonstrating that younger
age at Fontan is associated with prolonged recovery and
Fontan failure (244,246,247). Regardless of timing, the
Fontan circulation results in several physiological and ana-
tomic consequences stemming from the increased pressure
seen in the Fontan circulation and include right atrial
dilation, inefficient flow dynamics, baffle thrombus, repeated
subclinical pulmonary emboli, and atrial arrhythmias. These
can coalesce to cause the Fontan circulation to fail
(248–250). This is magnified in HLHS patients in whom
there is a systemic RV and accompanying tricuspid valve,
which are at risk for failure over time. RV dysfunction will
lead to dilation and tricuspid insufficiency. Likewise, pri-
mary tricuspid insufficiency will lead to RV volume overload
and dysfunction (251). This potential for negative synergy
merits an aggressive approach towards tricuspid valve repair
at the time of TCPC that is essential for longevity.
Extracardiac Conduit Versus Lateral Tunnel Fontan
The lateral tunnel (LT) Fontan connection has been the
most extensively studied and most used configuration for
completion of the TCPC. The use of the extracardiac
conduit (ECC) technique to complete the Fontan, connect-
ing the inferior vena cava to the pulmonary arteries via a
conduit (most often Gore-Tex [W. L. Gore & Associates,
Elkton, Maryland] and ranging in size from 18 to 24 mm,
most commonly 18 to 20 mm), was introduced in 1990
(252), although it was not until this past decade that it
gained widespread popularity. The ECC has several theo-
retical advantages, including flexibility in anatomically dif-
ficult situations (i.e., heterotaxy), the avoidance of sinus
node manipulation, decreased suture lines and pressure in
the right atrium (decreasing arrhythmogenic potential), low
potential for dilation, and avoidance of cardioplegic arrest
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even circulatory arrest may preserve cardiac function,
though this has not been clearly demonstrated when study-
ing all single ventricles undergoing Fontan (254,255). Ad-
vantages for the LT include growth potential and all of the
advantages associated with the avoidance of a conduit,
particularly in the low-pressure, right-sided circulation,
which include the risk of thromboembolism. As with
the ECC, these theoretical LT advantages have not been
clearly demonstrated (253,255). Fluid dynamic, geometric,
and mathematical models have confirmed the hemodynamic
advantages of both the LT and ECC techniques
(256,257).
Even though the advantages of avoiding cardiac arrest,
systemic cooling, and extensive atrial manipulation appear
obvious, studies comparing the LT and ECC Fontan
procedures have not consistently shown an advantage of
either technique (253–255). Also, there are many series
reporting excellent outcomes in which either the ECC or
LT strategy is almost exclusively used (245,258–261).
HLHS patients are unique patient cohorts that often
highlight subtle differences between surgical and medical
therapies because of their tenuous hemodynamic state and
reliance on a systemic RV and tricuspid valve. Unfortu-
nately, there has not been a study in this cohort to see
whether the theoretical advantages of either the LT or ECC
Fontan are magnified to a point of consistently changing
Figure 6
Fontan Surgical Techniques
The original atriopulmonary Fontan (A) has been replaced with the lateral tunnel (B)outcomes.Fenestration. Fenestration has been employed to minimize
post-operative complications, including low post-operative
cardiac output, pleural and pericardial effusions, and ascites,
as well as long-term complications such as diminished
exercise performance, and protein-losing enteropathy
(PLE) (246,262–266). Despite the potential benefits of
fenestration, drawbacks include the risks of systemic embo-
lization, systemic desaturation, and need for late catheter
interventions for fenestration closure (264,267,268). There
have been a number of studies including one from the
Pediatric Heart Network Fontan cross-sectional study
group (269), as well as a prospective randomized study by
Lemler et al. (266) that have demonstrated that fenestration
decreases length of post-operative pleural effusions requiring
chest tubes and hospital length of stay.
The emergence of the ECC Fontan in many programs
has led to questioning the need for fenestration, and several
centers have adopted a highly selective strategy for Fontan
fenestration with encouraging and possibly even better
results than those after fenestrated Fontan (245,270–272).
Fenestration is reserved for the highest-risk patients, which
may include those undergoing significant concomitant pro-
cedures or single-lung Fontan palliation, patients with
elevated PVR or transpulmonary gradient, those having
significant atrioventricular valve regurgitation or poor ven-
tricular function, and patients with intracardiac anatomy not
amenable to extracardiac conduit (263,264). HLHS patients
xtracardiac conduit (C) Fontan. Reprinted with permission from de Leval (488).and eare at particular risk for poor systemic ventricular function
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require fenestration more often than patients with other
types of single ventricles. However, this has not been
consistently seen in centers that are using fenestration
selectively (245). These centers believe that the HLHS
candidates for TCPC currently are better candidates than in
the past because of the advances in all aspects of patient
management, from improved outcomes after first- and
second-stage single-ventricle palliation, as well as better
medical management and interstage surveillance. Centers
using the nonfenestrated Fontan strategy also tend to
palliate their patients at an older age (3 to 5 years)
(243,245). Salazar et al. (245) reported similar outcomes
over a 6-year period whether patients were fenestrated or
not. The nonfenestrated patients had a shorter hospital and
intensive care unit length of stay and less need for re-
intervention. These outcomes are confounded by the higher
rate of extubation in the operating room for nonfenes-
trated patients, which this center, in the past, has shown
to result in a shorter duration of intensive care unit and
hospital stay, chest tube requirement, and lower resource
utilization. The immediate reduction in Fontan baffle
pressure and ability to mobilize these patients early may
explain these findings (273).
As the pre-operative state (i.e., hemodynamics and/or
age), operative techniques (i.e., ECC), and post-operative
care (i.e., immediate extubation and mobilization) of Fon-
tan patients continue to change, the benefit of fenestration
must be readdressed. It is also very important to realize that
practices and patient populations (i.e., ventricular morphol-
ogy, age at Fontan, operating room extubation) at different
centers may vary greatly and thus so may the usefulness of
fenestration in any particular practice. With this in mind,
the cohort of HLHS should be separately evaluated in the
current era with regard to fenestration, controlling for
important factors such as age.
Cardiopulmonary bypass. In the late 1990s, with the
spreading popularity of the ECC Fontan, surgeons began to
investigate how completion of the TCPC could occur
without cardiopulmonary bypass. Starting in 1998, a series
of reports from different centers established the feasibility
and safety of avoiding bypass when creating an ECC Fontan
(274–277). The proinflammatory and vasoactive substances
caused by cardiopulmonary bypass and their ill effect on the
myocardium, the coagulation system, and the pulmonary
vasculature have been well established (234). However, this
relationship is dependent on time, the conduct of bypass,
and many other factors. Therefore, whether avoidance of
bypass during Fontan completion has clinical significance is
unclear. Off-bypass Fontan completion has been demon-
strated to attenuate proinflammatory markers; however,multiple studies have been unable to establish consistent
clinical improvements (278,279). The largest and most
recent series to evaluate Fontan completion without cardio-
pulmonary bypass found no difference in immediate post-
operative pressures or in early outcomes including chest tube
drainage, arrhythmias, or mechanical ventilation (280).
Although avoidance of cardiopulmonary bypass at comple-
tion Fontan in HLHS is safe and can be done with
consistent results, it appears at this juncture to have no
clinical benefit to patient care and will require more study if
it is to become widely adopted.
Outcomes. Hospital mortality after Fontan completion for
HLHS is excellent, with short-term survival averaging
95% (258,259,281,282). Intermediate and long-term sur-
vival rates are 77% to 95% at 5 years and 72% to 91% at 10
years (245,258,281). Right ventricular morphology contin-
ues to be a risk factor highly associated with long-term
mortality and heart failure after Fontan.
Fifty percent to 70% of newborns with HLHS will
survive the 3 surgeries and live to the age of 5 (31,79,283).
Increasingly, there is recognition that the major determi-
nants of outcome following surgical intervention for HLHS
have less to do with intraoperative support strategies than
with patient-related factors such as gestational age, associ-
ated genetic syndromes, and genetic susceptibility, such as
apolipoprotein polymorphisms (284,285).
International Experience
Although a complete review of the international perspective on
HLHS is beyond the scope of this paper, differences exist in
both logistical and management approaches to the patient with
HLHS. Perhaps one of the greatest differences between the
United States and abroad is the concept of regionalization.
Larger center volumes and regionalization of patients
with complex congenital heart disease has been shown to
improve outcomes (286). Numerous countries, including
Sweden and the United Kingdom, and the continent of
Australia use this approach in the treatment of children with
congenital heart disease, especially HLHS.
As in the United States, pre-operative management
strategies are not standardized (26). In some centers in
Germany, for example, to minimize pulmonary hyperper-
fusion and an increase in vascular resistance, avoidance of
pre-operative ventilation and inotropic support are com-
bined with systemic afterload reduction (29).
Most European centers perform the Norwood operation
with a modified BT shunt rather than an RV-PA conduit,
although some centers have adopted this modification with
improved outcomes (283). A small number advocate the
hybrid approach (131), and transplantation as an initial
option is rarely used due to poor donor availability. In the
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phosphodiesterase inhibitors, sodium nitroprusside, or the
alpha blocker phentolamine (83). Phenoxybenzamine is
rarely in use in Europe due to the long half life.
The bidirectional Glenn is preferred over the hemi-
Fontan for the second stage, whereas for the final stage,
great differences exist in the type of procedure performed
and the timing. One explanation of the timing differences
(Germany early, United Kingdom later) could be insurance
system related. Both the use of fenestrations and/or antico-
agulation varies throughout Europe.
Pleural Effusions
The same principles underlying the development of effu-
sions in the patient with HLHS undergoing Glenn or
hemi-Fontan repairs apply to the patient proceeding to
Fontan. In particular, specific hemodynamic factors that
seem to increase the incidence of pleural effusions include
higher mean pre-operative pulmonary artery pressure
(230,287) and higher mean post-operative CVP (230).
Retrospective data comparing bypass versus off-bypass pro-
cedures, LT versus ECC, and modified ultrafiltration versus
none have mixed results (255,279,287,288). However, a
prospective randomized trial of the Fontan with and with-
out fenestration suggests use of fenestration decreases the
duration of post-operative effusions and reduces the length
of hospital stay (266). Fenestration may result in creation of
a “pop-off valve” to reduce CVPs and thereby reduce the
hemodynamic conditions that lead to pleural effusion, partic-
ularly for patients with high pulmonary vascular resistance.
One retrospective review of nearly 100 patients undergo-
ing Fontan suggested that operating during the winter
respiratory viral season was associated with a higher risk of
pleural effusions (230). As a result, some have suggested that
if the Fontan cannot be postponed past the respiratory viral
season, screening for subclinical respiratory syncytial virus
may detect patients at high risk for effusive complications
and other morbidities.
Chronic Medications
Afterload reduction. Increased afterload is a fundamental
feature of baseline hemodynamics in patients with HLHS.
In patients with good functional outcome following the
Fontan repair, preload conditions and ventricular contrac-
tility may be normal, but measures of increased afterload
(including arterial elastance, end-systolic elastance and pres-
sure, and CVP) account for reduced cardiac index and
exercise performance (289). In single-ventricle patients,
reducing both systemic afterload and PVR might theoreti-
cally improve cardiac performance and clinical outcome. (Most large centers discharge HLHS patients on ACE
inhibitors (27), and ACE inhibitors have documented
success in treating children with heart failure (290). How-
ever, case-control studies of captopril and enalapril, and
randomized, controlled trials of enalapril and lisinopril
suggest that ACE inhibitors are not associated with de-
creased pleural drainage or effusions in the weeks following
Fontan surgery (235,291), improved exercise capacity years
following surgery (288), general somatic growth, favorable
ventricular remodeling and function, or Ross classification
of congestive heart failure (292,293).
ACE inhibitors may be associated with improved neuro-
developmental outcome (292), improved endothelial func-
tion (294), and reduced renal injury (295) following the
Fontan. Therefore, on a case-by-case basis, each patient on
ACE inhibitors should be monitored to ensure that mea-
surable benefit justifies use. Angiotensin receptor blockers,
such as valsartan, are newer afterload-reducing agents em-
ployed in pediatric cardiovascular diseases, but no evidence
exists for use in patients with HLHS following any stage of
palliation.
Success in treating children with pulmonary hypertension
and recent understanding of endothelial dysfunction in
patients with single ventricles (295) and patients with
Fontan circulation (296) has led to use of selective pulmo-
nary vasodilators and endothelin receptor blockers. Use of
sildenafil, a phosodiesterase-5 inhibitor, improved plastic
bronchitis in a single case of a child with HLHS following
Fontan surgery (297). A randomized, controlled study of
sildenafil showed that a single dose improved cardiac index
and exercise capacity in teens and young adults with Fontan
circulation (298), and a recent abstract reporting on a
double-blind, placebo-controlled crossover trial in 28 chil-
dren and teens with Fontan circulation suggests sildenafil
improves myocardial performance and may increase cardiac
output (299). The dual-endothelin receptor antagonist,
osentan, has also been associated with improved symptoms
nd reduced pulmonary artery pressure, pulmonary vascular
esistance, and pulmonary blood flow in patients with
ontan circulation (300–302). Further trials of these after-
oad reducers in patients with HLHS would clearly be
arranted and helpful.
nticoagulation and hematologic issues. Thromboembolic
vents (TE), which occur more frequently after Fontan
peration than for any other form of cardiac surgery except
rosthetic valve replacement, may be due to inherited,
cquired, and/or associated factors (e.g., cyanosis) (303).
ne-quarter of patients with Fontan physiology are at risk
or the development of thrombus in the venous system
ecause of the low-flow state of the cavopulmonary baffle
267). Levels of protein C, factors II, V, VII, IX, and X,
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significantly lower in Stage I infants (304). Stage II patients
have significantly lower levels of protein C, protein S,
ATIII, and factors II, V, VII, and X (305). Despite these
coagulation factor abnormalities, these patients do not
commonly have an increased risk for clinical TE complica-
tions, with the isolated documented exception being Stage
II patients with elevated levels of factor II and low levels of
ATIII (306). Fontan patients have been shown to exhibit
low levels of protein C, factors II, V, VII, and X, plasmin-
ogen, and ATIII, and elevated levels of factor VIII. Mon-
itoring factor VIII level may help identify a subset of
patients at risk for thrombosis, especially those with low
levels of protein C (307).
Thromboembolic events after Fontan occur in a bimodal
distribution peaking during the first post-operative year,
and again 10 years later (249,308 –312). Several cross-
sectional series report the incidence of TE to be between
0.8% (313) and 33% (314), and mortality following TE is
as high as 25% in pediatric series (315). Risk factors for
thrombosis include dehydration, low-flow state, stasis in
the Fontan or pulmonary circuit, increased venous pres-
sure, right-to-left shunt, hepatic dysfunction, PLE, pro-
longed post-operative immobilization, azygous continu-
ation of the inferior vena cava (316), blind cul-de-sacs,
prosthetic material, hypercoagulable states, ventricular
dysfunction, atrial arrhythmias, and pulmonary embo-
lism. The incidence of cerebrovascular accidents is re-
ported as 1.4% to 19% (311,315).
There is no consensus in the literature as to the optimal
type of anticoagulation therapy or whether therapy is
warranted at all (309,317,318). Aspirin is often used at a
dose of 1 to 5 mg/kg/day. Clopidogrel, a glycoprotein
IIb/IIIa inhibitor and antiplatelet aggregation agent, may
provide an additive antiplatelet effect if combined with
aspirin. Mutations in the CYP2C19 gene render certain
patients unable to respond to clopidogrel. Warfarin is a
vitamin K antagonist and is usually recommended in Fontan
patients with documented thrombosis, poor hemodynamics
(with or without chronic venous hypertension), those un-
dergoing Fontan revision, and those with atrial tachyar-
rhythmias (310,318,319).
A recent multicenter, prospective, randomized trial com-
paring heparin/warfarin with aspirin as primary throm-
boprophylaxis found no significant difference in safety or
efficacy in the first 2 years after Fontan. In the 111 patients
(57 received aspirin, 54 received heparin/warfarin), the
overall thrombosis rate was 23% (18% aspirin, 9% heparin/
warfarin) despite medical prophylaxis. Major bleeding oc-
curred in 1 patient in each group (320).Patients with thrombosis while receiving aspirin should
be switched to warfarin or low molecular weight heparin
(LMWH). Although LMWH has become more commonly
used in pediatric patients due to its ease of monitoring
(anti-factor Xa level 4 h after an injection) and its relative
lack of interference by other drugs or diet, there is no
consensus on the benefits of LMWH over warfarin, and
reports of failure of LMWH as bridging therapy exist.
Thrombolytic therapy is reserved for those patients with
thrombosis of immediate clinical importance. Tissue plas-
minogen activator, which converts endogenous plasminogen
to plasmin, is most commonly employed. There are a
significant number of bleeding complications associated
with thrombolytic therapy in children, occurring in 30% to
68% of patients (321).
Currently, long-term anticoagulation therapy is influ-
enced by the provider’s preference, anticipated risk for
thrombosis, presence of arrhythmias, and patient’s func-
tional status. As a result of the multiple factors contributing
to thrombus formation, it is unlikely that a single therapy or
drug will provide complete prophylaxis.
Long-Term Outcomes
The original selection criteria for patients undergoing atrio-
pulmonary connection for tricuspid atresia were laid out by
Choussat and Fontan (Table 3) and remain relevant phys-
iologic risk factors for Fontan outcomes (322). Because
Fontan physiology requires systemic venous baffle pressure
to be higher than left atrial pressure in order for the systemic
and pulmonary circulations to work in series, many of the
long-term outcomes post-Fontan may be a reflection of this
relatively elevated pressure in the systemic venous system.
Over the past 2 decades, the outcome after Fontan
operations has improved, with actuarial survival of 87% at
20 years in one study for all underlying diagnoses (265). The
current literature on long-term outcome after the Fontan
operation reflects primarily single LV physiology; however,
studies increasingly include single RVs and mixed physiol-
ogy. Regardless of underlying diagnosis, late complications
present ongoing management challenges in the adult Fon-
tan patient. These long-term outcomes (262) include im-
paired systemic ventricular systolic and diastolic function,
progressive hypoxemia, elevated pulmonary vascular resis-
tance, and complications including arrhythmias, thrombo-
embolism, and hepatic dysfunction. Maximal exercise tol-
erance is impaired in individuals with a Fontan and worsens
with age as well. The majority of these changes, demon-
strated late after Fontan operation, are not specific to
HLHS. However, “failing Fontan” physiology, including
the development of plastic bronchitis and PLE, may be
increasingly prevalent in the HLHS Fontan population.
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intermediate-term mortality; however, it is associated with
poorer ventricular and valvular function, as well as heart
failure–related death in the long term (323). Gradual
attrition in Fontan patients is most frequently secondary to
thromboembolic or heart failure–related deaths and sudden
cardiac death (thought to be associated with arrhythmia).
Risk factors associated with late thromboembolic mortality
include lack of antiplatelet or anticoagulant therapy and
intracardiac thrombus, whereas heart failure–related mor-
tality is predicted by the development of PLE, high right
atrial pressures, and single RV morphology (281), and
therefore may become more prevalent as the HLHS Fontan
population ages.
Long-term outcomes in the Fontan circulation are re-
flected in exercise capacity. These individuals demonstrate a
unique physiological response to exercise, and although
there is a range of exercise responses, most individuals have
reduced exercise tolerance. The etiology of this limitation is
multifactorial and involves cardiac, pulmonary, systemic
venous, and muscular contributions. Most well defined is an
inadequate preload reserve limiting inotropic cardiac aug-
mentation (324). During exercise, the increase in pulmonary
blood flow leads to an increase in pressure, because the
pulmonary vasculature is unable to vasodilate as in normal
biventricular physiology. This increased demand is reflected
into the Fontan circulation, and without a subpulmonary
ventricle to increase pressure, LV filling is diminished and
cardiac output does not increase normally. There is likely
also diastolic dysfunction of the single ventricle with aging
that further impairs passive LV filling (325).
These physiological changes can be measure with cardio-
pulmonary exercise testing (326). In patients with Fontan
Table 3
Original Criteria for Fontan’s Operation:
The “10 Anatomic and Physiologic Commandments”
● Age 4–15 yrs
● Sinus rhythm
● Normal drainage of the caval veins
● Normal right atrial volume
● Low pulmonary artery pressure (15 mm Hg)
● Pulmonary resistance 4 WU/m2
● Adequate pulmonary artery size (PA/AO ratio 0.75)
● Normal ventricular function
● No mitral insufficiency
● No pulmonary artery distortion (from the BT shunt)AO  aorta; BT  Blalock Taussig; PA  pulmonary artery; WU  Wood units.circulation, peak oxygen uptake is diminished for age, peak
heart rate is decreased, with likely chronotropic incompe-
tence, and arterial oxygen saturation is also decreased at
peak exercise. Cardiac output is subnormal, secondary to
reduced stroke volume, heart rate response, and diminished
pulmonary venous return. Ventilatory anaerobic threshold is
below normal values, and the ventilatory equivalent for
carbon dioxide is higher than normal ranges for age. With
training and cardiac rehabilitation, many of these parame-
ters may demonstrate improvement (327). Further study
of the effect of structured cardiopulmonary rehabilitation in
the adult Fontan patient are underway.
“Routine” Follow-Up and Testing
As improved early outcomes lead to greater longevity in
post-Fontan patients, caregivers are increasingly faced with
recognizing and managing long-term complications of Fon-
tan physiology including the “failing Fontan.” The failing
Fontan population is broad and may include individuals
limited by impaired ventricular function but also includes
patients with preserved ventricular function with additional
devastating and challenging complications such as PLE and
plastic bronchitis. Essential to treatment in these patients is
vigilance and a high index of suspicion to make an early
diagnosis, with hopes that persistent optimization of the
entirety of the Fontan circulation and physiology will aid in
decreasing the rates of “failing Fontan” as the new genera-
tion of HLHS patients age.
There are no standard algorithms for long-term follow-up
of children and adults who have undergone staged palliation
for HLHS, but suggested guidelines have been published
(328). The Fontan circulation is an unnatural cardiovascular
state with risk for pathophysiological aberration that does not
diminish over time. In fact, risks likely increase as these
patients age. Patients with Fontan physiology have elevated
systemic venous pressure, low cardiac output, and endothelial
dysfunction (329–331). Over their lifetime, these significant
morbidities require aggressive long-term follow-up and surveil-
lance with cardiac testing to identify potentially serious com-
plications. Moreover, transition to adult congenital heart dis-
ease specialists should occur as patients enter adulthood. Of
note, the oldest patients with HLHS who have experienced
“current” Fontan strategies are only now entering their third
decade of life, and as such, the long-term consequences of the
Fontan physiology in the setting of a single RV remain
unknown.
If patients are clinically well without significant compli-
cations, visits to the cardiologists can be every 6 to 12
months. In addition to routine vital signs, physical exami-
nation should include pulse oximetry and upper and lower
extremity blood pressures (to assess for recurrent distal arch
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be asked about development of diarrhea and/or abdominal
swelling (signs of PLE), palpitations, and syncope and
exercise intolerance. Testing at regular intervals should
include echocardiography, electrocardiograms, Holter mon-
itoring, and exercise stress testing. Some suggest the addi-
tion of other tests to this long-term regimen including
cardiac MRI, cardiac catheterization, and laboratory screen-
ing for PLE, coagulation, and/or hepatic abnormalities.
Echocardiography as a screening tool is useful to assess
for ventricular dysfunction, tricuspid regurgitation, and
function of the neoaortic root and valve. Neoaortic root
dilation and valve regurgitation are common after the
Fontan palliation and have as yet unknown long-term
consequences (332). Echocardiography can be useful in
identifying thrombus formation though thrombus can be
missed on transthoracic imaging. If there is a high index of
suspicion, transesophageal echocardiography may be re-
quired (314,318). In patients with known thrombus forma-
tion, a coagulation profile with consultation from hematol-
ogy is warranted.
Assessment for symptomatic and asymptomatic arrhythmias
is useful as many can be treated with medical therapy. Elec-
trocardiograms and Holter monitors may identify some of
these rhythm disturbances. When symptoms are infrequent,
transtelephonic event monitoring may be useful. Exercise stress
testing is also useful to determine whether there is sinus node
dysfunction or exercise-induced arrhythmias.
More controversial is whether other monitoring should
be routinely performed in patients with HLHS after the
Fontan procedure. Cardiac MRI, though noninvasive, often
requires conscious sedation. The benefits of cardiac MRI
include accurate assessment of ventricular ejection fraction
and cardiac output, good visualization of branch pulmonary
arteries, and estimation of the impact of aortopulmonary
collaterals on the Fontan circulation (333,334). Echocardi-
ography cannot accurately and consistently provide the same
information and some suggest routine cardiac MRI every 3
to 5 years after the Fontan procedure. Cardiac catheteriza-
tion is no longer routinely performed after Fontan comple-
tion because of the inherent risks of an invasive procedure.
However, catheterization provides important hemodynamic
information and allows for catheter-directed interventions
such as fenestration enlargement or closure, coil emboliza-
tion of aortopulmonary collateral vessels, and dilation of
residual or recurrent distal arch obstruction. In some cen-
ters, cardiac catheterization is recommended in the asymp-
tomatic HLHS patient 3 to 5 years after Fontan and/or
before they transition to adult cardiology caretakers (328).
Liver pathology runs the spectrum of congestion to
cirrhosis and hepatocellular carcinoma after the Fontanoperation (335). Some patients with failing Fontan circula-
tion are found to have hepatic cirrhosis and thus are no
longer candidates for cardiac transplantation, whereas oth-
ers have undergone heart–liver transplant. Unfortunately,
there is no good screening tool for cirrhosis. In patients with
Fontan circulation, abnormal liver histology may be patchy
and missed on single liver biopsies. No laboratory values
definitively make the diagnosis or are markers for early
stages of the disease (336). Despite these obstacles, some
suggest that screening for liver abnormalities should be a
part of routine follow-up in patients with Fontan physiology
and that a liver biopsy before adulthood is warranted. Both
PLE and hepatic cirrhosis require consultation with gastro-
intestinal specialists.
Associated Conditions
Protein-losing enteropathy. PLE is an excessive loss of
proteins across the intestinal mucosa, and its occurrence in
Fontan patients was first reported in 1980 (337). Loss of
protein in the bowel may be secondary to lymphatic disten-
sion as a result of elevated systemic venous pressure;
however, PLE has been seen in patients with normal
Fontan pressures, and the exact etiology of PLE remains
elusive. Presenting symptoms include peripheral edema,
ascites, and pleural or pericardial effusions, unlike the
gastrointestinal symptoms of diarrhea and abdominal pain
seen in patients with a primary gastrointestinal, rather than
cardiac, etiology (338).
The prevalence of PLE as cited in the literature ranges
from 3.7% to 24% (339), with a cumulative risk at 10 years
of 13.4% (338). Risk factors associated with PLE include
non-LV anatomy as in HLHS, long hospital stay at the
time of Fontan surgery, prolonged cardiopulmonary bypass
time, and renal failure in the immediate post-operative
period (338,340). High systemic venous pressure, elevated
right atrial diastolic or ventricular end-diastolic pressure,
and high mesenteric vascular resistance (341,342) have all
been associated with PLE in Fontan patients (343). Neither
medical nor surgical interventions guarantee complete res-
olution in all patients with PLE. PLE after Fontan opera-
tion is associated with a very high mortality and morbidity
rate with a 5-year actuarial survival rate of 46% (338,344);
transplantation does improve overall survival in this subset
of patients (345). The diagnosis of PLE is made clinically
with supporting lab results including hypoalbuminemia,
hypoproteinemia, hypocalcemia, lymphocytopenia, elevated
stool alpha-1 antitrypsin, and increased alpha-1 antitrypsin
clearance.
Medical management of PLE should include treatment
optimization of medical therapy (diuretics, afterload reduc-
tion), use of parenteral albumin, and dietary changes includ-
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medium-chain triglyceride diet. Pulmonary vasodilators
(346) have been used to lower elevated Fontan pressures,
and systemic steroids (347,348) and heparin may stabilize
intestinal capillary endothelial cell membranes. Intervention
to relieve obstruction in the Fontan pathway, closure of
residual systemic to pulmonary arterial shunts and aortopul-
monary collaterals (349), and creation of fenestrations in the
Fontan circuit (350) have also been suggested. Pacing to
create atrioventricular synchrony and improve cardiac out-
put (351), conversion of the atriopulmonary Fontan (352) to
an extracardiac conduit (353), and heart transplantation
(354,355) have been proposed, though mortality remains
high.
Plastic bronchitis. Plastic bronchitis is a rare but potentially
fatal complication after Fontan operation characterized by
recurrent expectoration of long, branching bronchial casts
which may manifest as airway obstruction. Although the
pathogenesis is not well defined, similar factors to the
development of PLE may contribute, including increased
systemic venous pressure, elevated pulmonary venous pres-
sure, and endobronchial lymphatic leakage. Diagnosis is
generally made at the time of clinical pulmonary decom-
pensation, although computed tomography can identify
early stages as well as used to guide bronchoscopy or
monitor treatment response (356). Treatment modalities are
primarily reported in the literature as case reports, and
include interventions such as optimization of heart failure
therapy and similar medical therapy to PLE (357), Fontan
fenestration (358), short-term, high-frequency jet ventila-
tion in intubated patients (359), aerosolized urokinase or
tissue plasminogen activator (360), pulmonary arterial vaso-
dilators (297), thoracic duct ligation, and cardiac transplan-
tation have been proposed.
Arrhythmias. One of the major causes of long-term mor-
bidity and mortality in patients following the Fontan
procedure is arrhythmia. In a study of long-term survival of
260 Fontan patients with a median follow-up of 12.2 years,
the majority of deaths outside of the perioperative period
were classified as sudden and were presumed to be arrhyth-
mic in origin (281). The incidence of arrhythmia in Fontan
patients range from 7% to 50% depending on Fontan type,
era, and years of follow-up (361–364).
Chronic arrhythmia in the Fontan population has been
associated with multiple hemodynamic issues, and a lower
functional status has independently been associated with the
development of intra-atrial re-entrant tachycardia (IART)
following Fontan (362). Several atrial arrhythmias have
been reported following the Fontan procedure, including
atrial tachycardia, atrial fibrillation, and sinus node dysfunc-
tion (365,366). Table 4 lists potential or well recognized riskactors for the development of supraventricular tachycardia
362,367).
There have been several studies assessing the relationship
f arrhythmia formation and type of Fontan. Historically,
hese studies have suggested the extracardiac Fontan oper-
tion has a lower incidence of post-operative arrhythmias
hen compared with the LT (8% to 10% vs. 30% to 50%)
368,369). More recently, a multicenter cohort study of
ontan patients did not find a difference in the prevalence of
ART between these subgroups. This difference may relate
o patient age at the time of study.
Ventricular rates typically range from 110 to 250 beats/min
uring atrial tachycardia as opposed to the usually 50 to 70
eats/min seen when in normal sinus rhythm. Thus, persistent
ild tachycardia 100 beats/min at rest should raise the
uspicion of atrial tachycardia. Symptoms may be nonspecific,
uch as general malaise, abdominal pain, or nausea, or include
alpitations (62%), fatigue (44%), dyspnea (23%), edema
21%), presyncope (21%), or syncope (3%) due to rapid 1:1
trioventricular conduction (361). Therapeutic modalities for
cute cardioversion of IART include transesophageal or intra-
trial pacing, intravenous diltiazem or ibutilide, or synchro-
ized cardioversion; evaluation for atrial thrombus prior to
lectrical or medical cardioversion is advised as chronic antico-
gulation may be needed. Propafenone, beta-blockers, sotalol,
nd dofetilide have all been used in Fontan patients. Unfortu-
ately, medical therapy tends to be effective in only one-third
f patients (361,370).
Transcatheter ablation may decrease the frequency of
achycardia episodes and the need for repeated cardioversion
nd anti-arrhythmic drugs. Although an acute success of
2% has been reported in Fontan patients, recurrence rates
re high, ranging from 30% to 60% (371,372). Atrial
e-entry circuits tend to be multiple, and may occur in the
Table 4
Risk Factors for the Development of SVT
● Elevated pre-operative pulmonary artery pressures
● Pre-operative arrhythmia
● Older age at Fontan operation
● Type of Fontan repair
● Longer follow-up interval
● Increased right atrial size and pressure
● Sinus node dysfunction
● Heterotaxy
● Atrioventricular valve regurgitation
● Post-operative SVTSVT  supraventricular tachycardia.
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mapping techniques and higher energy sources may improve
the short-term outcome of catheter ablation, but the marked
atrial hypertrophy in atriopulmonary Fontan patients limits
catheter ablation success.
Pacemaker implantation in Fontan patients is reported to
be 23% by 20 years of follow-up (265). Pacing strategies
have progressed from basic ventricular pacing for bradycar-
dia, to sophisticated antitachycardia pacing algorithms for
atrial arrhythmias (374). Epicardial leads are generally utilized
due to limitations of venous accessibility and risk for thrombus
formation. Chronic atrial pacing may decrease atrial ectopy and
the ability to trigger tachycardia. Implantable cardioverter-
defibrillators have been used in patients following the Fontan
procedure, but no organized retrospective or prospective study
of utility or risk factors has been undertaken. Novel implant-
able cardioverter-defibrillator configurations are often re-
quired in congenital heart disease patients, specifically those
with single ventricles and usually consist of an epicardial
pace/sense lead on the ventricle and defibrillator coil placed
in the pericardial, thoracic or subcutaneous space (375).
These devices pose significant technical challenges and have
a higher failure rate than conventional devices (376).
Conversion of the initial Fontan anastomosis to an extra-
cardiac total cavopulmonary connection with arrhythmia sur-
gery and pacemaker implantation, has demonstrated the ability
to eliminate IART and atrial fibrillation, while improving
exercise capacity in selected patients (377,378). Indications for
conversion include Fontan pathway obstruction, cyanosis, ex-
ercise intolerance, and/or refractory arrhythmias. During mid-
term follow-up, the modified right atrial maze procedure,
intended to address the multiplicity of atrial re-entrant circuits,
has essentially eliminated recurrence of IART. The left atrial
maze essentially eliminates the recurrence of atrial fibrillation,
but has been associated with recurrent organized tachycardia in
approximately 15% of patients (379). The maze procedures are
not suitable for focal atrial tachycardia, or tachycardia utilizing
accessory connections; these mechanisms are ideally treated
with catheter ablation techniques. One report on 127 Fontan
conversions demonstrated a surgical mortality of 1.6% and a
subsequent need for transplantation in 6% (380). Optimal
therapeutic approaches are selected based on the type of prior
Fontan procedure, mechanism of tachycardia, and associated
comorbidities. Efforts to limit the development of bradycardia,
perhaps with earlier atrial pacing, and modification of the
Fontan surgery are needed to minimize tachycardia develop-
ment from this palliative surgical intervention.
Adult Congenital Considerations
Survival. Until recently, studies have shown those born
with HLHS in the early 1980s had 30% chance ofsurviving to adulthood (149,381). Most of the mortality
occurred early within the first year of life, and stabilized over
the next 10 years. Given the overall improvement in survival
for HLHS, larger percentages are reaching adulthood than
in the past. In a study of over 300 patients (53% HLHS) at
a single institution, from 1992 to 1999, overall 1-year
mortality following the Fontan procedure was 6.6%, and
decreased to 1% after 1994. HLHS was not associated with
increased morality compared with other univentricular anat-
omies (323). Therefore, the expectation that 70% of HLHS
patients will survive to adulthood may be achievable.
However, reaching adulthood does not imply continued
success. Outcome data for the post-surgical Fontan popu-
lation suggest the morbidity and mortality risks are substan-
tial. Since there are no long-term data regarding adults with
repaired HLHS, conclusions can be drawn from the current
Fontan population with additional caveats related to aortic
arch repair, and a systemic RV. In a multicenter study from
European adult congenital heart disease (ACHD) pro-
grams, morbidity and mortality were assessed for a variety of
CHD lesions over a 5-year period. With 4,110 patients
followed (including 198 Fontan patients), the highest mor-
tality was found in those with cyanotic heart disease and
Fontan circulation. The Fontan patients had an 8.2% 5-year
mortality. In comparison, repaired tetralogy of Fallot, co-
arctation of the aorta, and D-transposition of the great
arteries all were 3% over the same time period (382).
Although the cause of death was not specifically stated, the
Fontan patients had significant morbidity, with the overall
highest percentage of cerebral vascular accidents and su-
praventricular arrhythmias over the 5-year follow-up. Also,
the Fontan group had significant heart failure that worsened
over time, with 10% classified as heart failure functional
class III/IV. In another study from Toronto evaluating the
mean age of death in ACHD patients, those with univen-
tricular anatomy status post-Fontan had an astonishing
mean age of death 30 yrs (383). The most common cause
of death was perioperative. Therefore, assuming the re-
paired HLHS patients would, at a minimum, follow a
similar survival pattern, we would expect a continual decline
in survival once reaching adulthood.
Morbidity. Complications leading to significant morbidity
in adults after Fontan operation are well established, and the
adult with repaired HLHS carries additional “potential”
risks yet to be fully clarified. Known risks, however, include
ongoing risk of arrhythmias, thromboembolism, heart fail-
ure, exercise intolerance, PLE, Fontan circulation obstruc-
tion, pulmonary vein obstruction (right pulmonary veins
with atrial-to-pulmonary connection), hepatic dysfunction,
and cyanosis from residual or developing right-to-left
shunts.
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incidence of supraventricular arrhythmias, and 3% for ven-
tricular arrhythmias (382,384). Intra-atrial re-entry tachy-
cardia is the most common form of arrhythmia in this
population, and re-entrant circuits tend to be multiple. Any
arrhythmia presentation should initiate a work-up for he-
modynamic etiologies. Sudden death, presumably from
arrhythmias, is found to be the cause of death in approxi-
mately 30% of adults with Fontan circulation (383).
Over time, functional class seems to worsen. In a study
following 39 adults with Fontan circulation, functional class
worsened from predominately class II 10 years out from
repair, to functional class III 20 years from Fontan opera-
tion (385). A morphologic LV was associated with a higher
VO2 max. In general, patients have a lower exercise capacity
than expected with a VO2 max % predicted ranging from
55% to 63% (386). With improved surgical techniques, that
is, from atrial pulmonary connections to LT and extracar-
diac Fontan, some of the morbidity related to atrial arrhyth-
mias and heart failure will hopefully improve and will be
sustained into adulthood.
There are additional potential complications to consider
in the adult with repaired HLHS. Close attention to
ventricular function and clinical signs and symptoms of
heart failure are warranted in the adult patient, and studies
evaluating the benefits of medical therapies are indicated.
Additionally, previous studies have demonstrated aortic root
and valve abnormalities in those with repaired HLHS. In a
study of 53 patients, median follow-up of 9.2 years, 98%
developed progressive neoaortic root dilation with a z-score
2. Neoaortic valve regurgitation progressed over time in
49% (332). Therefore, with some follow-up reaching into
adolescence, early data suggest neoaortic root dilation and
neoaortic valve regurgitation are potential problems and
warrant close surveillance. Lastly, unique to the repaired
HLHS Fontan patient is an obligatory aortic arch repair.
Whether the arch will have a tendency toward restenosis,
dilation/aneurysm formation, or both is yet to be deter-
mined and also requires close surveillance. It is unclear
whether the adult with repaired HLHS will have a risk,
similar to the adult with repaired coarctation of the aorta,
for systemic hypertension, cerebrovascular disease, and pre-
mature coronary artery disease.
Follow-Up. As repaired HLHS patients enter adulthood,
the recommended follow-up should reflect our current
knowledge of potential complications as stated above. Re-
cently published ACHD care guidelines do not specifically
address the repaired HLHS patient (387). However, rec-
ommendations for the care of those with Fontan circulation
and aortic arch repair are applicable, with follow-up per-
formed by staff with expertise in ACHD: tf Lifelong, at a minimum yearly, follow-up by cardiologists;
f Periodic echocardiography;
f Periodic monitoring of liver health, including serum
albumin and liver function as well as imaging studies;
f Periodic cardiac MRI to evaluate the thoracic aorta;
f Warfarin for patients with right-to-left shunts, atrial
thrombus, atrial arrhythmias, and/or a TE;
f Close monitoring for arrhythmias and consultation with
electrophysiologists should be considered.
regnancy. Women with Fontan circulation are able to
chieve successful pregnancy and delivery. However, the
emodynamic changes associated with pregnancy, delivery,
nd post-partum period have the potential to lead to
ignificant complications. The expected increase in plasma
olume and heart rate during pregnancy would increase the
lready substantial risk for atrial arrhythmias. Cardiac out-
ut increases and systemic vascular resistance is reduced
uring pregnancy and usually is well tolerated with Fontan
irculation. However, at the time of delivery, cardiac output
ust increase further and immediately after delivery sys-
emic afterload increases along with a drop in preload from
lood loss. This set of hemodynamic changes, especially if
entricular systolic function is diminished, has the potential
o be detrimental to maternal Fontan circulation.
Thromboembolic events are increased as a consequence
f the expected hypercoagulable state during pregnancy.
ith Fontan circulation and an existing right-to-left shunt,
he risk for a cerebral vascular event would potentially
ncrease during pregnancy.
There are only limited studies retrospectively evaluating
omen following Fontan operation that have either at-
empted pregnancy or become pregnant. In one study, a
igher than expected incidence of infertility and miscar-
iages were found when Fontan patients attempted preg-
ancy (388). In another study of 14 women with Fontan
irculation who became pregnant, only 2 cardiovascular
vents occurred. One developed supraventricular tachycar-
ia, and 1 developed heart failure symptoms during preg-
ancy. Both had noncomplicated deliveries and survived
389). It is recommended that all women undergo pre-
regnancy evaluation with a team consisting of high-risk
bstetricians, anesthesiologists, and ACHD experts.
ransplant. Heart transplantation may be utilized as res-
ue therapy at all stages of palliation for HLHS (390) and
ost often after completion Fontan for single-ventricle
natomies (391–393). One large multicenter study reviewed
utcomes of 97 Fontan patients listed at 17 pediatric centers
rom 1993 to 2001. In this series, 25% were 4 years of age
t time of listing, only 70 of 97 patients survived to
ransplant, and 1-year survival was 76%, which is in contrast
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recipients (394). Infection was the most common cause of
death (30%). Importantly, PLE resolved in all 34 patients
who survived 30 days after transplant (393).
There is no clear consensus on the optimal timing of
transplantation, and suggested indications for transplanta-
tion are summarized in Table 5. In one small series of
patients with single-ventricle physiology, there was a signif-
icant difference in outcomes between patients transplanted
following bidirectional Glenn (100% late survival, n  9)
versus after Fontan (33% survival, n  6). These authors
concluded that for selected high-risk single-ventricle pa-
tients, transplant should be considered as an alternative to
Fontan completion (393). However, a recent large multi-
center study from the Pediatric Heart Transplant Study
group found similar outcomes for patients listed after
bidirectional Glenn (n  189) versus those transplanted
after Fontan (n  194); in this series, patients transplanted
with Fontan who became ventilator dependent had poor
survival (395).
A further factor that affects decisions about timing of
transplantation is that children listed for transplant have the
highest waiting list mortality in solid organ transplantation.
In one multicenter series, 20.6% of listed Fontan patients
died waiting (393). A review of U.S. registry data of 3,098
children listed for transplant from 1999 to 2006 found 17%
of patients died waiting, with risk factors for death includ-
ing HLHS, ECMO, ventilator support, congenital heart
disease, dialysis, and nonwhite ethnicity (141).
Transplant centers in the United States, as well as
Canada and Europe have improved waitlist times by listing
infants for ABO-incompatible transplantation, which has
improved donor scarcity, with acceptable outcomes (396).
However, in the United States at the present time, only
Table 5
Indications for Heart Transplantation
With HLHS
● Primary transplantation: infants with HLHS and poor RV function
● HLHS s/p Stage I palliation: poor candidates for proceeding to Stage 2
● HLHS s/p Stage II palliation: poor RV function  moderate/severe TR
● HLHS s/p Stage III palliation with Fontan procedure and:
Œ Ventricular systolic dysfunction
Œ Ventricular diastolic dysfunction
Œ Protein-losing enteropathy
Œ Plastic bronchitis
Œ Refractory arrhythmias (and not suitable for Fontan conversion surgery)
Œ Cyanosis: saturation 80% (Fontan), 70% (Glenn); pulmonary AVMs
AVMs  arteriovenous malformations; HLHS  hypoplastic left heart syndrome; RV  right
entricle; TR  tricuspid regurgitation.infants 18 months of age are eligible for ABO-incompatible transplants. Patients with single-ventricle
physiology are particularly difficult to support while listed
with measures other than ventilation and high-dose ino-
tropes, as no ideal ventricular assist device exists. Limited
success has been reported with ECMO as well as with the
Berlin Heart Ventricular Assist Device, which is awaiting
U.S. Food and Drug Administration approval (397,398).
Children who survive to transplant after Stage I, II, or III
palliation commonly have multiple complex technical sur-
gical challenges and medical comorbidities, such as renal,
pulmonary, and hepatic insufficiency, which complicate
their post-operative course. In addition to these challenges,
many of these patients have the added concern of “pre-
sensitization.” Single-ventricle patients may develop pre-
formed antibodies to donor human leukocyte antigens,
either due to multiple prior blood transfusions, or the
presence of prior homograft material (396). Of rescue
transplants in children who had HLHS, half had a panel
reactive antibody test 10% (390), which may cause mor-
bidity from antibody-mediated rejection (399), and lead to
a higher risk of allograft vasculopathy (400). Most trans-
plant centers are incorporating protocols to address sensiti-
zation, attempting to desensitize patients at the time of
transplant, for example with plasmapheresis, intravenous
immunoglobulin (401), and utilizing virtual cross-match
protocols, so as not to limit the donor selection pool (402).
Other Topics
Fetal Interventions
Fetal cardiac interventions can be performed for 2 types of
HLHS. Most enticingly, it can be performed for severe
aortic stenosis (AS) in an attempt to prevent progression to
HLHS. At the other end of the spectrum, it can be
performed for the otherwise lethal HLHS with intact atrial
septum in an attempt to improve perinatal survival and
surgical outcome.
Fetal aortic stenosis with evolving HLHS. The first fetal
cardiac interventions (FCI) for AS with LV dilation and
dysfunction were performed by Maxwell et al. (403) in
London, United Kingdom, in the late 1980s, and this defect
remains the major focus of current FCI (404). Although
there are only a few studies describing the natural history of
fetal AS and the evolution to HLHS, there are no papers
proposing otherwise (405–407). Conventional thinking has
proposed that valvar AS is the dominant lesion resulting in
LV myocardial and mitral valve damage and dysfunction
with resultant growth arrest and HLHS at birth. This is
likely oversimplifying the pathogenesis, because a primary
genetic disorder that simultaneously affects myocardial and
valvar development may be a significant contributor to the
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FCI during the 1990s, the hypotheses behind HLHS in this
unique subgroup have remained an area of focus in the field
of fetal therapy (408–410). To this end, since 2000, the
cardiology and perinatal groups in Boston, and other centers
around the world have continued to pursue AS dilation in
mid-gestation to prevent progression to HLHS, with in-
creasing technical and clinical success (411–416). Despite
increasing experience and technical success, fetal loss from
the procedure remains around 10% to 15%. If fetal therapy
is considered, early referral to a FCI center for evaluation is
important because AS, LV dysfunction, and irreversible
damage can progress rapidly. Patient selection for FCI for
AS continues to evolve. Currently, FCI is not recom-
mended, but instead, close follow-up is undertaken in
fetuses with AS with preserved LV function and antegrade
arch flow because they might achieve a biventricular repair
without FCI. Additionally, FCI is not recommended in
fetuses where the LV has gone through the dilation phase
and is shrinking, generating low pressure, and has signifi-
cant endocardial fibroelastosis. Current selection of “appro-
priate” candidates for FCI are those who are predicted to
evolve to HLHS (moderate or more LV dysfunction and
retrograde arch flow) but whose LV is still dilated and
generating at least fetal systemic pressure as measured by
mitral regurgitation jet velocity or aortic stenosis gradient
(20 mm Hg or similar to gestational age) (414,417).
HLHS with highly restrictive or intact atrial septum. There
re several convincing papers illustrating the highly lethal
ature of this subgroup of HLHS (6,418,419). Thus,
renatal creation of an adequate sized atrial septal defect
hould, in theory, allow for decompression of pulmonary
enous return prenatally, and potentially benefit lung and
ulmonary vascular development. Fetal creation of an atrial
efect can be achieved via percutaneous, transpulmonary
arenchymal, right or left atrial puncture, with balloon or
tent dilation of the commonly thick atrial septum
420,421). Although creating an adequate atrial defect
2.5 mm) prenatally in this group will likely lead to
mproved clinical stability in the neonatal period, it is likely
hat the pulmonary parenchymal and pulmonary arterial and
enous damage previously incurred during gestation may
ake these patients poor candidates for early surgical and
edium-term survival. Preferably, an atrial defect should be
reated as early as possible (20 to 25 weeks) to potentially
revent or reverse this damage. However, cannula puncture
hrough the thin atrial wall can lead to fatal hemopericar-
ium in mid-gestation. Thus, most procedures for this
efect have been performed in the third trimester. Although
he short-term survival in published series may be better
han the natural history, the medium-term outcome isunknown (421). Not surprisingly, some patients, both those
who underwent a successful fetal intervention and those
born with an intact, highly restrictive atrial septum, have
developed late pulmonary vein stenosis and pulmonary
hypertension. Therefore, it behooves us in this field to work
towards the creation of novel and miniaturized tools that
would enable procedures to be performed earlier in gestation
to allow creation of a larger atrial septal defect on a thinner
atrial septum, more time for pulmonary parenchymal, lym-
phatic, and vascular remodeling, and a more stable perinatal
transition.
Genetics/Genomics
In addition to hypoplasia of the LV and ascending aorta, the
pathological anatomy of the aortic and mitral valves defines
HLHS (422–424). Pathology series have shown aortic valve
malformation is universal, and mitral valve abnormalities are
common, with tricuspid and/or pulmonary valve dysplasia
less frequently observed (425–428). The presence of bicus-
pid aortic valve (BAV) in family members of HLHS
probands, the observation that HLHS is part of the in utero
natural history of aortic stenosis (414), and the frequent
occurrence of left- and right-sided valve dysplasia in HLHS
probands suggests that HLHS is a severe form of valve
malformation (428).
Genetic origins of HLHS
HLHS is heritable and has been linked with several cyto-
genetic abnormalities, including Turner and Jacobsen syn-
dromes (20,429,430), and heterozygous mutations in
NKX2.5 and GJA1 have been reported in a small number of
cases (431,432). However, the genetic basis of HLHS
remains largely unknown. Family clustering of HLHS and
other cardiovascular malformations has long been known.
Pedigree analyses have been interpreted as indicating simple
Mendelian inheritance of HLHS (433), but this interpre-
tation has been challenged (434). To determine the size of
the genetic effect (heritability) in families ascertained by a
child with HLHS proband, echocardiograms were per-
formed on participating family members using a sequential
sampling strategy. All HLHS patients had aortic valve
hypoplasia and dysplasia; in addition, dysplasia of the mitral
(94%), tricuspid (56%), and pulmonary (11%) valves was
also noted. Over half the families had 1 affected individ-
ual, and 36% of participants had cardiovascular malforma-
tions, including 11% with BAV. Maximum likelihood–
based variance decomposition showed that HLHS is a
complex trait with a heritability of h2  0.99 (428).
HLHS links to chromosomes 10q and 6q and is genet-
ically related to BAV. To demonstrate this, family-based
nonparametric genome-wide linkage analysis to identify
S27JACC Vol. 59, No. 1, Suppl S, 2012 Feinstein et al.
December 27, 2011/January 3, 2012:S1–S42 HLHS: Current Considerations and Expectationsdisease loci for HLHS and evaluate the genetic relationship
between HLHS and BAV was performed. Families ascer-
tained by either HLHS (n  33) or BAV (n  102)
proband were evaluated. The recurrence risk ratio of BAV
in HLHS families (8.05) was nearly identical to that in
BAV families (8.77). In addition, 5 suggestive loci suggest-
ing linkage were identified (435). These studies indicate
that HLHS is determined largely by genetic effects, and
specifically, the linkage to multiple loci identifies HLHS as
genetically heterogeneous, and suggest complex inheritance
of HLHS.
The grouping of left-sided malformations (BAV, aortic
coarctation, and HLHS) as causally related was based on
epidemiology studies that identified these defects in the
same kindreds (436,437). Further support is provided by the
occurrence of these defects in patients with Turner syn-
drome (429), and identical twins with discordant pheno-
types of BAV and HLHS (428). In addition, when families
exhibiting these phenotypes are grouped, heritability is
identified (438). However, the first evidence of a direct
genetic relationship between HLHS and BAV came from
the identification of shared loci in a combined cohort of
HLHS and BAV families (435); still, the majority of
linkage peaks, including the strongest HLHS and BAV loci,
could not be confirmed in a combined cohort. This finding
suggests that the genetic relationship between HLHS and
BAV may not be as strong as has been presumed (439) and
suggests that future genetic studies should focus on specific
phenotypes to reduce background noise. In addition, several
studies have questioned simple Mendelian inheritance of
HLHS and BAV (428,434,438,440,441) and suggested
they are complex traits.
Neurodevelopment Outcomes
There are now numerous studies of neurodevelopmental
outcome after palliative surgery or transplantation for
HLHS. There is a distinctive pattern of neurodevelopmen-
tal and behavioral dysfunction characterized by mild cogni-
tive impairment, impaired social interaction, and deficits in
core communication skills including pragmatic language, as
well as inattention, impulsive behavior, and impaired exec-
utive function (442,443). School-age survivors more com-
monly require remedial services including tutoring, special
education, and physical, occupational, and speech therapy.
There are several factors that may pose additional risks for
neurodevelopmental outcome in HLHS. It is now widely
recognized that prior to birth, children with CHD may have
impaired brain growth as well as delayed brain maturity. A
recent study demonstrated that fetal brain growth is in-
versely proportional to the proportion of combined ventric-
ular output through the aortic valve (444). It is alsorecognized that somatic growth in the first year of life—a
critical time for brain development—may play a major role
in later developmental outcome.
For those children undergoing the Norwood procedure,
aortic arch reconstruction historically has necessitated the
use of deep hypothermic circulatory arrest (DHCA). Pro-
longed periods of DHCA—generally greater than 40
min—have been associated with later neurological impair-
ment in some studies. As such, certain investigators have
suggested that regional low-flow perfusion be used to
augment cerebral blood flow during deep hypothermia. To
date, the neuroprotective benefits of this strategy in HLHS
surgery are unproven. A single-institution randomized trial
comparing DHCA with regional low-flow perfusion did not
demonstrate any difference in the primary outcome measure,
the Bayley Scales of Infant Development-II, assesses at 1
year of age (445).
Infant heart transplantation has been undertaken in many
centers as an alternative management approach to recon-
structive surgery. In general, these studies have reported
intermediate-term neurodevelopmental outcomes quite
comparable to the assessment following staged surgical
palliation (446). Interestingly, one study found that patients
who waited longer for transplantation had significantly
lower scores on cognitive testing, estimating a 4.5-point fall
in IQ for each month on the waiting list. This finding is in
keeping with numerous other studies that have reported
hospital length of stay to be an important predictor of later
developmental status. To date, there are very limited data
regarding neurodevelopmental outcome following hybrid-
type management of HLHS. Hopefully, recently instituted
studies can shed light on neurological implications of this
novel approach.
In reviewing published reports, group data must be
interpreted with caution: “HLHS” represents a heteroge-
neous spectrum of disease, both from an anatomic and a
physiological perspective, with multiple risk factors for
adverse neurodevelopmental outcomes. Patients with ge-
netic syndromes, low birth weight, shock at presentation, or
with intraoperative or post-operative complications may
have a guarded neurological prognosis, whereas those with a
smooth transition to the operating room, an anatomically
and physiologically sound repair, and uneventful post-
operative course are likely to do well over the long run.
Future research should be directed at optimal pre- and
post-operative oxygen delivery, further improvements in
intraoperative support techniques, and a better understand-
ing and recognition of “neurological resuscitation” after
complex open heart surgery in neonates to not only optimize
outcomes but to define realistic, risk-adjusted outcome data
so that realistic expectations may be obtained.
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Minimizing Pulmonary Vascular Resistance
Energy efficiency in the Fontan circuit is dependent on low
vascular resistance. Altitude may impact outcomes of cavo-
pulmonary palliation by elevating baseline pulmonary artery
pressures and PVR attributable to pulmonary vasoconstric-
tion and alveolar hypoxia. Thus, in theory, cavopulmonary
palliation of single-ventricle physiology should be less ef-
fective at elevated altitude. However, the elevation at which
clinically significant deterioration in the Fontan palliation
occurs is uncertain. Some patients may seemingly do well at
elevations of 1,600 m or less, whereas others do poorly. One
study noted a trend toward increased survival at altitude in
fenestrated patients with mean pulmonary artery pressure
15 mm Hg (447). In a more recent retrospective study at
a mean altitude of 1,600 m, the average pre-bidirectional
Glenn pulmonary arterial pressure was 15.4 mm Hg and
transpulmonary gradient of 8.1 mm Hg (448). Despite these
elevated values for this patient cohort, a substantial propor-
tion of patients had favorable outcomes after cavopulmonary
palliation, with a survival after bidirectional Glenn of 92.4%
at 5 years, and freedom from palliation failure, defined as
death, transplant, bidirectional Glenn/Fontan takedown, or
revision of 81% at 5 years. Factors for palliation failure at
elevated altitude include pulmonary artery pressure 15
mm Hg, and transpulmonary gradient 8 mm Hg, and
higher mean altitude than those patients who were asymp-
tomatic at follow-up (1,706 270 m versus 1,579 313 m,
p  0.05). It is interesting that a portion of patients
undergoing heart transplantation for failed Fontan circula-
tion may unmask pulmonary vascular disease once cardiac
output through the pulmonary circulation is normalized
(449). Most centers performing a Fontan procedure at
moderate altitude include a fenestration because lack of
fenestration at the time of the initial procedure is associated
with marginal status in the midterm.
Quality of Life/Air Travel
The complex nature of HLHS and limited information on
long-term physical and psychosocial morbidity demand
attention to quality-of-life (QOL) issues for survivors.
Strategies to minimize limitations and empower parents to
pursue therapies, such as early intervention for motor or
cognitive delay, should be used to achieve optimal function-
ing (450). It is important for providers and parents to
understand that high treatment burden does not necessarily
translate to poor QOL (33), and the majority of patients
and families will adapt well to the challenges faced
(451,452).
Findings from QOL research in CHD have been incon-
sistent (453). This is due in part to methodological issues qsuch as small sample size, use of proxy-reporters, and
variable approaches to the measurement of QOL (454,455).
The inconsistency in findings also reflects that the psycho-
logical response to the stress of chronic illness is highly
individual and is influenced by many factors including
personal perceptions, expectations, and values that likely
exert far more influence than a specific diagnosis
(451,452,456).
Severity of disease is not a reliable predictor of QOL.
Other outcomes, such as New York Heart Association
functional status, level of education, employment, or exer-
cise tolerance, although they may contribute to QOL, are
not adequate substitutes for assessment of QOL directly.
The presence of functional limitations, cognitive delays,
comorbid conditions, and a higher perceived daily burden of
disease have been found to be related to reports of poorer
QOL (453,457–460). Patients, parents, and clinicians may
have different perspectives on which aspects of a disease and
treatment impact QOL (461).
Most studies exploring QOL in CHD have involved
heterogeneous groups of patients. Only 2 studies were
identified that examined QOL in HLHS exclusively, and
both have limitations. In a sample of 38 infants and children
with HLHS operated on in the 1990s, parents reported the
lowest QOL in infants following Stage II surgical palliation.
In the portion of the sample greater than 5 years of age and
after Fontan completion, psychosocial function was noted to
be lower than a healthy reference sample, but physical
function was not different (462). In 18 children with HLHS
born from 1993 to 2005 and assessed at 2.7 to 10.6 years of
age, parents reported that their children had lower self-
esteem, more psychosomatic symptoms, and lower peer
acceptance than age- and gender-matched healthy children.
The presence of neurological sequelae was an added risk
factor for poorer outcomes (459).
Several studies have explored QOL and functional health
status in survivors of the Fontan procedure for multiple forms
of single ventricle CHD (455). In one study, 67 adults living
with single-ventricle CHD reported QOL scores that were
similar to a healthy population. Older age and residual cyanosis
were related to poorer outcomes (463). Using a cardiac-specific
QOL measure, QOL scores were reported to be significantly
lower for those with single-ventricle CHD compared with
biventricular CHD for children (age 8 to 12 years), adolescents
(age 12 to 18 years), and by parent-proxy report (464). A
ulticenter, cross-sectional study of 537 children with Fontan
hysiology at a mean age of 11.9 years explored QOL, heart
hythm, exercise tolerance, and the presence of other physical
orbidities (458,465). In this study, parent-reported scores foruality of physical health were approximately 1 standard
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were one-half standard deviation lower than normative values.
Prospective, longitudinal assessment of QOL and its
determinants is needed to understand the impact of this
disease. Emphasis should be placed on seeking self-report
from adolescents and adults as they adjust to increasing
demands for social and role functioning.
Air Travel
There are no specific guidelines regarding air travel for
patients with CHD, and providers should address specific
concerns with their individual patients. Concern has been
raised that high altitudes may induce hypoxemia in patients
with heart or lung disease. One study examined the effects
of altitude in adults with cyanotic CHD using both simu-
lated and actual flight conditions. In both patients and
control subjects, transcutaneous SaO2 decreased at a maxi-
um cabin altitude of 8,000 feet. Reductions in SaO2 as
compared with sea level values averaged 8.8% in patients
and 7.0% in control subjects. These changes were well
tolerated, and all patients returned to baseline values in
ground conditions (466). A subsequent study documented
safe air travel for patients with Eisenmenger syndrome and
acyanotic CHD (467). Both studies concluded that there is
no justification for limiting air travel in these patient
populations.
Patients who require supplemental oxygen need to make
special arrangements with their airline prior to air travel. A
prescription for oxygen should be provided to the patient.
Policies for onboard oxygen vary by carrier, and oxygen
service may not be provided. Federal regulations prohibit
passengers from bringing or checking their own oxygen
canisters on a flight. Some brands of oxygen concentrators
are allowed, or canisters can be purchased for use during the
flight (468,469). Patients with pacemakers traveling via air
should carry a pacemaker identification card and request a
private security screening that does not involve a metal
detector or hand-wanding (468).
Cardiac Resynchronization
Very little data are available regarding the use of resynchro-
nization therapy in children, and even less in multisite
pacing in patients with single ventricles. Friedberg et al.
showed that patients with HLHS, a group that is known to
be at high risk of RV failure, do indeed have RV mechanical
dyssynchrony unrelated to electrical dyssynchrony (470). In
17 children with HLHS, they found that although electrical
dyssynchrony was not seen in this group (median QRS
duration of 93 ms [71 to 140 ms]), patients did have
significant abnormalities in strain and strain rate when
compared with controls (time to peak strain 37  35 ms inatients with HLHS vs. 8  8 ms in controls). This
uggests part of the ventricular dysfunction often seen in
LHS may be related to mechanical dyssynchrony and may
e amenable to resynchronization therapy.
Bacha et al. (471) Zimmerman et al. (472) evaluated the
se of multisite pacing in patients with univentricular hearts
n an acute post-operative setting. They compared acute
emodynamic parameters (systolic blood pressure, cardiac
ndex) as well as 3-dimensional echo measurements before
nd after a brief (20 min) pacing intervention of atrial-
ultisite ventricular pacing. Ventricular leads were placed
n the outflow tract near the semilunar valve, on the right
ide of the anterior wall, near the atrioventricular groove,
nd on the ventricular apex. Simultaneous ventricular stim-
lation at 2 sites was used for this study. The authors found
ignificant improvement in mechanical synchrony, as mea-
ured by 3-dimensional echo, which resulted in hemody-
amic improvement.
There have been 3 large studies of chronic resynchroni-
ation in CHD patients (473–475). Each of these studies
ad a subgroup of patients with single-ventricle physiology,
ut the underlying diagnosis of HLHS was found in only a
mall number of patients. The evaluation of chronic resyn-
hronization therapy by Dubin et al. (475) included 7
atients with single ventricles. Patients had no change in
jection fraction (as measured by radionuclide scan) but did
ave a decrease in QRS duration. Clinical improvement was
een in 2 of the 7. Janousek et al. (474) had 4 patients with
functional single ventricle (1 HLHS), with clinical im-
rovement (New York Heart Association functional class)
een in 3 patients. Cechin et al. (473) 13 patients with
ingle-ventricle physiology (473) and found clinical im-
rovement in 7 of 11 patients, and ejection fraction im-
rovement in 10 of 11 patients. These data, although
omewhat encouraging, need to be interpreted with caution;
here are extremely limited data regarding the use of
ultisite pacing in patients with univentricular hearts, and
here are no data regarding appropriate lead placement in
hese patients. It appears from Friedberg et al. (470) that the
ubstrate of mechanical dyssynchrony is present, and that
here may be some potential benefit of this therapy in this
omplex group, but much more research needs to be done as
o where and how resynchronization occurs.
omputational Simulation
The role of computational simulations in the treatment of
HLHS patients is increasing, although currently still limited
in its direct clinical application. Although there have been
many advances in patient-specific modeling and simulation
techniques in recent years, these tools are not yet used as
standard of care in day-to-day clinical practice. In a recent
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increase the sophistication and clinical impact of Fontan
simulations. In particular, this paper cited a need for, among
other things, more realistic methods for modeling respira-
tion, wall compliance, exercise, and increased anatomic
sophistication. Above all else, the biggest need in increasing
clinical applicability is validation with in vivo data, and
direct comparison of simulation parameters to clinical out-
comes and patient data.
With that said, there have been impressive advances in
the areas of patient-specific modeling, fluid structure inter-
action, closed-loop circulation modeling, and surgery opti-
mization in recent years. Simulations are now being used to
evaluate new surgical designs for the Fontan and Glenn, as
well as the first-stage Norwood and BT shunt procedures.
These tools are now poised to make significant contribu-
tions towards clinical decision making and surgical plan-
ning, particularly in the customization of surgeries for
individual patients.
The clinical impact of simulation methods on the Fontan
procedure began with pioneering computational simulations
by de Leval et al. that compared energy loss associated with
the standard T-junction Fontan procedure with a newly
proposed “offset” model (477,478). This work subsequently
led to the adoption of the offset model as the currently
preferred surgical method.
During the ensuing 10 years, there has been ongoing and
Figure 7
Computational Simulation as an Emerging Tool
Representative Fontan model showing angiography and computational simulation-de
ompared with blue or green).increasing interest in modeling the Fontan circulation, withcontributions in several clinically relevant areas. Simulations
have been used to study exercise hemodynamics following
the Fontan surgery (479,480). This helps to fill a much-
needed gap, as current diagnostic methods have limited
capabilities for determining in vivo flow and pressure during
exercise.
Most of the recent Fontan simulation work has focused
on a single energy-loss parameter for evaluating Fontan
performance. Simulations are now being used to evaluate a
broader range of parameters that are believed to be clinically
relevant, including wall shear stress (Fig. 7), particle resi-
dence times, hepatic flow distribution, and changes in
pressure levels and pressure drops (481,482).
Patient-specific simulations also provide a means to
evaluate new surgical methods and interventions at no risk
to the patient. As an example of this, simulations have
recently been used to evaluate a new bifurcated Y-graft
design for the ECC Fontan surgery, and the design has
proven to decrease energy losses and improve flow distribu-
tion in both idealized and patient specific models (483,484).
Surgery optimization methods are now being expanded to
take advantage of sophisticated and efficient tools developed
for optimal shape design in the aeronautics industry (485).
Multiscale modeling and lumped parameter networks
have been increasing in sophistication in the past several
years, and it is now possible to model the entire circulatory
system as a closed loop. Whereas uncoupled simulations
easures of wall shear stress. The red areas indicate higher levels of shear (whenrived mprovide insight only into local hemodynamics, full circula-
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heart rate, cardiac output, and other parameters. These tools
have recently been applied to both the Fontan and Norwood
surgeries (486).
Ongoing efforts are also underway to design and simulate
mechanical circulatory support devices for Fontan patients.
Recent work has pioneered an expandable rotary impeller
pump, which is being tested in simulations and mock
circuits. Simulations are also being used to design next-
generation pediatric ventricular assist devices, which may
hold promise for bridge to transplant use in single-ventricle
patients (487).
Summary
The dramatic improvements in the treatment and outcomes
for HLHS over the past 3 decades have been accomplished
through the efforts of many dedicated providers, families,
and patients. Current successes and expectations that 70%
of newborns born today with HLHS may reach adulthood
are exciting, yet one must always remember that the current
surgical strategies remain palliative. Caution must be exer-
cised because a great deal remains to be understood as it
relates to this group of patients, their QOL, their long-term
morbidities, and the sequelae of recent surgical modifica-
tions. The work of the Joint Commission on Congenital
Heart Disease, the recent publication from the first multi-
center randomized surgical trial in congenital heart disease
(SVR), and the increased awareness surrounding the CHD
population (both pediatric and adult). all herald a new
“infancy” in the field of CHD and should give both
providers and family members a great deal of hope for the
future. Emerging knowledge around fetal interventions,
genetics of the disease, computational simulations, and
neurodevelopmental outcomes will all likely shape our
understanding and may affect future management decisions.
Reprint requests and correspondence: Dr. Jeffrey A. Feinstein,
Department of Pediatrics (Cardiology)/Stanford University School
of Medicine, 750 Welch Road, Suite 305, Palo Alto, California
94304. E-mail: jeff.feinstein@stanford.edu.
REFERENCES
1. Schidlow DN, Anderson JB, Klitzner TS, et al. Variation in
interstage outpatient care after the Norwood procedure: a report from
the Joint Council on Congenital Heart Disease National Quality
Improvement Collaborative. Congenit Heart Dis 2011;6:98–107.
2. Galindo A, Nieto O, Villagra´ S, Grañeras A, Herraiz I, Mendoza A.
Hypoplastic left heart syndrome diagnosed in fetal life: associated
findings, pregnancy outcome and results of palliative surgery. Ultra-
sound Obstet Gynecol 2009;33:560–6.
3. Hinton RB, Andelfinger G, Sekar P, et al. Prenatal head growth and
white matter injury in hypoplastic left heart syndrome. Pediatr Res
2008;64:364–9.4. Feit LR, Copel JA, Kleinman CS. Foramen ovale size in the normal
and abnormal human fetal heart: an indicator of transatrial flow
physiology. Ultrasound Obstet Gynecol 1991;1:313–9.
5. Chin AJ, Weinberg PM, Barber G. Subcostal two-dimensional
echocardiographic identification of anomalous attachment of septum
primum in patients with left atrioventricular valve underdevelopment.
J Am Coll Cardiol 1990;15:678–81.
6. Rychik J, Rome JJ, Collins MH, DeCampli WM, Spray TL. The
hypoplastic left heart syndrome with intact atrial septum: atrial
morphology, pulmonary vascular histopathology and outcome. J Am
Coll Cardiol 1999;34:554–60.
7. Lurie PR. Changing concepts of endocardial fibroelastosis. Cardiol
Young 2010;20:115–23.
8. Allan LD, Sharland G, Tynan MJ. The natural history of the
hypoplastic left heart syndrome. Int J Cardiol 1989;25:341–3.
9. Danford DA, Cronican P. Hypoplastic left heart syndrome: progres-
sion of left ventricular dilation and dysfunction to left ventricular
hypoplasia in utero. Am Heart J 1992;123:1712–3.
10. Fishman N, Hof R, Rudolph A, Heymann M. Models of congenital
heart disease in fetal lambs. Circulation 1978;58:354–64.
11. Harh JY, Paul MH, Gallen WJ, Friedberg DZ, Kaplan S. Experi-
mental production of hypoplastic left heart syndrome in the chick
embryo. Am J Cardiol 1973;31:51–6.
12. Silverman N, Kleinman C, Rudolph A, et al. Fetal atrioventricular
valve insufficiency associated with nonimmune hydrops: a two-
dimensional echocardiographic and pulsed Doppler ultrasound study.
Circulation 1985;72:825–32.
13. Mahle WT, Clancy RR, McGaurn SP, Goin JE, Clark BJ. Impact of
prenatal diagnosis on survival and early neurologic morbidity in
neonates with the hypoplastic left heart syndrome. Pediatrics 2001;
107:1277–82.
14. Satomi G, Yasukochi S, Shimizu T, Takigiku K, Ishii T. Has fetal
echocardiography improved the prognosis of congenital heart disease?
Comparison of patients with hypoplastic left heart syndrome with
and without prenatal diagnosis. Pediatr Int 1999;41:728–32.
15. Sivarajan V, Penny DJ, Filan P, Brizard C, Shekerdemian LS. Impact
of antenatal diagnosis of hypoplastic left heart syndrome on the
clinical presentation and surgical outcomes: the Australian experi-
ence. J Paediatr Child Health 2009;45:112–7.
16. Tworetzky W, McElhinney DB, Reddy VM, Brook MM, Hanley
FL, Silverman NH. Improved surgical outcome after fetal diagnosis
of hypoplastic left heart syndrome. Circulation 2001;103:1269–1273.
17. Verheijen PM, Lisowski LA, Stoutenbeek P, et al. Prenatal diagnosis
of congenital heart disease affects preoperative acidosis in the new-
born patient. J Thorac Cardiovasc Surg 2001;121:798–803.
18. Shillingford AJ, Ittenbach RF, Marino BS, et al. Aortic morphom-
etry and microcephaly in hypoplastic left heart syndrome. Cardiol
Young 2007;17:189–195.
19. Ohye RG, Sleeper LA, Mahony L, et al. Comparison of shunt types
in the norwood procedure for single-ventricle lesions. N Engl J Med
2010;362:1980–92.
20. Ye M, Coldren C, Lai X Liang, et al. Deletion of ETS-1, a gene in
the Jacobsen syndrome critical region, causes ventricular septal defects
and abnormal ventricular morphology in mice. Hum Mol Genet
2010;19:648–56.
21. Natowicz M, Chatten J, Clancy R, et al. Genetic disorders and major
extracardiac anomalies associated with the hypoplastic left heart
syndrome. Pediatrics 1988;82:698–706.
22. Stasik CN, Goldberg CS, Bove EL, Devaney EJ, Ohye RG. Current
outcomes and risk factors for the Norwood procedure. J Thorac
Cardiovasc Surg 2006;131:412–7.
23. McElhinney DB, Tworetzky W, Lock JE. Current status of fetal
cardiac intervention. Circulation 2010;121:1256–63.
24. Pollock-Barziv SM, McCrindle BW, West LJ, Dipchand AI. Wait-
ing before birth: outcomes after fetal listing for heart transplantation.
Am J Transplant 2008;8:412–8.
25. Hospital Stays, Hospital Charges, and In-Hospital Deaths Among
Infants with Selected Birth Defects — United States, 2003. MMWR
Morb Mortal Wkly Rep 2007;56:25–9.
26. Johnson B, Mussatto K, Uhing M, Zimmerman H, Tweddell J,
Ghanayem N. Variability in the preoperative management of infants
with hypoplastic left heart syndrome. Pediatr Cardiol 2008;29:
515–20.
S32 Feinstein et al. JACC Vol. 59, No. 1, Suppl S, 2012
HLHS: Current Considerations and Expectations December 27, 2011/January 3, 2012:S1–S4227. Wernovsky G, Ghanayem N, Ohye RG, et al. Hypoplastic left heart
syndrome: consensus and controversies in 2007. Cardiol Young
2007;17:75–86.
28. Graham E, Bradley S, Atz A. Preoperative management of hypoplas-
tic left heart syndrome. Expert Opin Pharmacother 2005;6:687–93.
29. Stieh J, Fischer G, Scheewe J, et al. Impact of preoperative treatment
strategies on the early perioperative outcome in neonates with
hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 2006;131:
1122–9.e2.
30. Tabbutt S, Ramamoorthy C, Montenegro LM, et al. Impact of
inspired gas mixtures on preoperative infants with hypoplastic left
heart syndrome during controlled ventilation. Circulation 2001;104:
I-159–64.
31. Bove EL, Ohye RG, Devaney EJ. Hypoplastic left heart syndrome:
conventional surgical management. Semin Thorac Cardiovasc Surg
Pediatr Card Surg Annu 2004;7:3–10.
32. Chrisant MRK, Naftel DC, Drummond-Webb J, et al. Fate of
infants with hypoplastic left heart syndrome listed for cardiac trans-
plantation: a multicenter study. J Heart Lung Transplant 2005;24:
576–82.
33. Wernovsky G. The paradigm shift toward surgical intervention for
neonates with hypoplastic left heart syndrome. Arch Pediatr Adolesc
Med 2008;162:849–54.
34. Kon AA. Healthcare providers must offer palliative treatment to
parents of neonates with hypoplastic left heart syndrome. Arch
Pediatr Adolesc Med 2008;162:844–8.
35. Sinha SN, Rusnak SL, Sommers HM, Cole RB, Muster AJ, Paul
MH. Hypoplastic left ventricle syndrome: analysis of thirty autopsy
cases in infants with surgical considerations. Am J Cardiol 1968;21:
166–73.
36. Deely W, Ehlers K, Levin A, Engle M. Hypoplastic left heart
syndrome. Anatomic, physiologic, and therapeutic consideraons.
Am J Dis Child 1971;121:168–75.
37. Knott H, Doty D. Experimental bypass of the left ventricle. J Thorac
Cardiovasc Surg 1977;74:436–9.
38. Doty D, Knott H. Hypoplastic left heart syndrome. Experience with
an operation to establish functionally normal circulation. J Thorac
Cardiovasc Surg 1977;74:624–30.
39. Mohri H, Horiuchi T, Haneda K, et al. Surgical treatment for
hypoplastic left heart syndrome: case reports. J Thorac Cardiovasc
Surg 1979;78:223–8.
40. Milo S, Ho S, Anderson R. Hypoplastic left heart syndrome: can this
malformation be treated surgically? Thorax 1980;35:351–4.
41. Doty D, Marvin W Jr., Schieken R, Lauer R. Hypoplastic left heart
syndrome: successful palliation with a new operation. J Thorac
Cardiovasc Surg 1980;80:148–52.
42. Behrendt D, Rocchini A. An operation for the hypoplastic left heart
syndrome: preliminary report. Ann Thorac Surg 1981;32:284–8.
43. Norwood W, Kirklin J. Hypoplastic left heart syndrome: experience
with palliative surgery. Am J Cardiol 1980;45:87–91.
44. Norwood W, Lang P, Casteneda A, Campbell D. Experience with
operations for hypoplastic left heart syndrome. J Thorac Cardiovasc
Surg 1981;82:511–9.
45. Norwood WI, Lang P, Hansen DD. Physiologic repair of aortic
atresia-hypoplastic left heart syndrome. N Engl J Med 1983;308:
23–6.
46. Sano S, Ishino K, Kawada M, et al. Right ventricle-pulmonary artery
shunt in first-stage palliation of hypoplastic left heart syndrome.
J Thorac Cardiovasc Surg 2003;126:504–9.
47. Freed MD, Heymann MA, Lewis AB, Roehl SL, Kensey RC.
Prostaglandin E1 infants with ductus arteriosus-dependent congen-
ital heart disease. Circulation 1981;64:899–905.
48. Linday LA, Engle MA. Prostaglandin treatment of newborns with
ductal-dependent congenital heart disease. Pediatr Ann 1981;10:
29–38.
49. Donahoo JS, Roland JM, Kan J, Gardner TJ, Kidd BS. Prostaglandin
E1 as an adjunct to emergency cardiac operation in neonates.
J Thorac Cardiovasc Surg 1981;81:227–31.
50. Schleman MM, Casta A, Mongkolsmai C, Black IF. Prostaglandin
E1 in the neonate with heart disease. Adv Prostaglandin Thrombox-
ane Res 1980;7:879–81.
51. Olley PM, Coceani F, Rowe RD, Swyer PR. Clinical use of
prostaglandins and prostaglandin synthetase inhibitors in cardiacproblems of the newborn. Adv Prostaglandin Thromboxane Res
1980;7:913–6.
52. Yabek SM, Mann JS. Prostaglandin E1 infusion in the hypoplastic
left heart syndrome. Chest 1979;76:330–1.
53. Browdie DA, Norberg W, Agnew R, Altenburg B, Ignacio R,
Hamilton C. The use of prostaglandin E1 and Blalock-Taussig
shunts in neonates with cyanotic congenital heart disease. Ann
Thorac Surg 1979;27:508–13.
54. Graham TP Jr., Atwood GF, Boucek RJ Jr. Pharmacologic dilatation
of the ductus arteriosus with prostaglandin E1 in infants with
congenital heart disease. South Med J 1978;71:1238–41,46.
55. Lewis AB, Takahashi M, Lurie PR. Administration of prostaglandin
E1 in neonates with critical congenital cardiac defects. J Pediatr
1978;93:481–5.
56. Neutze JM, Starling MB, Elliott RB, Barratt-Boyes BG. Palliation of
cyanotic congenital heart disease in infancy with E-type prostaglan-
dins. Circulation 1977;55:238–41.
57. Olley PM, Coceani F. Proceedings: emergency treatment of certain
cyanotic heart defects with prostaglandin E2. Br Heart J 1976;38:877.
58. Khouri EM, Gregg DE, Rayford CR. Effect of exercise on cardiac
output, left coronary flow and myocardial metabolism in the unanes-
thetized dog. Circ Res 1965;17:427–37.
59. Ohye RG, Ludomirsky A, Devaney EJ, Bove EL. Comparison of
right ventricle to pulmonary artery conduit and modified Blalock-
Taussig shunt hemodynamics after the Norwood operation. Ann
Thorac Surg 2004;78:1090–3.
60. Donnelly JP, Raffel DM, Shulkin BL, et al. Resting coronary flow
and coronary flow reserve in human infants after repair or palliation
of congenital heart defects as measured by positron emission tomog-
raphy. J Thorac Cardiovasc Surg 1998;115:103–10.
61. Azakie A, Merklinger SL, McCrindle BW, et al. Evolving strategies
and improving outcomes of the modified Norwood procedure: a
10-year single-institution experience. Ann Thorac Surg 2001;72:
1349–53.
62. Charpie JR, Dekeon MK, Goldberg CS, Mosca RS, Bove EL, Kulik
TJ. Serial blood lactate measurements predict early outcome after
neonatal repair or palliation for complex congenital heart disease.
J Thorac Cardiovasc Surg 2000;120:73–80.
63. Mahle WT, Spray TL, Gaynor JW, Clark BJ. Unexpected death after
reconstructive surgery for hypoplastic left heart syndrome. Ann
Thorac Surg 2001;71:61–5.
64. Kishimoto H, Kawahira Y, Kawata H, Miura T, Iwai S, Mori T. The
modified norwood palliation on a beating heart. J Thorac Cardiovasc
Surg 1999;118:1130–2.
65. Sano S, Ishino K, Kawada M, Honjo O. Right ventricle-pulmonary
artery shunt in first-stage palliation of hypoplastic left heart syn-
drome. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu
2004;7:22–31.
66. Takabayashi S, Shimpo H, Yokoyama K, Onoda K, Mitani Y.
Reduced regional right ventricular wall motion after transventricular
repair of tetralogy of Fallot. J Thorac Cardiovasc Surg 2007;133:
1656–8.
67. Mahle WT, Cuadrado AR, Tam VKH. Early experience with a
modified norwood procedure using right ventricle to pulmonary
artery conduit. Ann Thorac Surg 2003;76:1084–8.
68. Mair R, Tulzer G, Sames E, et al. Right ventricular to pulmonary
artery conduit instead of modified Blalock-Taussig shunt improves
postoperative hemodynamics in newborns after the norwood opera-
tion. J Thorac Cardiovasc Surg 2003;126:1378–84.
69. Pizarro C, Malec E, Maher KO, et al. Right ventricle to pulmonary
artery conduit improves outcome after stage I Norwood for hypoplas-
tic left heart syndrome. Circulation 2003;108:II155–60.
70. Azakie A, Martinez D, Sapru A, Fineman J, Teitel D, Karl TR. Impact
of right ventricle to pulmonary artery conduit on outcome of the
modified norwood procedure. Ann Thorac Surg 2004;77:1727–33.
71. Tabbutt S, Dominguez TE, Ravishankar C, et al. Outcomes after the
stage I reconstruction comparing the right ventricular to pulmonary
artery conduit with the modified Blalock Taussig shunt. Ann Thorac
Surg 2005;80:1582–91.
72. Wernovsky G, Wypij D, Jonas RA, et al. Postoperative course and
hemodynamic profile after the arterial switch operation in neonates
and infants: a comparison of low-flow cardiopulmonary bypass and
circulatory arrest. Circulation 1995;92:2226–35.
11
1
1
1
1
1
1
1
1
1
1
1
1
1
1
S33JACC Vol. 59, No. 1, Suppl S, 2012 Feinstein et al.
December 27, 2011/January 3, 2012:S1–S42 HLHS: Current Considerations and Expectations73. Tweddell JS, Hoffman GM, Fedderly RT, et al. Phenoxybenzamine
improves systemic oxygen delivery after the Norwood procedure. Ann
Thorac Surg 1999;67:161–7.
74. Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of
milrinone in preventing low cardiac output syndrome in infants and
children after corrective surgery for congenital heart disease. Circu-
lation 2003;107:996–1002.
75. Tweddell J, Hoffman G. Postoperative management in patients with
complex congenital heart disease. Semin Thorac Cardiovasc Surg
Pediatr Card Surg Annu 2002;5:187–205.
76. Bartram U, Grünenfelder J, Van Praagh R. Causes of death after the
modified Norwood procedure: a study of 122 postmortem cases. Ann
Thorac Surg 1997;64:1795–802.
77. Rossi AF, Sommer RJ, Lotvin A, et al. Usefulness of intermittent
monitoring of mixed venous oxygen saturation after stage I palliation
for hypoplastic left heart syndrome. Am J Cardiol 1994;73:1118–23.
78. Hoffman GM, Ghanayem NS, Kampine JM, et al. Venous saturation
and the anaerobic threshold in neonates after the Norwood procedure
for hypoplastic left heart syndrome. Ann Thorac Surg 2000;70:
1515–20.
79. Tweddell JS, Hoffman GM, Mussatto KA, et al. Improved survival of
patients undergoing palliation of hypoplastic left heart syndrome:
lessons learned from 115 consecutive patients. Circulation 2002;106:
I-82–9.
80. Tweddell JS, Ghanayem NS, Mussatto KA, et al. Mixed venous
oxygen saturation monitoring after stage 1 palliation for hypoplastic
left heart syndrome. Ann Thorac Surg 2007;84:1301–11.
81. Hoffman GM, Tweddell JS, Ghanayem NS, et al. Alteration of the
critical arteriovenous oxygen saturation relationship by sustained
afterload reduction after the norwood procedure. J Thorac Cardiovasc
Surg 2004;127:738–745.
82. Srinivasan C, Sachdeva R, Morrow WR, et al. Standardized man-
agement improves outcomes after the Norwood procedure. Congenit
Heart Dis 2009;4:329–337.
83. Furck AK, Hansen JH, Uebing A, Scheewe J, Jung O, Kramer H-H.
The impact of afterload reduction on the early postoperative course
after the Norwood operation — a 12-year single-centre experience.
Eur J Cardiothorac Surg 2010;37:289–95.
84. Barnea O, Santamore WP, Rossi A, Salloum E, Chien S, Austin
EH. Estimation of oxygen delivery in newborns with a univentricular
circulation. Circulation 1998;98:1407–13.
85. Jobes DR, Nicolson SC, Steven JM, Miller M, Jacobs ML, Norwood
WI. Carbon dioxide prevents pulmonary overcirculation in hypoplas-
tic left heart syndrome. Ann Thorac Surg 1992;54:150–1.
86. Mora G, Pizarro C, Jacobs M, Norwood W. Experimental model of
single ventricle. Influence of carbon dioxide on pulmonary vascular
dynamics. Circulation 1994;90:II43–6.
87. Riordan CJ, Randsbaek F, Storey JH, Montgomery WD, Santamore
WP, Austin EH 3rd. Effects of oxygen, positive end-expiratory
pressure, and carbon dioxide on oxygen delivery in an animal model
of the univentricular heart. J Thorac Cardiovasc Surg 1996;112:
644–54.
88. Ramamoorthy C, Tabbutt S, Kurth CD, et al. Effects of inspired
hypoxic and hypercapnic gas mixtures on cerebral oxygen saturation
in neonates with univentricular heart defects. Anesthesiology 2002;
96:283–8.
89. Taeed R, Schwartz SM, Pearl JM, et al. Unrecognized pulmonary
venous desaturation early after Norwood palliation confounds Gp:Gs
assessment and compromises oxygen delivery. Circulation 2001;103:
2699–704.
90. Hoffman GM, Mussatto KA, Brosig CL, et al. Systemic venous
oxygen saturation after the Norwood procedure and childhood
neurodevelopmental outcome. J Thorac Cardiovasc Surg 2005;130:
1094–100.
91. Tortoriello TA, Stayer SA, Mott AR, et al. A noninvasive estimation
of mixed venous oxygen saturation using near-infrared spectroscopy
by cerebral oximetry in pediatric cardiac surgery patients. Paediatr
Anaesth 2005;15:495–503.
92. Ranucci M, Isgro´ G, De La Torre T, Romitti F, Conti D, Carlucci
C. Near-infrared spectroscopy correlates with continuous superior
vena cava oxygen saturation in pediatric cardiac surgery patients.
Paediatr Anaesth 2008;18:1163–9.
93. Kaufman J, Almodovar M, Zuk J, Friesen R. Correlation of abdom-
inal site near-infrared spectroscopy with gastric tonometry in infantsfollowing surgery for congenital heart disease. Pediatr Crit Care Med
2008;9:62–8.
94. Chakravarti SB, Mittnacht AJC, Katz JC, Nguyen K, Joashi U,
Srivastava S. Multisite near-infrared spectroscopy predicts elevated
blood lactate level in children after cardiac surgery. J Cardiothorac
Vasc Anesth 2009;23:663–7.
95. Phelps HM, Mahle WT, Kim D, et al. Postoperative cerebral
oxygenation in hypoplastic left heart syndrome after the Norwood
procedure. Ann Thorac Surg 2009;87:1490–4.
96. Chang AC, Atz AM, Wernovsky G, Burke RP, Wessel DL.
Milrinone: systemic and pulmonary hemodynamic effects in neonates
after cardiac surgery. Crit Care Med 1995;23:1907–14.
97. De Oliveira NC, Ashburn DA, Khalid F, et al. Prevention of early
sudden circulatory collapse after the Norwood operation. Circulation
2004;110:II-133–8.
98. Wright GE, Crowley DC, Charpie JR, Ohye RG, Bove EL, Kulik
TJ. High systemic vascular resistance and sudden cardiovascular
collapse in recovering norwood patients. Ann Thorac Surg 2004;77:
48–52.
99. Tabbutt S, Duncan BW, McLaughlin D, Wessel DL, Jonas RA,
Laussen PC. Delayed sternal closure after cardiac operations in a
pediatric population. J Thorac Cardiovasc Surg 1997;113:886–93.
00. Gaynor JW, Mahle WT, Cohen MI, et al. Risk factors for mortality
after the Norwood procedure. Eur J Cardiothorac Surg 2002;22:
82–9.
01. Wernovsky G, Kuijpers M, Van Rossem MC, et al. Postoperative
course in the cardiac intensive care unit following the first stage of
Norwood reconstruction. Cardiol Young 2007;17:652–65.
02. Blackwood J, Joffe AR, Robertson CMT, et al. Association of
hemoglobin and transfusion with outcome after operations for
hypoplastic left heart. Ann Thorac Surg 2010;89:1378–84.e2.
03. Jeffries HE, Wells WJ, Starnes VA, Wetzel RC, Moromisato DY.
Gastrointestinal morbidity after norwood palliation for hypoplastic
left heart syndrome. Ann Thorac Surg 2006;81:982–987.
04. Gaynor JW, Jarvik GP, Bernbaum J, et al. The relationship of
postoperative electrographic seizures to neurodevelopmental outcome
at 1 year of age after neonatal and infant cardiac surgery. J Thorac
Cardiovasc Surg 2006;131:181–9.
05. Clancy RR, Sharif U, Ichord R, et al. Electrographic neonatal
seizures after infant heart surgery. Epilepsia (Series 4) 2005;46:
84–90.
06. Andropoulos DB, Mizrahi EM, Hrachovy RA, et al. Electroenceph-
alographic seizures after neonatal cardiac surgery with high-flow
cardiopulmonary bypass. Anesth Analg 2010;110:1680–5.
07. Gaynor JW, Nicolson SC, Jarvik GP, et al. Increasing duration of
deep hypothermic circulatory arrest is associated with an increased
incidence of postoperative electroencephalographic seizures. J Thorac
Cardiovasc Surg 2005;130:1278–86.
08. Galli KK, Zimmerman RA, Jarvik GP, et al. Periventricular leu-
komalacia is common after neonatal cardiac surgery. J Thorac
Cardiovasc Surg 2004;127:692–704.
09. Dent CL, Spaeth JP, Jones BV, et al. Brain magnetic resonance
imaging abnormalities after the Norwood procedure using regional
cerebral perfusion. J Thorac Cardiovasc Surg 2005;130:1523–30.
10. Sachdeva R, Hussain E, Moss MM, et al. Vocal cord dysfunction and
feeding difficulties after pediatric cardiovascular surgery. J Pediatr
2007;151:312–5.e2.
11. Skinner ML, Halstead LA, Rubinstein CS, Atz AM, Andrews D,
Bradley SM. Laryngopharyngeal dysfunction after the Norwood
procedure. J Thorac Cardiovasc Surg 2005;130:1293–301.
12. Edwards L, Morris KP, Siddiqui A, Harrington D, Barron D, Brawn
W. Norwood procedure for hypoplastic left heart syndrome: BT
shunt or RV-PA conduit? Arch Dis Child Fetal Neonatal Ed
2007;92:F210–4.
13. Ichihashi K, Matsui A, Yanagisawa M, Yamada S. Hepatic cell
necrosis with congenital heart disease in the newborn. Acta Paediatr
Jpn 1991;33:87–92.
14. Ghanayem NS, Hoffman GM, Mussatto KA, et al. Home surveil-
lance program prevents interstage mortality after the Norwood
procedure. J Thorac Cardiovasc Surg 2003;126:1367–1375.
15. Bautista-Hernandez V, Marx GR, Gauvreau K, et al. Coarctectomy
reduces neoaortic arch obstruction in hypoplastic left heart syndrome.
J Thorac Cardiovasc Surg 2007;133:1540–6.
S34 Feinstein et al. JACC Vol. 59, No. 1, Suppl S, 2012
HLHS: Current Considerations and Expectations December 27, 2011/January 3, 2012:S1–S42116. Lamers L, Frommelt P, Musatto K, Mitchell M, Tweddell J.
Abstract 2351: decreased incidence of recurrent coarctation of the
aorta following the Norwood procedure (abstr). Circulation 2007;
116:II515.
117. Burkhart HM, Ashburn DA, Konstantinov IE, et al. Interdigitating
arch reconstruction eliminates recurrent coarctation after the Nor-
wood procedure. J Thorac Cardiovasc Surg 2005;130:61–5.
118. Soongswang J, McCrindle B, Jones T, Vincent R, Hsu D, Kuhn M.
Outcomes of transcatheter balloon angioplasty of obstruction in the
neo-aortic arch after the Norwood operation. Cardiol Young 2001;
11:54–61.
119. Ballweg JD, Dominguez TE, Ravishankar C, et al. Re-coarctation
following stage 1 reconstruction does not adversely affect survival or
outcome at Fontan completion (abstr). 35th Annual Meeting of the
Western Thoracic Surgical Association. Banff, Alberta, Canada:
Western Thoracic Surgical Association, 2009:109–10.
120. Zeltser I, Menteer J, Gaynor JW, et al. Impact of re-coarctation
following the Norwood operation on survival in the balloon angio-
plasty era. J Am Coll Cardiol 2005;45:1844–1848.
121. Jonas R, Lang P, Hansen D, Hickey P, Castaneda A. First-stage
palliation of hypoplastic left heart syndrome. The importance of
coarctation and shunt size. J Thorac Cardiovasc Surg 1986;92:6–13.
122. Gibbs JL, Rothman MT, Rees MR, Parsons JM, Blackburn ME,
Ruiz CE. Stenting of the arterial duct: a new approach to palliation
for pulmonary atresia. Brit Heart J 1992;67:240–5.
123. Ruiz CE, Gamra H, Zhang HP, Garcia EJ, Boucek MM. Stenting
of the ductus arteriosus as a bridge to cardiac transplantation in
infants with the hypoplastic left-heart syndrome. N Engl J Med
1993;328:1605–8.
124. Gibbs JL, Wren C, Watterson KG, Hunter S, Hamilton JR. Stenting
of the arterial duct combined with banding of the pulmonary arteries
and atrial septectomy or septostomy: a new approach to palliation for
the hypoplastic left heart syndrome. Br Heart J 1993;69:551–5.
125. Artrip JH, Campbell DN, Ivy DD, et al. Birth weight and complexity
are significant factors for the management of hypoplastic left heart
syndrome. Ann Thorac Surg 2006;82:1252–9.
126. Bacha EA, Daves S, Hardin J, et al. Single-ventricle palliation for
high-risk neonates: The emergence of an alternative hybrid stage I
strategy. J Thorac Cardiovasc Surg 2006;131:163–171.e2.
127. Egan MJ, Hill SL, Boettner BL, et al. Predictors of retrograde aortic
arch obstruction after hybrid palliation of hypoplastic left heart
syndrome. Pediatr Cardiol 2011;32:67–75.
128. Caldarone C, Benson L, Holtby H, Van Arsdell G. Main
pulmonary artery to innominate artery shunt during hybrid palli-
ation of hypoplastic left heart syndrome. J Thorac Cardiovasc Surg
2005;130:e1–2.
129. Caldarone CA, Benson L, Holtby H, Li J, Redington AN, Van Arsdell
GS. Initial experience with hybrid palliation for neonates with single-
ventricle physiology. Ann Thorac Surg 2007;84:1294–300.
130. Akintuerk H, Michel-Behnke I, Valeske K, et al. Stenting of the
arterial duct and banding of the pulmonary arteries: basis for
combined Norwood stage I and II repair in hypoplastic left heart.
Circulation 2002;105:1099–103.
131. Akintürk H, Michel-Behnke I, Valeske K, et al. Hybrid transcath-
eter–surgical palliation. Pediatr Cardiol 2007;28:79–87.
132. Michel-Behnke I, Akintuerk H, Marquardt I, et al. Stenting of the
ductus arteriosus and banding of the pulmonary arteries: basis for
various surgical strategies in newborns with multiple left heart
obstructive lesions. Heart 2003;89:645–50.
133. Müller M, Akintürk H, Schindler E, et al. A combined stage 1 and
2 repair for hypoplastic left heart syndrome: anaesthetic consider-
ations. Paediatr Anaesth 2003;13:360–5.
134. Hill SL, Galantowicz M, Cheatham JP. Emerging strategies in the
treatment of hlhs: combined transcatheter & surgical techniques.
Pediatr Cardiol Today 2003;1:1–4.
135. Galantowicz M, Cheatham JP. Lessons learned from the develop-
ment of a new hybrid strategy for the management of hypoplastic left
heart syndrome. Pediatr Cardiol 2005;26:190–9. Erratum in: Pediatr
Cardiol 2005;26:307.
136. Galantowicz M, Cheatham JP, Phillips A, et al. Hybrid approach for
hypoplastic left heart syndrome: intermediate results after the learn-
ing curve. Ann Thorac Surg 2008;85:2063–71.137. Holzer R, Wood A, Chisolm J, et al. Atrial septal interventions in
patients with hypoplastic left heart syndrome. Catheter Cardiovasc
Interv 2008;72:696–704.
138. Fenstermaker B, Berger G, Rowland D, et al. Interstage echocardio-
graphic changes in patients undergoing hybrid stage I palliation for
hypoplastic left heart syndrome. J Am Soc Echocardiogr 2008;21:
1222–8.
139. Holzer R, Green J, Bergdall V, et al. An animal model for hybrid
stage I palliation of hypoplastic left heart syndrome. Pediatr Cardiol
2009;30:922–7.
140. Bailey L. Role of cardiac replacement in the neonate. J Heart
Transplant 1985;4:506–9.
141. Almond CSD, Thiagarajan RR, Piercey GE, et al. Waiting list
mortality among children listed for heart transplantation in the
United States. Circulation 2009;119:717–27.
142. Boucek RJ, Chrisant M. Cardiac transplantation for hypoplastic left
heart syndrome. Cardiol Young 2004;14:83–7.
143. West LJ, Pollock-Barziv SM, Dipchand AI, et al. ABO-
incompatible heart transplantation in infants. N Engl J Med 2001;
344:793–800.
144. Kirk R, Edwards LB, Kucheryavaya AY, et al. The Registry of the
International Society for Heart and Lung Transplantation: thirteenth
official pediatric heart transplantation report—2010. J Heart Lung
Transplant 2010;29:1119–28.
145. Hehir DA, Dominguez TE, Ballweg JA, et al. Risk factors for interstage
death after stage 1 reconstruction of hypoplastic left heart syndrome and
variants. J Thorac Cardiovasc Surg 2008;136:94–99.e3.
146. Furck AK, Uebing A, Hansen JH, et al. Outcome of the Norwood
operation in patients with hypoplastic left heart syndrome: a 12-year
single-center survey. J Thorac Cardiovasc Surg 2010;139:359–65.
147. Tweddell JS, Hoffman GM, Fedderly RT, et al. Patients at risk for
low systemic oxygen delivery after the Norwood procedure. Ann
Thorac Surg 2000;69:1893–9.
148. Jonas R, Hansen D, Cook N, Wessel D. Anatomic subtype and
survival after reconstructive operation for hypoplastic left heart
syndrome. J Thorac Cardiovasc Surg 1994;107:1121–7; discussion
1127–8.
149. Mahle WT, Spray TL, Wernovsky G, Gaynor JW, Clark BJ 3rd.
Survival after reconstructive surgery for hypoplastic left heart syn-
drome: a 15-year experience from a single institution. Circulation
2000;102:III136–41.
150. Tsao S, Pigula F, Siewers R, et al. Viral illness may be detrimental to
patients with HLHS post stage1 Norwood procedure. Paper pre-
sented at: Midwest Pediatric Cardiology Meeting; 2000; WI: Sep-
tember 15, 2000.
151. Kugler JD, III RHB, Rosenthal GL, et al. Development of a
pediatric cardiology quality improvement collaborative: from incep-
tion to implementation. From the Joint Council on Congenital Heart
Disease Quality Improvement Task Force. Congenit Heart Dis
2009;4:318–28.
152. Rudd N, Steltzer M, Buckles C, et al. Home surveillance program
detects at-risk infants following Norwood palliation. Cardiology
2008: 11th Annual Update on Pediatric Cardiovascular Disease–
Abstracts. Cardiol Young 2008;18:191–235.
153. Nieves J. Safely transitioning the fragile neonate to a home environment
by utilizing a focused neonatal outpatient clinic. Presented at: the 12th
Annual Update on Pediatric and Congenital Cardiovascular Disease,
2009; February 4–8, 2009; Paradise Island, Nassau, Bahamas.
154. Kelleher D, Laussen P, Teixeira-Pinto A, Duggan C. Growth and
correlates of nutritional status among infants with hypoplastic left
heart syndrome (HLHS) after stage 1 Norwood procedure. Nutrition
2006;22:237–44.
155. Parsons JM, Ladusans EJ, Qureshi SA. Balloon dilatation of a
stenosed modified (polytetrafluoroethylene) Blalock-Taussig shunt.
Brit Heart J 1989;62:228–9.
156. Marasini M, Dalmonte P, Pongiglione G, et al. Balloon dilatation of
critically obstructed modified (polytetrafluoroethylene) Blalock-
Taussig shunts. Am J Cardiol 1994;73:405–7.
157. Wang J-K, Wu M-H, Chang C-I, Chiu I-S, Lue H-C. Balloon
angioplasty for obstructed modified systemic-pulmonary artery
shunts and pulmonary artery stenoses. J Am Coll Cardiol 2001;37:
940–7.
S35JACC Vol. 59, No. 1, Suppl S, 2012 Feinstein et al.
December 27, 2011/January 3, 2012:S1–S42 HLHS: Current Considerations and Expectations158. Robinson A, Fellows KE, Bridges ND, Rome JJ. Effectiveness of
pharmacomechanical thrombolysis in infants and children. Am J
Cardiol 2001;87:496–9, A8.
159. Whisenant BK, Baim DS, Kuntz RE, Garcia LA, Ramee SR,
Carrozza JP. Rheolytic thrombectomy with the Possis AngioJet:
technical considerations and initial clinical experience. J Invasive
Cardiol 1999;11:421–6.
160. Singh M, Tiede DJ, Mathew V, et al. Rheolytic thrombectomy with
Angiojet in thrombus-containing lesions. Catheter Cardiovasc Interv
2002;56:1–7.
161. Zahn EM, Chang AC, Aldousany A, Burke RP. Pediatric interven-
tions: emergent stent placement for acute Blalock-Taussig shunt
obstruction after stage 1 Norwood surgery. Catheter Cardiovasc
Diagn 1997;42:191–4.
162. Lee KJ, Humpl T, Hashmi A, Nykanen DG, Williams WG, Benson
LN. Restoration of aortopulmonary shunt patency. Am J Cardiol
2001;88:325–8.
163. Petit CJ, Gillespie MJ, Kreutzer J, Rome JJ. Endovascular stents for
relief of cyanosis in single-ventricle patients with shunt or conduit-
dependent pulmonary blood flow. Catheter Cardiovasc Interv 2006;
68:280–6.
164. Kogon B, Villari C, Shah N, et al. Occlusion of the modified
Blalock-Taussig shunt: unique methods of treatment and review of
catheter-based intervention. Congenit Heart Dis 2007;2:185–90.
165. Gillespie MJ, Rome JJ. Transcatheter treatment for systemic-to-
pulmonary artery shunt obstruction in infants and children. Catheter
Cardiovasc Interv 2008;71:928–35.
166. Moszura T, Zubrzycka M, Michalak K, et al. Acute and late
obstruction of a modified Blalock-Taussig shunt: a two-center
experience in different catheter-based methods of treatment. Interact
Cardiovasc Thorac Surg 2010;10:727–31.
167. Eicken A, Genz T, Sebening W. Stenting of stenosed shunts in
patients after a Norwood-Sano operation. Catheter Cardiovasc Interv
2006;68:301–3.
168. Dahnert I, Riede FT, Razek V, et al. Catheter interventional
treatment of Sano shunt obstruction in patients following modified
Norwood palliation for hypoplastic left heart syndrome. Clin Res
Cardiol 2007;96:719–22.
169. Muyskens S, Nicolas R, Foerster S, Balzer D. Endovascular stent
placement for right ventricle to pulmonary artery conduit stenosis in
the Norwood with Sano modification. Congenit Heart Dis 2008;3:
185–90.
170. Desai T, Stumper O, Miller P, et al. Acute interventions for stenosed
right ventricle-pulmonary artery conduit following the right-sided
modification of Norwood-Sano procedure. Congenit Heart Dis
2009;4:433–9.
171. Brown DW, Gauvreau K, Moran AM, et al. Clinical outcomes and
utility of cardiac catheterization prior to superior cavopulmonary
anastomosis. J Thorac Cardiovasc Surg 2003;126:272–81.
172. del Cerro M, Fernndez A, Espinosa S, et al. Interventional cathe-
terization after the Norwood procedure. Rev Esp Cardiol 2008;61:
146–53.
173. Moszura T, Mazurek-Kula A, Dryzek P, et al. Interventions com-
plementing surgery as part of multistage treatment for hypoplastic left
heart syndrome: one center’s experience. Pediatr Cardiol 2009;30:
106–13.
174. Zellers TM. Balloon angioplasty for recurrent coarctation of the aorta
in patients following staged palliation for hypoplastic left heart
syndrome. Am J Cardiol 1999;84:231–3.
175. Chessa M, Dindar A, Vettukattil JJ, et al. Balloon angioplasty in
infants with aortic obstruction after the modified stage I Norwood
procedure. Am Heart J 2000;140:227–31.
176. Tworetzky W, McElhinney DB, Burch GH, Teitel DF, Moore P.
Balloon arterioplasty of recurrent coarctation after the modified
Norwood procedure in infants. Catheter Cardiovasc Interv 2000;50:
54–8.
177. Moore JW, Spicer RL, Mathewson JW, Kirby WC. High-risk
angioplasty. Coarctation of the aorta after Norwood Stage 1. Tex
Heart Inst J 1993;20:48–50.
178. Magee AG, McCrindle BW, Mawson J, Benson LN, Williams WG,
Freedom RM. Systemic venous collateral development after the
bidirectional cavopulmonary anastomosis: prevalence and predictors.
J Am Coll Cardiol 1998;32:502–8.179. Andrews RE, Tulloh RMR, Anderson DR. Coil occlusion of
systemic venous collaterals in hypoplastic left heart syndrome. Heart
2002;88:167–9.
180. Spicer RL, Uzark KC, Moore JW, Mainwaring RD, Lamberti JJ.
Aortopulmonary collateral vessels and prolonged pleural effusions
after modified Fontan procedures. Am Heart J 1996;131:1164–8.
181. McElhinney DB, Reddy VM, Tworetzky W, Petrossian E, Hanley
FL, Moore P. Incidence and implications of systemic to pulmonary
collaterals after bidirectional cavopulmonary anastomosis. Ann Tho-
rac Surg 2000;69:1222–8.
182. Bradley SM, McCall MM, Sistino JJ, Radtke WAK. Aortopulmo-
nary collateral flow in the Fontan patient: does it matter? Ann Thorac
Surg 2001;72:408–15.
183. Kanter K. Management of single ventricle and cavopulmonary
connection. In: Sellke F, del Nido P, Swanson S, eds. Sabiston and
Spencer’s Surgery of the Chest, 8th Edition. Philadelphia, PA:
Saunders Elsevier, 2010:2041–54.
184. Ring W. Cavopulmonary shunts and the Hemi-Fontan operation. In:
Kaiser L, Kron I, Spray T, eds. Mastery of Cardiothoracic Surgery.
Philadelphia, PA: Lippincott-Raven, 1998:839–47.
185. Jacobs M. Hypoplastic left heart syndrome. In: Kaiser L, Kron I,
Spray T, eds. Mastery of Cardiothoracic Surgery. Philadelphia, PA:
Lipponcott-Ravens, 1998:858–66.
186. Kogon BE, Plattner C, Leong T, Simsic J, Kirshbom PM, Kanter
KR. The bidirectional Glenn operation: a risk factor analysis for
morbidity and mortality. J Thorac Cardiovasc Surg 2008;136:
1237– 42.
187. Scheurer M, Hill E, Vasuki N, et al. Survival after bidirectional
cavopulmonary anastomosis: analysis of preoperative risk factors.
J Thorac Cardiovasc Surg 2007;134:82–9, 9.e1.
188. Manning PB, Mayer JE Jr., Wernovsky G, Fishberger SB, Walsh
EP. Staged operation to fontan increases the incidence of sinoatrial
node dysfunction. J Thorac Cardiovasc Surg 1996;111:833–40.
189. Norwood WI, Jacobs ML. Fontan’s procedure in two stages. Am J
Surg 1993;166:548–51.
190. Kanter KR, Vincent RN, Raviele AA. Importance of acquired
systemic-to-pulmonary collaterals in the Fontan operation. Ann
Thorac Surg 1999;68:969–74.
191. Cohen MI, Bridges ND, Gaynor JW, et al. Modifications to the
cavopulmonary anastomosis do not eliminate early sinus node dys-
function. J Thorac Cardiovasc Surg 2000;120:891–901.
192. Douglas WI, Goldberg CS, Mosca RS, Law IH, Bove EL. Hemi-
Fontan procedure for hypoplastic left heart syndrome: outcome and
suitability for Fontan. Ann Thorac Surg 1999;68:1361–7.
193. Jaquiss RDB, Ghanayem NS, Hoffman GM, et al. Early cavopul-
monary anastomosis in very young infants after the Norwood proce-
dure: impact on oxygenation, resource utilization, and mortality.
J Thorac Cardiovasc Surg 2004;127:982–9.
194. Sano S, Huang S-C, Kasahara S, Yoshizumi K, Kotani Y, Ishino K.
Risk factors for mortality after the Norwood procedure using right
ventricle to pulmonary artery shunt. Ann Thorac Surg 2009;87:
178–86.
195. Liu J, Lu Y, Chen H, Shi Z, Su Z, Ding W. Bidirectional Glenn
procedure without cardiopulmonary bypass. Ann Thorac Surg 2004;
77:1349–52.
196. Jonas R. Commentary on should the bidirectional Glenn procedure
be performed through a thoracotomy without cardiopulmonary by-
pass? J Thorac Cardiovasc Surg 1999;118:367–8.
197. Jahangiri M, Keogh B, Shinebourne EA, Lincoln C. Should the
bidirectional Glenn procedure be performed through a thoracotomy
without cardiopulmonary bypass? J Thorac Cardiovasc Surg 1999;
118:367–8.
198. Hopkins RA, Armstrong BE, Serwer GA, Peterson RJ, Oldham
HN. Physiological rationale for a bidirectional cavopulmonary shunt.
A versatile complement to the Fontan principle. J Thorac Cardiovasc
Surg 1985;90:391–8.
199. Bridges N, Jonas R, Mayer J, Flanagan M, Keane J, Castaneda A.
Bidirectional cavopulmonary anastomosis as interim palliation for
high-risk Fontan candidates. Early results. Circulation 1990;82:IV
170–6.
200. Jacobs ML, Rychik J, Rome JJ, et al. Early reduction of the volume
work of the single ventricle: the hemi-fontan operation. Ann Thorac
Surg 1996;62:575–6.
S36 Feinstein et al. JACC Vol. 59, No. 1, Suppl S, 2012
HLHS: Current Considerations and Expectations December 27, 2011/January 3, 2012:S1–S42201. Gray R, Altmann K, Mosca R, et al. Persistent antegrade pulmonary
blood flow post-glenn does not alter early post-Fontan outcomes in
single-ventricle patients. Ann Thorac Surg 2007;84:888–93.
202. Yoshida M, Yamaguchi M, Yoshimura N, Murakami H, Matsuhisa
H, Okita Y. Appropriate additional pulmonary blood flow at the
bidirectional Glenn procedure is useful for completion of total
cavopulmonary connection. Ann Thorac Surg 2005;80:976–81.
203. Rabinovitch M, Haworth S, Castaneda A, Nadas A, Reid L. Lung
biopsy in congenital heart disease: a morphometric approach to
pulmonary vascular disease. Circulation 1978;58:1107–22.
204. Fraisse A, Colan SD, Jonas RA, Gauvreau K, Geva T. Accuracy of
echocardiography for detection of aortic arch obstruction after stage
I Norwood procedure. Am Heart J 1998;135:230–6.
205. McMahon C, Eidem B, Bezold L, et al. Is cardiac catheterization a
prerequisite in all patients undergoing bidirectional cavopulmonary
anastomosis? J Am Soc Echocardiogr 2003;16:1068–72.
206. Geva T, Greil G, Marshall A, Landzberg M, Powell A. Gadolinium-
enhanced 3-dimensional magnetic resonance angiography of pulmo-
nary blood supply in patients with complex pulmonary stenosis or
atresia: comparison with x-ray angiography. Circulation 2002;106:
473–8.
207. Tsai-Goodman B, Geva T, Odegard K, Sena L, Powell A. Clinical
role, accuracy, and technical aspects of cardiovascular magnetic
resonance imaging in infants. Am J Cardiol 2004;94:69–74.
208. Muthurangu V, Taylor AM, Hegde SR, et al. Cardiac magnetic
resonance imaging after stage I Norwood operation for hypoplastic
left heart syndrome. Circulation 2005;112:3256–3263.
209. Brown DW, Gauvreau K, Powell AJ, et al. Cardiac magnetic
resonance versus routine cardiac catheterization before bidirectional
Glenn anastomosis in infants with functional single ventricle: a
prospective randomized trial. Circulation 2007;116:2718–25.
210. Fogel MA. Is routine cardiac catheterization necessary in the man-
agement of patients with single ventricles across staged Fontan
reconstruction? No! Pediatr Cardiol 2005;26:154–8.
211. Nakanishi T. Cardiac catheterization is necessary before bidirectional
Glenn and Fontan procedures in single ventricle physiology. Pediatr
Cardiol 2005;26:159–61.
212. Triedman JK, Bridges ND, Mayer JE, Lock JE. Prevalence and risk
factors for aortopulmonary collateral vessels after Fontan and bidi-
rectional Glenn procedures. J Am Coll Cardiol 1993;22:207–15.
213. Lai L, Laussen P, Cua C, et al. Outcomes after bidirectional Glenn
operation: Blalock-Taussig shunt versus right ventricle-to-pulmonary
artery conduit. Ann Thorac Surg 2007;83:1768–73.
214. Jaquiss RDB, Siehr S, Ghanayem N, et al. Early cavopulmonary
anastomosis after Norwood procedure results in excellent Fontan
outcome. Ann Thorac Surg 2006;82:1260–5.
215. Ghanayem N, Tweddell J, Hoffman G, Mussatto K, Jaquiss RDB.
Optimal timing of the second stage of palliation for hypoplastic left
heart syndrome facilitated through home monitoring, and the results
of early cavopulmonary anastomosis. Cardiol Young 2006;16 Suppl
1:61–6.
216. Mainwaring RD, Lamberti JJ, Uzark K. The bidirectional Glenn
procedure: palliation of the univentricular heart. Advances in cardiac
surgery 1994;5:115–40.
217. Ishiwata T, Kondo C, Nakanishi T, Nakazawa M, Imai Y, Momma
K. Nonobstructive ASD creation to qualify patients for the Fontan
operation: effects on pulmonary hypertension due to restrictive left
atrioventricular valve and interatrial communication. Catheter Car-
diovasc Interv 2002;56:528–32.
218. Jonas RA. Intermediate procedures after first-stage Norwood opera-
tion facilitate subsequent repair. Ann Thorac Surg 1991;52:696–700.
219. Yahagi N, Kumon K, Tanigami H, et al. Cardiac surgery and inhaled
nitric oxide: indication and follow-up (2–4 years). Artif Organs
1998;22:886–91.
220. Nemoto S, Umehara E, Ikeda T, Itonaga T, Komeda M. Oral
sildenafil ameliorates impaired pulmonary circulation early after
bidirectional cavopulmonary shunt. Ann Thorac Surg 2007;83:e11–3.
221. McElhinney DB, Reddy VM, Hanley FL, Moore P. Systemic venous
collateral channels causing desaturation after bidirectional cavopul-
monary anastomosis: evaluation and management. J Am Coll Cardiol
1997;30:817–24.
222. Joho-Arreola A, Bauersfeld U, Stauffer U, Baenziger O, Bernet V.
Incidence and treatment of diaphragmatic paralysis after cardiac
surgery in children. Eur J Cardiothorac Surg 2005;27:53–7.223. Jonas R, Jonas RA. Cardiac surgery and neurological injury in
children. Heart Lung Circ 2000;9:16–22.
224. Wegria R, Zekert H, Entrup RW, et al. Effect of an increase in
systemic venous pressure on the formation and evacuation of lymph.
Acta Cardiol 1964;19:193–216.
225. Wegria R, Zekert H, Walter KE, et al. Effect of systemic venous
pressure on drainage of lymph from thoracic duct. Am J Physiol
1963;204:284–8.
226. Berdat P, Belli E, Lacour-Gayet F, Planch C, Serraf A. Additional
pulmonary blood flow has no adverse effect on outcome after
bidirectional cavopulmonary anastomosis. Ann Thorac Surg 2005;79:
29–36.
227. Thompson LD, McElhinney DB, Culbertson CB, et al. Periopera-
tive administration of angiotensin converting enzyme inhibitors
decreases the severity and duration of pleural effusions following
bidirectional cavopulmonary anastomosis. Cardiol Young 2001;11:
195–200.
228. Mott AR, Spray TL, Gaynor JW, et al. Improved early results with
cavopulmonary connections. Cardiol Young 2001;11:3–11.
229. Jacobs ML, Norwood WI. Fontan operation: influence of modifica-
tions on morbidity and mortality. Ann Thorac Surg 1994;58:945–51.
230. Fedderly RT, Whitstone BN, Frisbee SJ, Tweddell JS, Litwin SB.
Factors related to pleural effusions after Fontan procedure in the era
of fenestration. Circulation 2001;104:I-148–51.
231. Pizarro C, Mroczek T, Gidding SS, Murphy JD, Norwood WI.
Fontan completion in infants. Ann Thorac Surg 2006;81:2243–9.
232. Cava J, Bevandic S, Steltzer M, Tweddell J. A medical strategy to
reduce persistent chest tube drainage after the fontan operation. Am J
Cardiol 2005;96:130–3.
233. Mainwaring RD, Lamberti JJ, Uzark K, Spicer RL, Cocalis MW,
Moore JW. Effect of accessory pulmonary blood flow on survival after
the bidirectional Glenn procedure. Circulation 1999;100:II-151–6.
234. Mainwaring RD, Lamberti JJ, Hugli TE. Complement activation
and cytokine generation after modified Fontan procedure. Ann
Thorac Surg 1998;65:1715–20.
235. François K, Bové T, De Groote K, et al. Pleural effusions, water
balance mediators and the influence of lisinopril after completion
Fontan procedures. Eur J Cardiothorac Surg 2009;36:57–62.
236. Alkan T, Sariog˘lu A, Samanli UB, et al. Atrial natriuretic peptide:
could it be a marker for postoperative recurrent effusions after Fontan
circulation in complex congenital heart defects? ASAIO J 2006;52:
543–8.
237. Caspi J, Pettitt TW, Mulder T, Stopa A. Development of the
pulmonary arteries after the norwood procedure: comparison between
Blalock-Taussig shunt and right ventricular-pulmonary artery con-
duit. Ann Thorac Surg 2008;86:1299–304.
238. Mainwaring RD, Lamberti JJ, Uzark K, Spicer RL. Bidirectional
Glenn: is accessory pulmonary blood flow good or bad? Circulation
1995;92:294–7.
239. Wright S, Mainwaring R. Octreotide for management of chylothorax
following bidirectional Glenn in a three-month-old infant. J Card
Surg 2009;24:216–8.
240. Mainwaring RD, Lamberti JJ, Carter TL, Moore JW, Nelson JC.
Renin, angiotensin II, and the development of effusions following
bidirectional Glenn and Fontan procedures. J Card Surg 1995;10:
111–8.
241. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax
1971;26:240–8.
242. Pridjian AK, Mendelsohn AM, Lupinetti FM, et al. Usefulness of
the bidirectional Glenn procedure as staged reconstruction for the
functional single ventricle. Am J Cardiol 1993;71:959–62.
243. Hirsch JC, Goldberg C, Bove EL, et al. Fontan operation in the
current era: a 15-year single institution experience. Ann Surg 2008;
248:402–10.
244. Salvin JW, Scheurer MA, Laussen PC, et al. Factors associated with
prolonged recovery after the Fontan operation. Circulation 2008;118:
S171–6.
245. Salazar J, Zafar F, Siddiqui K. Fenestration during Fontan palliation:
now the exception instead of the rule. J Thorac Cardiovasc Surg
2010;140:129–36.
246. Gentles TL, Mayer JJE, Gauvreau K, et al. Fontan operation in five
hundred consecutive patients: factors influencing early and late
outcome. J Thorac Cardiovasc Surg 1997;114:376–91.
S37JACC Vol. 59, No. 1, Suppl S, 2012 Feinstein et al.
December 27, 2011/January 3, 2012:S1–S42 HLHS: Current Considerations and Expectations247. Van Arsdell GS, McCrindle BW, Einarson KD, et al. Interventions
associated with minimal Fontan mortality. Ann Thorac Surg 2000;
70:568–74.
248. Morales DLS, Dibardino DJ, Braud BE, et al. Salvaging the failing
Fontan: lateral tunnel versus extracardiac conduit. Ann Thorac Surg
2005;80:1445–52.
249. Jahangiri M, Ross DB, Redington AN, Lincoln C, Shinebourne EA.
Thromboembolism after the Fontan procedure and its modifications.
Ann Thorac Surg 1994;58:1409–13.
250. Morales D, Fraser C. Surgical strategies for the failing systemic
ventricle. In: Chang A, Towbin J, eds. Heart Failure in Children and
Young Adults: From Molecular Mechanisms to Medical and Surgical
Strategies. Philadelphia, PA: Saunders Elsevier, 2006:591–606.
251. Ohye RG, Gomez CA, Goldberg CS, Graves HL, Devaney EJ, Bove
EL. Tricuspid valve repair in hypoplastic left heart syndrome.
J Thorac Cardiovasc Surg 2004;127:465–72.
252. Marcelletti C, Corno A, Giannico S, Marino B. Inferior vena
cava-pulmonary artery extracardiac conduit. A new form of right
heart bypass. J Thorac Cardiovasc Surg 1990;100:228–32.
253. Robbers-Visser D, Miedema M, Nijveld A, et al. Results of staged
total cavopulmonary connection for functionally univentricular
hearts; comparison of intra-atrial lateral tunnel and extracardiac
conduit. Eur J Cardiothorac Surg 2010;37:934–41.
254. Kumar SP, Rubinstein CS, Simsic JM, Taylor AB, Saul JP, Bradley
SM. Lateral tunnel versus extracardiac conduit fontan procedure: a
concurrent comparison. Ann Thorac Surg 2003;76:1389–97.
255. Fiore AC, Turrentine M, Rodefeld M, et al. Fontan operation: a
comparison of lateral tunnel with extracardiac conduit. Ann Thorac
Surg 2007;83:622–30.
256. KrishnankuttyRema R, Dasi LP, Pekkan K, et al. Quantitative
analysis of extracardiac versus intraatrial fontan anatomic geometries.
Ann Thorac Surg 2008;85:810–7.
257. Amodeo A, Grigioni M, Oppido G, et al. The beneficial vortex and
best spatial arrangement in total extracardiac cavopulmonary connec-
tion. J Thorac Cardiovasc Surg 2002;124:471–8.
258. Hirsch JC, Ohye RG, Devaney EJ, Goldberg CS, Bove EL. The
lateral tunnel Fontan procedure for hypoplastic left heart syndrome:
results of 100 consecutive patients. Pediatr Cardiol 2007;28:426–32.
259. Mitchell ME, Ittenbach RF, Gaynor JW, Wernovsky G, Nicolson S,
Spray TL. Intermediate outcomes after the Fontan procedure in the
current era. J Thorac Cardiovasc Surg 2006;131:172–80.
260. Meyer D, Zamora G, Wernovsky G, et al. Outcomes of the Fontan
procedure using cardiopulmonary bypass with aortic cross-clamping.
Ann Thorac Surg 2006;82:1611–8.
261. Kim S-J, Kim W-H, Lim H-G, Lee J-Y. Outcome of 200 patients
after an extracardiac Fontan procedure. J Thorac Cardiovasc Surg
2008;136:108–16.
262. Anderson PA, Sleeper LA, Mahony L, et al. Contemporary out-
comes after the Fontan procedure: a Pediatric Heart Network
multicenter study. J Am Coll Cardiol 2008;52:85–98.
263. Hosein RBM, Clarke AJB, McGuirk S, et al. Factors influencing
early and late outcome following the Fontan procedure in the current
era. The ’Two Commandments’? Eur J Cardiothorac Surg 2007;31:
344–52.
264. Bridges N, Lock J, Castaneda A. Baffle fenestration with subsequent
transcatheter closure. Modification of the Fontan operation for
patients at increased risk. Circulation 1990;82:1681–9.
265. Ono M, Boethig D, Goerler H, Lange M, Westhoff-Bleck M,
Breymann T. Clinical outcome of patients 20 years after Fontan
operation—effect of fenestration on late morbidity. Eur J Cardiotho-
rac Surg 2006;30:923–9.
266. Lemler MS, Scott WA, Leonard SR, Stromberg D, Ramaciotti C.
Fenestration improves clinical outcome of the fontan procedure: a
prospective, randomized study. Circulation 2002;105:207–12.
267. Monagle P, Karl T. Thromboembolic problems after the Fontan
operation. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu
2002;5:36–47.
268. Kaulitz R, Ziemer G, Paul T, Peuster M, Bertram H, Hausdorf G.
Fontan-type procedures: residual lesions and late interventions. Ann
Thorac Surg 2002;74:778–85.
269. Atz A, Travison T, McCrindle B. Impact of surgical fenestration in
a cohort of Fontan patients (abstr). J Am Coll Cardiol 2009;53:361A.270. Thompson LD, Petrossian E, McElhinney DB, et al. Is it necessary
to routinely fenestrate an extracardiac Fontan? J Am Coll Cardiol
1999;34:539–44.
271. Hsu D, Quaegebeur J, Ing F, Selber E, Lamour J, Gersony W.
Outcome after the single-stage, nonfenestrated Fontan procedure.
Circulation 1997;96:II-335–40.
272. Harada Y, Uchita S, Sakamoto T, et al. Do we need fenestration
when performing two-staged total cavopulmonary connection using
an extracardiac conduit? Interact Cardiovasc Thorac Surg 2009;9:
50–4.
273. Morales DLS, Carberry KE, Heinle JS, McKenzie ED, Fraser CD
Jr, Diaz LK. Extubation in the operating room after Fontan’s
procedure: effect on practice and outcomes. Ann Thorac Surg
2008;86:576–82.
274. Uemura H, Yagihara T, Yamashita K, Ishizaka T, Yoshizumi K,
Kawahira Y. Establishment of total cavopulmonary connection with-
out use of cardiopulmonary bypass. Eur J Cardiothorac Surg 1998;
13:504–7.
275. McElhinney DB, Petrossian E, Reddy VM, Hanley FL. Extracardiac
conduit fontan procedure without cardiopulmonary bypass. Ann
Thorac Surg 1998;66:1826–8.
276. Tam VKH, Miller BE, Murphy K. Modified Fontan without use of
cardiopulmonary bypass. Ann Thorac Surg 1999;68:1698–703.
277. Yetman A, Drummond-Webb J, Fiser W, et al. The extracardiac
Fontan procedure without cardiopulmonary bypass: technique and
intermediate-term results. Ann Thorac Surg 2002;74:S1416–21.
278. Kawahira Y, Uemura H, Yagihara T. Impact of the off-pump fontan
procedure on complement activation and cytokine generation. Ann
Thorac Surg 2006;81:685–9.
279. Shikata F, Yagihara T, Kagisaki K, et al. Does the off-pump Fontan
procedure ameliorate the volume and duration of pleural and perito-
neal effusions? Eur J Cardiothorac Surg 2008;34:570–5.
280. Navabi MA, Rastegar SM, Kiani A, et al. Avoiding cardiopulmonary
bypass in extracardiac cavopulmonary connection: does it really
matter? J Thorac Cardiovasc Surg 2010;139:1183–8.
281. Khairy P, Fernandes SM, Mayer JE Jr. et al. Long-term survival,
modes of death, and predictors of mortality in patients with Fontan
surgery. Circulation 2008;117:85–92.
282. d’Udekem Y, Iyengar A, Cochrane A, et al. The Fontan procedure:
contemporary techniques have improved long-term outcomes. Cir-
culation 2007;116:I157–64.
283. McGuirk SP, Griselli M, Stumper OF, et al. Staged surgical
management of hypoplastic left heart syndrome: a single institution
12 year experience. Heart 2006;92:364–70.
284. Gaynor JW, Gerdes M, Zackai EH, et al. Apolipoprotein E genotype
and neurodevelopmental sequelae of infant cardiac surgery. J Thorac
Cardiovasc Surg 2003;126:1736–45.
285. Gaynor JW, Wernovsky G, Jarvik GP, et al. Patient characteristics
are important determinants of neurodevelopmental outcome at one
year of age after neonatal and infant cardiac surgery. J Thorac
Cardiovasc Surg 2007;133:1344–53.e3.
286. Hirsch J, Gurney J, Donohue J, Gebremariam A, Bove E, Ohye R.
Hospital mortality for Norwood and arterial switch operations as a
function of institutional volume. Pediatr Cardiol 2008;29:713–7.
287. Mascio CE, Wayment M, Colaizy TT, Mahoney LT, Burkhart HM.
The modified Fontan procedure and prolonged pleural effusions. Am
Surg 2009;75:175–7.
288. Koutlas TC, Gaynor JW, Nicolson SC, Steven JM, Wernovsky G,
Spray TL. Modified ultrafiltration reduces postoperative morbidity
after cavopulmonary connection. Ann Thorac Surg 1997;64:37–43.
289. Senzaki H, Masutani S, Ishido H, et al. Cardiac rest and reserve
function in patients with Fontan circulation. J Am Coll Cardiol
2006;47:2528–2535.
290. Momma K. ACE inhibitors in pediatric patients with heart failure.
Paediatr Drugs 2006;8:55–69.
291. Heragu N, Mahony L. Is captopril useful in decreasing pleural
drainage in children after modified Fontan operation? Am J Cardiol
1999;84:1109–12.
292. Hsu DT, Zak V, Mahony L, et al. Enalapril does not improve growth
or ventricular function in infants with single ventricle: a multicenter
clinical trial (abstr). Circulation 2009;120:S560–1.
293. Hsu D, Mital S, Ravishankar C, et al. Rationale and design of a trial
of angiotensin-converting enzyme inhibition in infants with single
ventricle. Am Heart J 2009;157:37–45.
33
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
S38 Feinstein et al. JACC Vol. 59, No. 1, Suppl S, 2012
HLHS: Current Considerations and Expectations December 27, 2011/January 3, 2012:S1–S42294. Jin SM, Noh CI, Bae EJ, Choi JY, Yun YS. Impaired vascular
function in patients with Fontan circulation. Int J Cardiol 2007;120:
221–6.
295. Anne P, Du W, Mattoo TK, Zilberman MV. Nephropathy in
patients after Fontan palliation. Int J Cardiol 2009;132:244–7.
296. Natarajan S, Heiss C, Yeghiazarians Y, Fineman J, Teitel D, Tacy T.
Peripheral arterial function in infants and young children with
one-ventricle physiology and hypoxemia. Am J Cardiol 2009;103:
862–6.
297. Haseyama K, Satomi G, Yasukochi S, Matsui H, Harada Y, Uchita
S. Pulmonary vasodilation therapy with sildenafil citrate in a patient
with plastic bronchitis after the Fontan procedure for hypoplastic left
heart syndrome. J Thorac Cardiovasc Surg 2006;132:1232–3.
298. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M,
Picchio F. Effect of sildenafil on haemodynamic response to exercise
and exercise capacity in Fontan patients. Eur Heart J 2008;29:
1681–7.
299. Goldberg DJ, Szwast AL, Marino BS, et al. Abstract 2161: sildenafil
improves ventricular performance in children and young adults after
the Fontan operation (abstr). Circulation 2009;120:S603-b.
300. Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces
clinical, exercise and hemodynamic improvement in a pre-transplant
patient with plastic bronchitis after Fontan operation. J Heart Lung
Transplant 2005;24:1174–6.
301. Votava-Smith JK, Perens GS, Alejos JC. Bosentan for increased
pulmonary vascular resistance in a patient with single ventricle
physiology and a bidirectional Glenn shunt. Pediatr Cardiol 2007;
28:314–6.
302. Ovaert C, Thijs D, Dewolf D, et al. The effect of bosentan in patients
with a failing Fontan circulation. Cardiol Young 2009:1–9.
303. Horigome H, Murakami T, Isobe T, Nagasawa T, Matsui A. Soluble
P-selectin and thrombomodulin-protein C-Protein S pathway in
cyanotic congenital heart disease with secondary erythrocytosis.
Thromb Res 2003;112:223–7.
304. Odegard KC, McGowan FX, DiNardo JA, et al. Coagulation
abnormalities in patients with single-ventricle physiology precede the
Fontan procedure. J Thorac Cardiovasc Surg 2002;123:459–65.
305. Cheung EWY, Chay G, Ma ESK, Cheung Y-F. Systemic oxygen
saturation and coagulation factor abnormalities before and after the
fontan procedure. Am J Cardiol 2005;96:1571–5.
306. Butenas S, van’t Veer C, Mann KG. ”Normal” thrombin generation.
Blood 1999;94:2169–78.
307. Odegard KC, Zurakowski D, DiNardo JA, et al. Prospective longi-
tudinal study of coagulation profiles in children with hypoplastic left
heart syndrome from stage I through Fontan completion. J Thorac
Cardiovasc Surg 2009;137:934–41.
308. Coon PD, Rychik J, Novello RT, Ro PS, Gaynor JW, Spray TL.
Thrombus formation after the Fontan operation. Ann Thorac Surg
2001;71:1990–4.
309. Seipelt RG, Franke A, Vazquez-Jimenez JF, et al. Thromboembolic
complications after Fontan procedures: comparison of different ther-
apeutic approaches. Ann Thorac Surg 2002;74:556–62.
310. Jacobs ML, Pourmoghadam KK. Thromboembolism and the role of
anticoagulation in the Fontan patient. Pediatr Cardiol 2007;28:
457–64.
311. Kaulitz R, Ziemer G, Rauch R, et al. Prophylaxis of thromboembolic
complications after the Fontan operation (total cavopulmonary anas-
tomosis). J Thorac Cardiovasc Surg 2005;129:569–75.
312. Hanseus K, Björkheim G, Sorenson G. Formation of thrombus and
thromboembolism after the bidirectional Glenn anastomosis, total
cavopulmonary connection and the Fontan operation. Cardiol Young
1998;8:211–6.
313. Mahnke CB, Boyle GJ, Janosky JE, Siewers RD, Pigula FA.
Anticoagulation and incidence of late cerebrovascular accidents fol-
lowing the Fontan procedure. Pediatr Cardiol 2005;26:56–61.
314. Balling G, Vogt M, Kaemmerer H, Eicken A, Meisner H, Hess J.
Intracardiac thrombus formation after the Fontan operation. J Tho-
rac Cardiovasc Surg 2000;119:745–51.
315. Monagle P, Cochrane A, McCrindle B, Benson L, Williams W,
Andrew M. Editorial: thromboembolic complications after fontan
procedures—the role of prophylactic anticoagulation. J Thorac Car-
diovasc Surg 1998;115:493–8.
316. Konstantinov IE, Puga FJ, Alexi-Meskishvili VV. Thrombosis of
intracardiac or extracardiac conduits after modified Fontan operationin patients with azygous continuation of the inferior vena cava. Ann
Thorac Surg 2001;72:1641–4.
17. Jacobs ML, Pourmoghadam KK, Geary EM, et al. Fontan’s opera-
tion: is aspirin enough? Is Coumadin too much? Ann Thorac Surg
2002;73:64–8.
18. Walker HA, Gatzoulis MA. Prophylactic anticoagulation following
the Fontan operation. Heart 2005;91:854–56.
19. Shirai LK, Rosenthal DN, Reitz BA, Robbins RC, Dubin AM.
Arrhythmias and thromboembolic complications after the extracar-
diac Fontan operation. J Thorac Cardiovasc Surg 1998;115:499–505.
20. Monagle P, Cochrane A, Roberts R, et al. Abstract 1157: a
multicenter randomized trial comparing Heparin/warfarin versus
aspirin as primary thromboprophylaxis for two years after Fontan
procedure in children (abstr). Circulation 2008;118:S651.
21. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson A.
Antithrombotic therapy in children: the Seventh ACCP Conference
on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:
645S–87.
22. Driscoll DJ, Offord KP, Feldt RH, Schaff HV, Puga FJ, Danielson
GK. Five- to fifteen-year follow-up after Fontan operation. Circu-
lation 1992;85:469–96.
23. Gaynor JW, Bridges ND, Cohen MI, et al. Predictors of outcome
after the Fontan operation: is hypoplastic left heart syndrome still a
risk factor? J Thorac Cardiovasc Surg 2002;123:237–45.
24. La Gerche A, Gewillig M. What limits cardiac performance during
exercise in normal subjects and in healthy Fontan patients? Int
J Pediatr 2010;2010.
25. Nakamura Y, Yagihara T, Kagisaki K, Hagino I, Kobayashi J.
Ventricular performance in long-term survivors after Fontan opera-
tion. Ann Thorac Surg 2011;91:172–80.
26. Takken T, Tacken MH, Blank AC, Hulzebos EH, Strengers JL,
Helders PJ. Exercise limitation in patients with Fontan circulation: a
review. J Cardiovasc Med (Hagerstown) 2007;8:775–81.
27. Singh TP, Curran TJ, Rhodes J. Cardiac rehabilitation improves
heart rate recovery following peak exercise in children with repaired
congenital heart disease. Pediatr Cardiol 2007;28:276–9.
28. Wernovsky G, Rome J, Tabbutt S, et al. Guidelines for the
outpatient management of complex congenital heart disease. Con-
genit Heart Dis 2006;1:10–26.
29. Shachar G, Fuhrman B, Wang Y, Lucas R Jr, Lock J. Rest and
exercise hemodynamics after the Fontan procedure. Circulation
1982;65:1043–8.
30. Hsia T-Y, Khambadkone S, Deanfield JE, Taylor JFN, Migliavacca
F, de Leval MR. Subdiaphragmatic venous hemodynamics in the
Fontan circulation. J Thorac Cardiovasc Surg 2001;121:436–47.
31. Mahle W, Todd K, Fyfe D. Endothelial function following the
Fontan operation. Am J Cardiol 2003;91:1286–8.
32. Cohen MS, Marino BS, McElhinney DB, et al. Neo-aortic root
dilation and valve regurgitation up to 21 years after staged recon-
struction for hypoplastic left heart syndrome. J Am Coll Cardiol
2003;42:533–40.
33. Margossian R, Schwartz M, Prakash A, et al. Comparison of
echocardiographic and cardiac magnetic resonance imaging measure-
ments of functional single ventricular volumes, mass, and ejection
fraction (from the Pediatric Heart Network Fontan Cross-Sectional
Study). Am J Cardiol 2009;104:419–28.
34. Whitehead KK, Sundareswaran KS, Parks WJ, Harris MA, Yoga-
nathan AP, Fogel MA. Blood flow distribution in a large series of
patients having the Fontan operation: a cardiac magnetic resonance
velocity mapping study. J Thorac Cardiovasc Surg 2009;138:96–102.
35. Ghaferi AA, Hutchins GM. Progression of liver pathology in
patients undergoing the Fontan procedure: chronic passive conges-
tion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carci-
noma. J Thorac Cardiovasc Surg 2005;129:1348–52.
36. Kiesewetter CH, Sheron N, Vettukattill JJ, et al. Hepatic changes in
the failing Fontan circulation. Heart 2007;93:579–84.
37. Crupi G, Locatelli G, Tiraboschi R, Villani M, De Tommasi M,
Parenzan L. Protein-losing enteropathy after Fontan operation for
tricuspid atresia (imperforate tricuspid valve). Thorac Cardiovasc
Surg 1980;28:359–63.
38. Feldt RH, Driscoll DJ, Offord KP, et al. Protein-losing enteropathy
after the Fontan operation. J Thorac Cardiovasc Surg 1996;112:
672–80.
S39JACC Vol. 59, No. 1, Suppl S, 2012 Feinstein et al.
December 27, 2011/January 3, 2012:S1–S42 HLHS: Current Considerations and Expectations339. Malcic I, Sauer U, Stern H, et al. The influence of pulmonary artery
banding on outcome after the Fontan operation. J Thorac Cardiovasc
Surg 1992;104:743–7.
340. Powell AJ, Gauvreau K, Jenkins KJ, Blume ED, Mayer JE, Lock JE.
Perioperative risk factors for development of protein-losing enterop-
athy following a Fontan procedure. Am J Cardiol 2001;88:1206–9.
341. Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after
fontan operation: investigations into possible pathophysiologic mech-
anisms. Ann Thorac Surg 2006;82:695–700.
342. Rychik J. Protein-losing enteropathy after Fontan operation. Con-
genit Heart Dis 2007;2:288–300.
343. Hess J, Kruizinga K, Bijleveld CM, Hardjowijono R, Eygelaar A.
Protein-losing enteropathy after Fontan operation. J Thorac Cardio-
vasc Surg 1984;88:606–9.
344. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-
losing enteropathy after the Fontan operation: an international
multicenter study. PLE study group. J Thorac Cardiovasc Surg
1998;115:1063–73.
345. Griffiths ER, Kaza AK, Wyler von Ballmoos MC, et al. Evaluating
failing Fontans for heart transplantation: predictors of death. Ann
Thorac Surg 2009;88:558–63, discussion 563–4.
346. Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-
losing enteropathy and normalization of mesenteric Doppler flow
with sildenafil after Fontan. Ann Thorac Surg 2006;82:e39–40.
347. Rothman A, Snyder J. Protein-losing enteropathy following the
Fontan operation: resolution with prednisone therapy. Am Heart J
1991;121:618–9.
348. Rychik J, Piccoli DA, Barber G. Usefulness of corticosteroid therapy
for protein-losing enteropathy after the Fontan procedure. Am J
Cardiol 1991;68:819–21.
349. Masetti P, Marianeschi SM, Cipriani A, Iorio FS, Marcelletti CF.
Reversal of protein-losing enteropathy after ligation of systemic-
pulmonary shunt. Ann Thorac Surg 1999;67:235–6.
350. Jacobs ML, Rychik J, Byrum CJ, Norwood WI Jr. Protein-losing
enteropathy after Fontan operation: resolution after baffle fenestra-
tion. Ann Thorac Surg 1996;61:206–8.
351. Cohen MI, Rhodes LA, Wernovsky G, Gaynor JW, Spray TL,
Rychik J. Atrial pacing: an alternative treatment for protein-losing
enteropathy after the Fontan operation. J Thorac Cardiovasc Surg
2001;121:582–3.
352. Sheikh AM, Tang AT, Roman K, et al. The failing Fontan
circulation: successful conversion of atriopulmonary connections.
J Thorac Cardiovasc Surg 2004;128:60–6.
353. Weinstein S, Chan D. Extracardiac Fontan conversion, cryoablation,
and pacemaker placement for patients with a failed Fontan. Semin
Thorac Cardiovasc Surg 2005;17:170–8.
354. Brancaccio G, Carotti A, D’Argenio P, Michielon G, Parisi F.
Protein-losing enteropathy after Fontan surgery: resolution after
cardiac transplantation. J Heart Lung Transplant 2003;22:484–6.
355. Sierra C, Calleja F, Picazo B, Martinez-Valverde A. Protein-losing
enteropathy secondary to Fontan procedure resolved after cardiac
transplantation. J Pediatr Gastroenterol Nutr 1997;24:229–30.
356. Goo HW, Jhang WK, Kim YH, et al. CT findings of plastic
bronchitis in children after a Fontan operation. Pediatr Radiol
2008;38:989–93.
357. Barber BJ, Burch GH, Tripple D, Balaji S. Resolution of plastic
bronchitis with atrial pacing in a patient with fontan physiology.
Pediatr Cardiol 2004;25:73–6.
358. Wilson J, Russell J, Williams W, Benson L. Fenestration of the
Fontan circuit as treatment for plastic bronchitis. Pediatr Cardiol
2005;26:717–9.
359. Zahorec M, Kovacikova L, Martanovic P, Skrak P, Kunovsky P. The
use of high-frequency jet ventilation for removal of obstructing casts
in patients with plastic bronchitis. Pediatr Crit Care Med 2009;10:
e34–6.
360. Wakeham MK, Van Bergen AH, Torero LE, Akhter J. Long-term
treatment of plastic bronchitis with aerosolized tissue plasminogen
activator in a Fontan patient. Pediatr Crit Care Med 2005;6:76–8.
361. Ghai A, Harris L, Harrison DA, Webb GD, Siu SC. Outcomes of
late atrial tachyarrhythmias in adults after the Fontan operation. J Am
Coll Cardiol 2001;37:585–92.
362. Stephenson EA, Lu M, Berul CI, et al. Arrhythmias in a contem-
porary fontan cohort: prevalence and clinical associations in a mul-
ticenter cross-sectional study. J Am Coll Cardiol 2010;56:890–6.363. Giannico S, Hammad F, Amodeo A, et al. Clinical outcome of 193
extracardiac Fontan patients: the first 15 years. J Am Coll Cardiol
2006;47:2065–73.
364. Gewillig M, Wyse RK, de Leval MR, Deanfield JE. Early and late
arrhythmias after the Fontan operation: predisposing factors and
clinical consequences. Br Heart J 1992;67:72–9.
365. Kürer C, Tanner C, Norwood W, Vetter V. Perioperative arrhyth-
mias after Fontan repair. Circulation 1990;82:IV190–4.
366. Cohen M, Wernovsky G, Vetter V, et al. Sinus node function after
a systematically staged Fontan procedure. Circulation 1998;98:
II352–8, discussion II358–9.
367. Fishberger SB, Wernovsky G, Gentles TL, et al. Factors that
influence the development of atrial flutter after the fontan operation.
J Thorac Cardiovasc Surg 1997;113:80–6.
368. Ovroutski S, Dahnert I, Alexi-Meskishvili V, Nurnberg JH, Hetzer
R, Lange PE. Preliminary analysis of arrhythmias after the Fontan
operation with extracardiac conduit compared with intra-atrial lateral
tunnel. Thorac Cardiovasc Surg 2001;49:334–7.
369. Azakie A, McCrindle BW, Van Arsdell G, et al. Extracardiac
conduit versus lateral tunnel cavopulmonary connections at a single
institution: impact on outcomes. J Thorac Cardiovasc Surg 2001;122:
1219–28.
370. Deal BJ, Mavroudis C, Backer CL. Arrhythmia management in the
Fontan patient. Pediatr Cardiol 2007;28:448–56.
371. Collins KK, Love BA, Walsh EP, Saul JP, Epstein MR, Triedman
JK. Location of acutely successful radiofrequency catheter ablation of
intraatrial reentrant tachycardia in patients with congenital heart
disease. Am J Cardiol 2000;86:969–74.
372. Triedman JK, Alexander ME, Berul CI, Bevilacqua LM, Walsh EP.
Electroanatomic mapping of entrained and exit zones in patients with
repaired congenital heart disease and intra-atrial reentrant tachycar-
dia. Circulation 2001;103:2060–5.
373. De Groot N, Blom N, Wall EEV, Schalij M. Different mechanisms
underlying consecutive, postoperative atrial tachyArrhythmias in a
Fontan patient. Pacing Clin Electrophysiol 2009;32:e18–20.
374. Tsao S, Deal BJ, Backer CL, Ward K, Franklin WH, Mavroudis C.
Device management of arrhythmias after Fontan conversion. J Tho-
rac Cardiovasc Surg 2009;138:937–40.
375. Stephenson EA, Batra AS, Knilans TK, et al. A multicenter
experience with novel implantable cardioverter defibrillator configu-
rations in the pediatric and congenital heart disease population.
J Cardiovasc Electrophysiol 2006;17:41–6.
376. Radbill AE, Triedman JK, Berul CI, et al. System survival of
nontransvenous implantable cardioverter-defibrillators compared to
transvenous implantable cardioverter-defibrillators in pediatric and
congenital heart disease patients. Heart Rhythm 2010;7:193–8.
377. Mavroudis C, Backer CL, Deal BJ, Johnsrude CL. Fontan conver-
sion to cavopulmonary connection and arrhythmia circuit cryoabla-
tion. J Thorac Cardiovasc Surg 1998;115:547–56.
378. Marcelletti CF, Hanley FL, Mavroudis C, et al. Revision of previous
Fontan connections to total extracardiac cavopulmonary anastomosis:
A multicenter experience. J Thorac Cardiovasc Surg 2000;119:
340–6.
379. Mavroudis C, Deal BJ, Backer CL, et al. J. Maxwell Chamberlain
Memorial Paper for congenital heart surgery. 111 Fontan conversions
with arrhythmia surgery: surgical lessons and outcomes. Ann Thorac
Surg 2007;84:1457–66, discussion 1465–6.
380. Dearani J, Mavroudis C, Quintessenza J, et al. Surgical advances in
the treatment of adults with congenital heart disease. Curr Opin
Pediatr 2009;21:565–72.
381. Tibballs J, Kawahira Y, Carter BG, Donath S, Brizard C, Wilkinson
J. Outcomes of surgical treatment of infants with hypoplastic left
heart syndrome: an institutional experience 1983–2004. J Paediatr
Child Health. 2007;43:746–51.
382. Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult
congenital heart disease in Europe: morbidity and mortality in a 5
year follow-up period. Eur Heart J 2005;26:2325–33.
383. Oechslin EN, Harrison DA, Connelly MS, Webb GD, Siu SC.
Mode of death in adults with congenital heart disease. Am J Cardiol
2000;86:1111–6.
384. van der Velde ET, Vriend JWJ, Mannens MM, Uiterwaal CS, Brand
R, Mulder BJ. CONCOR, an initiative towards a national registry
and DNA-bank of patients with congenital heart disease in the
33
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
S40 Feinstein et al. JACC Vol. 59, No. 1, Suppl S, 2012
HLHS: Current Considerations and Expectations December 27, 2011/January 3, 2012:S1–S42Netherlands: rationale, design, and first results. Eur J Epidemiol
2005;20:549–57.
85. van den Bosch A, Roos-Hesselink J, Van Domburg R, Bogers AJJC,
Simoons M, Meijboom F. Long-term outcome and quality of life in
adult patients after the Fontan operation. Am J Cardiol 2004;93:
1141–5.
86. Ohuchi H, Yasuda K, Hasegawa S, et al. Influence of ventricular
morphology on aerobic exercise capacity in patients after the Fontan
operation. J Am Coll Cardiol 2001;37:1967–74.
87. Warnes C, Williams R, Bashore T, et al. ACC/AHA 2008 guide-
lines for the management of adults with congenital heart disease: a
report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Writing Committee
to Develop Guidelines on the Management of Adults With Con-
genital Heart Disease). J Am Coll Cardiol 2008;52:e1–121.
88. Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Pregnancy and
delivery in women after Fontan palliation. Heart 2006;92:1290–4.
89. Canobbio MM, Mair DD, van der Velde M, Koos BJ. Pregnancy
outcomes after the Fontan repair. J Am Coll Cardiol 1996;28:763–7.
90. Jacobs JP, Quintessenza JA, Chai PJ, et al. Rescue cardiac transplan-
tation for failing staged palliation in patients with hypoplastic left
heart syndrome. Cardiol Young 2006;16:556–62.
91. Gamba A, Merlo M, Fiocchi R, et al. Heart transplantation in
patients with previous Fontan operations. J Thorac Cardiovasc Surg
2004;127:555–62.
92. Bernstein D, Naftel D, Chin C, et al. Outcome of listing for cardiac
transplantation for failed Fontan: a multi-institutional study. Circu-
lation 2006;114:273–80.
93. Michielon G, Parisi F, Di Carlo D, et al. Orthotopic heart trans-
plantation for failing single ventricle physiology. Eur J Cardiothorac
Surg 2003;24:502–10.
94. Kirk R, Edwards L, Aurora P, et al. Registry of the International
Society for Heart and Lung Transplantation: Twelfth Official Pedi-
atric Heart Transplantation Report-2009. J Heart Lung Transplant
2009;28:993–1006.
95. Kovach J, Blume E, Naftel D. Comparison of risk factors and
outcomes for pediatric patients listed for heart transplantation after
bidirectional Glenn and after Fontan: a multi-institutional study.
J Heart Lung Transplant 2010;29:2:S71.
96. Dipchand AI, BarZiv SMP, Manlhiot C, West LJ, VanderVliet M,
McCrindle BW. Equivalent outcomes for pediatric heart transplan-
tation recipients: ABO-blood group incompatible versus ABO-
compatible. Am J Transplant 2010;10:389–97.
97. Nathan M, Baird C, Fynn-Thompson F, et al. Successful implanta-
tion of a Berlin heart biventricular assist device in a failing single
ventricle. J Thorac Cardiovasc Surg 2006;131:1407–8.
98. Calvaruso D, Ocello S, Salviato N, et al. Implantation of a Berlin
Heart as single ventricle by-pass on Fontan circulation in univen-
tricular heart failure. ASAIO J 2007;53:e1–2.
99. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-
mediated rejection of cardiac transplants. J Heart Lung Transplant
2006;25:153–9.
00. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic
antibody-mediated rejection after heart transplantation predicts poor
outcomes. J Heart Lung Transplant 2009;28:417–22.
01. Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in
pre-sensitized pediatric heart transplant recipients with a positive
donor crossmatch utilizing peri-operative plasmapheresis and cyto-
lytic therapy. J Heart Lung Transplant 2007;26:876–82.
02. Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J.
Practical application of the virtual crossmatch. Pediatr Transplant
2007;11:650–4.
03. Maxwell D, Allan L, Tynan MJ. Balloon dilatation of the aortic valve
in the fetus: a report of two cases. Brit Heart J 1991;65:256–8.
04. Kohl T, Sharland G, Allan LD, et al. World experience of percuta-
neous ultrasound-guided balloon valvuloplasty in human fetuses with
severe aortic valve obstruction. Am J Cardiol 2000;85:1230–3.
05. Simpson JM, Sharland GK. Natural history and outcome of aortic
stenosis diagnosed prenatally. Heart 1997;77:205–10.
06. McCaffrey FM, Sherman FS. Prenatal diagnosis of severe aortic
stenosis. Pediatr Cardiol 1997;18:276–81.
07. Makikallio K, McElhinney DB, Levine JC, et al. Fetal aortic valve
stenosis and the evolution of hypoplastic left heart syndrome: patient
selection for fetal intervention. Circulation 2006;113:1401–5.08. Kohl T, Szabo Z, Suda K, et al. Fetoscopic and open transumbilical
fetal cardiac catheterization in sheep: potential approaches for human
fetal cardiac intervention. Circulation 1997;95:1048–53.
09. Kohl T, Witteler R, Strmper D, et al. Operative techniques and
strategies for minimally invasive fetoscopic fetal cardiac interventions
in sheep. Surg Endosc 2000;14:424–30.
10. Kohl T, Strumper D, Witteler R, et al. Fetoscopic direct fetal cardiac
access in sheep : an important experimental milestone along the route
to human fetal cardiac intervention. Circulation 2000;102:1602–4.
11. Tworetzky W, Wilkins-Haug L, Jennings RW, et al. Balloon
dilation of severe aortic stenosis in the fetus: potential for prevention
of hypoplastic left heart syndrome: candidate selection, technique,
and results of successful intervention. Circulation 2004;110:2125–31.
12. Marshall A, Tworetzky W, Bergersen L, et al. Aortic valvuloplasty in
the fetus: technical characteristics of successful balloon dilation.
J Pediatr 2005;147:535–9.
13. Selamet Tierney ES, Wald RM, McElhinney DB, et al. Changes in
left heart hemodynamics after technically successful in-utero aortic
valvuloplasty. Ultrasound Obstet Gynecol 2007;30:715–20.
14. McElhinney DB, Marshall AC, Wilkins-Haug LE, et al. Predictors
of technical success and postnatal biventricular outcome after in utero
aortic valvuloplasty for aortic stenosis with evolving hypoplastic left
heart syndrome. Circulation 2009;120:1482–90.
15. Mizrahi-Arnaud A, Tworetzky W, Bulich L, et al. Pathophysiology,
management, and outcomes of fetal hemodynamic instability during
prenatal cardiac intervention. Pediatr Res 2007;62:325–30.
16. Vogel M, Wilkins-Haug L, McElhinney D, et al. Reversible ductus
arteriosus constriction due to maternal indomethacin after fetal
intervention for hypoplastic left heart syndrome with intact/restrictive
atrial septum. Fetal Diagn Ther 2010;27:40–5.
17. Johnson P, Maxwell DJ, Tynan MJ, Allan LD. Intracardiac pressures
in the human fetus. Heart 2000;84:59–63.
18. Vlahos AP, Lock JE, McElhinney DB, van der Velde ME. Hyp-
oplastic left heart syndrome with intact or highly restrictive atrial
septum: outcome after neonatal transcatheter atrial septostomy.
Circulation 2004;109:2326–30.
19. Glatz J, Tabbutt S, Gaynor JW, et al. Hypoplastic left heart
syndrome with atrial level restriction in the era of prenatal diagnosis.
Ann Thorac Surg 2007;84:1633–8.
20. Marshall A, Levine J, Morash D, et al. Results of in utero atrial
septoplasty in fetuses with hypoplastic left heart syndrome. Prenat
Diagn 2008;28:1023–8.
21. Marshall AC, van der Velde ME, Tworetzky W, et al. Creation of an
atrial septal defect in utero for fetuses with hypoplastic left heart
syndrome and intact or highly restrictive atrial septum. Circulation
2004;110:253–8.
22. Lev M. Pathologic anatomy and interrelationship of hypoplasia of the
aortic tract complexes. Lab Invest 1952;1:61–70.
23. Noonan JA, Nadas AS. The hypoplastic left heart syndrome; an
analysis of 101 cases. Pediatr Clin North Am 1958;5:1029–56.
24. Tchervenkov CI, Jacobs JP, Weinberg PM, et al. The nomenclature,
definition and classification of hypoplastic left heart syndrome.
Cardiol Young 2006;16:339–68.
25. Bharati S, Lev M. The surgical anatomy of hypoplasia of aortic tract
complex. J Thorac Cardiovasc Surg 1984;88:97–101.
26. Stamm C, Anderson RH, Ho SY. The morphologically tricuspid
valve in hypoplastic left heart syndrome. Eur J Cardiothorac Surg
1997;12:587–92.
27. Bharati S, Nordenberg A, Brock RR, Lev M. Hypoplastic left heart
syndrome with dysplastic pulmonary valve with stenosis. Pediatr
Cardiol 1984;5:127–30.
28. Hinton RB Jr., Martin LJ, Tabangin ME, Mazwi ML, Cripe LH,
Benson DW. Hypoplastic left heart syndrome is heritable. J Am Coll
Cardiol 2007;50:1590–5.
29. Surerus E, Huggon IC, Allan LD. Turner’s syndrome in fetal life.
Ultrasound Obstet Gynecol 2003;22:264–7.
30. Grossfeld PD, Mattina T, Lai Z, et al. The 11q terminal deletion
disorder: a prospective study of 110 cases. Am J Med Genet A
2004;129A:51–61.
31. Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL,
Fletcher WH. Identification of connexin43 (alpha1) gap junction
gene mutations in patients with hypoplastic left heart syndrome by
denaturing gradient gel electrophoresis (DGGE). Mutat Res 2001;
479:173–86.
44
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
S41JACC Vol. 59, No. 1, Suppl S, 2012 Feinstein et al.
December 27, 2011/January 3, 2012:S1–S42 HLHS: Current Considerations and Expectations432. Elliott DA, Kirk EP, Yeoh T, et al. Cardiac homeobox gene
NKX2-5 mutations and congenital heart disease: associations with
atrial septal defect and hypoplastic left heart syndrome. J Am Coll
Cardiol 2003;41:2072–6.
433. Shokeir MH. Hypoplastic left heart. Evidence for possible autosomal
recessive inheritance. Birth Defects Orig Artic Ser 1974;10:223–7.
434. Holmes LB, Rose V, Child AH, Kratzer W. Hypoplastic left heart.
Evidence for possible autosomal recessive inheritance. Comment.
Birth Defects Orig Artic Ser 1974;10:228–30.
435. Hinton RB, Martin LJ, Rame-Gowda S, Tabangin ME, Cripe LH,
Benson DW. Hypoplastic left heart syndrome links to chromosomes
10q and 6q and is genetically related to bicuspid aortic valve. J Am
Coll Cardiol 2009;53:1065–71.
436. Ferencz C, Rubin JD, McCarter RJ, et al. Congenital heart disease:
prevalence at livebirth. The Baltimore-Washington Infant Study.
Am J Epidemiol 1985;121:31–6.
437. Brenner JI, Berg KA, Schneider DS, Clark EB, Boughman JA.
Cardiac malformations in relatives of infants with hypoplastic left-
heart syndrome. Am J Dis Child 1989;143:1492–4.
438. McBride KL, Pignatelli R, Lewin M, et al. Inheritance analysis of
congenital left ventricular outflow tract obstruction malformations:
segregation, multiplex relative risk, and heritability. Am J Med Genet
A 2005;134A:180–6.
439. McBride KL, Zender GA, Fitzgerald-Butt SM, et al. Linkage
analysis of left ventricular outflow tract malformations (aortic valve
stenosis, coarctation of the aorta, and hypoplastic left heart syn-
drome). Eur J Hum Genet 2009;17:811–9.
440. Wessels MW, van de Laar IM, Roos-Hesselink J, et al. Autosomal
dominant inheritance of cardiac valves anomalies in two families:
extended spectrum of left-ventricular outflow tract obstruction. Am J
Med Genet A 2009;149A:216–25.
441. Martin LJ, Ramachandran V, Cripe LH, et al. Evidence in favor of
linkage to human chromosomal regions 18q, 5q and 13q for bicuspid
aortic valve and associated cardiovascular malformations. Hum Genet
2007;121:275–84.
442. Mahle WT, Clancy RR, Moss EM, Gerdes M, Jobes DR, Wer-
novsky G. Neurodevelopmental outcome and lifestyle assessment in
school-aged and adolescent children with hypoplastic left heart
syndrome. Pediatrics 2000;105:1082–9.
443. Goldberg CS, Schwartz EM, Brunberg JA, et al. Neurodevelopmen-
tal outcome of patients after the fontan operation: a comparison
between children with hypoplastic left heart syndrome and other
functional single ventricle lesions. J Pediatr 2000;137:646–52.
444. Limperopoulos C. Disorders of the fetal circulation and the fetal
brain. Clin Perinatol 2009;36:561–77.
445. Goldberg CS, Bove EL, Devaney EJ, et al. A randomized clinical
trial of regional cerebral perfusion versus deep hypothermic circula-
tory arrest: Outcomes for infants with functional single ventricle.
J Thorac Cardiovasc Surg 2007;133:880–7.e1.
446. Mahle W, Visconti K, Freier MC, et al. Relationship of surgical
approach to neurodevelopmental outcomes in hypoplastic left heart
syndrome. Pediatrics 2006;117:e90–7.
447. Day RW, Orsmond GS, Sturtevant JE, Hawkins JA, Doty DB,
McGough EC. Early and intermediate results of the Fontan proce-
dure at moderately high altitude. Ann Thorac Surg 1994;57:170–6.
448. Malhotra S, Ivy DD, Mitchell M, et al. Performance of cavopulmo-
nary palliation at elevated altitude: midterm outcomes and risk factors
for failure. Circulation 2008;118:S177–81.
449. Mitchell MB, Campbell DN, Ivy D, et al. Evidence of pulmonary
vascular disease after heart transplantation for Fontan circulation
failure. J Thorac Cardiovasc Surg 2004;128:693–702.
450. Rempel G, Harrison M, Williamson D. Is “treat your child normally”
helpful advice for parents of survivors of treatment of hypoplastic left
heart syndrome? Cardiol Young 2009;19:135–44.
451. Thompson R, Gustafson K. Adaptation to Chronic Childhood
Illness. 1st ed. Washington, DC: American Psychological Associa-
tion, 1999.
452. Wallander J, Thompson R, Alriksson-Schmidt A. Psychosocial
adjustment of children with chronic physical conditions. In: Roberts
M, ed. Handbook of Pediatric Psychology. New York, NY: Guilford
Press, 2003:772.
453. Latal B, Helfricht S, Fischer J, Bauersfeld U, Landolt M. Psycho-
logical adjustment and quality of life in children and adolescentsfollowing open-heart surgery for congenital heart disease: a
systematic review. BMC Pediatr 2009;9:6.
54. Moons P, Van Deyk K, Budts W, De Geest S. Caliber of quality-
of-life assessments in congenital heart disease: a plea for more
conceptual and methodological rigor. Arch Pediatr Adolesc Med
2004;158:1062–9.
55. Pike NA, Evangelista LS, Doering LV, Koniak-Griffin D, Lewis
AB, Child JS. Health-related quality of life: a closer look at related
research in patients who have undergone the Fontan operation over
the last decade. Heart Lung 2007;36:3–15.
56. Drotar D. Health status and quality of life. In: Naar-King S, Ellis D,
Frey M, eds. Assessing Children’s Well-Being : A Handbook of
Measures. Mahwah, NJ: Lawrence Erlbaum Associates, 2004.
57. Moons P, Van Deyk K, De Geest S, Gewillig M, Budts W. Is the
severity of congenital heart disease associated with the quality of life
and perceived health of adult patients? Heart 2005;91:1193–8.
58. McCrindle BW, Williams RV, Mitchell PD, et al. Relationship of
patient and medical characteristics to health status in children and
adolescents after the Fontan procedure. Circulation 2006;113:
1123–9.
59. Mellander M, Berntsson L, Nilsson B. Quality of life in children with
hypoplastic left heart syndrome. Acta Paediatr 2007;96:53–7.
60. Rose M, Köhler K, Köhler F, Sawitzky B, Fliege H, Klapp BF.
Determinants of the quality of life of patients with congenital heart
disease. Qual Life Res 2005;14:35–43.
61. Marino BS, Tomlinson RS, Drotar D, et al. Quality-of-life concerns
differ among patients, parents, and medical providers in children and
adolescents with congenital and acquired heart disease. Pediatrics
2009;123:e708–15.
62. Williams DL, Gelijns AC, Moskowitz AJ, et al. Hypoplastic left
heart syndrome: valuing the survival. J Thorac Cardiovasc Surg
2000;119:720–31.
63. Saliba Z, Butera G, Bonnet D, et al. Quality of life and perceived
health status in surviving adults with univentricular heart. Heart
2001;86:69–73.
64. Marino BS, Shera D, Wernovsky G, et al. The development of the
pediatric cardiac quality of life inventory: a quality of life measure for
children and adolescents with heart disease. Qual Life Res 2008;17:
613–26.
65. Clark B, Sleeper L, Anderson P. The Fontan cross-sectional study:
testing for correlations among health-related quality of life, maximal
exercise performance, and ventricular mass-to-volume ratio (abstr).
Circulation 2004;110:III441.
66. Harinck E, Hutter PA, Hoorntje TM, et al. Air travel and adults
with cyanotic congenital heart disease. Circulation 1996;93:272–6.
67. Broberg CS, Uebing A, Cuomo L, Thein SL, Papadopoulos MG,
Gatzoulis MA. Adult patients with Eisenmenger syndrome report
flying safely on commercial airlines. Heart 2007;93:1599–603.
68. TSA. Hidden Disabilities. Available at: http://www.tsa.gov/travelers/
airtravel/specialneeds/editorial_1374.shtm. Accessed November 8,
2011.
69. NHOPA. Airline Travel with Oxygen. Available at: http://
www.homeoxygen.org/airline-travel-with-oxygen. Accessed Novem-
ber 8, 2011.
70. Friedberg MK, Silverman NH, Dubin AM, Rosenthal DN. Me-
chanical dyssynchrony in children with systolic dysfunction secondary
to cardiomyopathy: a Doppler tissue and vector velocity imaging
study. J Am Soc Echocardiogr 2007;20:756–63.
71. Bacha EA, Zimmerman FJ, Mor-Avi V, et al. Ventricular resynchro-
nization by multisite pacing improves myocardial performance in the
postoperative single-ventricle patient. Ann Thorac Surg 2004;78:
1678–83.
72. Zimmerman FJ, Starr JP, Koenig PR, Smith P, Hijazi ZM, Bacha
EA. Acute hemodynamic benefit of multisite ventricular pacing after
congenital heart surgery. Ann Thorac Surg 2003;75:1775–80.
73. Cecchin F, Frangini PA, Brown DW, et al. Cardiac resynchroniza-
tion therapy (and multisite pacing) in pediatrics and congenital heart
disease: five years experience in a single institution. J Cardiovasc
Electrophysiol 2009;20:58–65.
74. Janousek J, Gebauer RA, Abdul-Khaliq H, et al. Cardiac resynchro-
nisation therapy in paediatric and congenital heart disease: differential
effects in various anatomical and functional substrates. Heart 2009;
95:1165–71.
S42 Feinstein et al. JACC Vol. 59, No. 1, Suppl S, 2012
HLHS: Current Considerations and Expectations December 27, 2011/January 3, 2012:S1–S42475. Dubin AM, Janousek J, Rhee E, et al. Resynchronization therapy in
pediatric and congenital heart disease patients: an international
multicenter study. J Am Coll Cardiol 2005;46:2277–83.
476. DeGroff CG. Modeling the fontan circulation: where we are and
where we need to go. Pediatr Cardiol 2008;29:3–12.
477. de Leval MR, Dubini G, Migliavacca F, et al. Use of computational
fluid dynamics in the design of surgical procedures: application to the
study of competitive flows in cavopulmonary connections. J Thorac
Cardiovasc Surg 1996;111:502–13.
478. Dubini G, de Leval MR, Pietrabissa R, Montevecchi FM, Fumero R.
A numerical fluid mechanical study of repaired congenital heart
defects. Application to the total cavopulmonary connection. J Bio-
mech 1996;29:111–21.
479. Marsden AL, Vignon-Clementel IE, Chan FP, Feinstein JA, Taylor
CA. Effects of exercise and respiration on hemodynamic efficiency in
CFD simulations of the total cavopulmonary connection. Ann
Biomed Eng 2007;35:250–63.
480. Whitehead KK, Pekkan K, Kitajima HD, Paridon SM, Yoganathan
AP, Fogel MA. Nonlinear power loss during exercise in single-
ventricle patients after the Fontan: insights from computational fluid
dynamics. Circulation 2007;116:I165–71.
481. Marsden A, Reddy V, Shadden S, Chan F, Taylor C, Feinstein J. A
new multiparameter approach to computational simulation for Fon-
tan assessment and redesign. Congenit Heart Dis 2010;5:104–17.
482. Sundareswaran K, de Zélicourt D, Sharma S, et al. Correction of
pulmonary arteriovenous malformation using image-based surgical
planning. J Am Coll Cardiol Img 2009;2:1024–30.483. Soerensen DD, Pekkan K, de Zelicourt D, et al. Introduction of a
new optimized total cavopulmonary connection. Ann Thorac Surg
2007;83:2182–90.
484. Marsden AL, Bernstein AJ, Reddy VM, et al. Evaluation of a novel
Y-shaped extracardiac Fontan baffle using computational fluid dy-
namics. J Thorac Cardiovasc Surg 2009;137:394–403.e2.
485. Marsden AL, Feinstein JA, Taylor CA. A computational framework
for derivative-free optimization of cardiovascular geometries. Com-
put Methods Appl Mech Eng 2008;197:1890–905.
486. Bove E, Migliavacca F, de Leval M, et al. Use of mathematic
modeling to compare and predict hemodynamic effects of the
modified Blalock-Taussig and right ventricle-pulmonary artery
shunts for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg
2008:312–20.
487. Hochareon P, Manning KB, Fontaine AA, Tarbell JM, Deutsch S.
Fluid dynamic analysis of the 50 cc Penn State artificial heart under
physiological operating conditions using particle image velocimetry.
J Biomech Eng 2004;126:585–93.
488. de Leval MR. The Fontan circulation: a challenge to William
Harvey? Nat Clin Pract Cardiovasc Med 2005;2:202–8.
Key Words: congenital heart defects y Fontan procedure y Glenn
procedure y hypoplastic left heart syndrome y Norwood procedure.
